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Cirrhosis is a significant cause of morbidity and mortality in our community and liver 
transplantation is a well-established treatment for patients with decompensated cirrhosis 
and hepatocellular carcinoma. However, there remains a proportion of patients who have 
adverse transplant outcomes. As such, there is an ongoing interest in strategies to identify 
patients at risk of life-threatening complications, as well as developing strategies to reduce 
the risk of these complications occurring. 
Prior evidence suggests patients with reduced skeletal muscle mass have increased 
morbidity and mortality both pre- and post-transplant [Chapter 1]. A large proportion of 
these studies have used computed tomography (CT) skeletal muscle area measured on a 
single transverse image to estimate overall body muscle stores. However, the thresholds 
used to define low muscle mass were derived from obese patients with malignancy. There 
is limited reported data on the healthy distribution of skeletal muscle and adipose tissue 
area on CT to confirm these cut-offs are appropriate for all patient cohorts. Chapter 3 
provides important normative CT data on skeletal muscle area, visceral adipose tissue 
area and subcutaneous adipose tissue area in a cohort of Australian Caucasians. 
Bedside methods used to assess skeletal muscle mass such as anthropometrics and 
bioelectrical impedance analysis (BIA) are considered inaccurate in patients with cirrhosis 
due to assumptions about the hydration fraction of fat-free mass which are not applicable 
to this patient cohort. Thus, there is a need to identify novel non-invasive, accurate and 
clinically significant methods of estimating muscle mass in patients with cirrhosis. Chapter 
4 evaluated the relationship of several muscle mass assessment methods to a body cell 
mass reference estimate in patients with cirrhosis. Advances in prior bedside methods, 
such as multifrequency bioelectrical impedance spectroscopy (BIS), and novel muscle 
mass estimates using ultrasound (US), were among the methods evaluated. Of the 
bedside muscle mass estimates, the BIS results had the strongest relationship to the body 
cell mass reference measurement. However, BIS resulted in misdiagnosis of skeletal 
muscle mass depletion when compared to dual-energy X-ray absorptiometry (DXA) 
skeletal muscle index criteria. Of the radiological methods, DXA appendicular lean mass 
(ALM) had the strongest relationship to the body cell mass reference estimate. CT skeletal 
muscle area results were consistently inferior to DXA ALM results. 
Expert panels on sarcopenia have highlighted the importance of measuring muscle 
strength and physical performance in addition to muscle mass when assessing for 
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sarcopenia. In Chapter 5, comprehensive sarcopenia assessment was performed on a 
cohort of patients with cirrhosis undergoing liver transplant. Several relationships were 
identified with pre- and post-transplant complications. In male patients, lower DXA skeletal 
muscle index had a trend towards an association with delayed extubation and sepsis post-
liver transplant. A lower sit-to-stand test score in men was independently associated with 
pre-transplant sepsis and encephalopathy related admission. In addition, impaired Short 
Physical Performance Battery was associated with post-transplant sepsis and impaired 
six-minute walk distance was a predictor of prolonged hospital length of stay. 
Cardiovascular disease post-liver transplantation is a significant problem and one of the 
strongest risk factors is post-transplant metabolic syndrome. Chapter 6 evaluates the pre-
transplant variables associated with the early onset of post-transplant metabolic syndrome 
and found that CT visceral adipose tissue is an independent risk factor on multivariate 
analysis. 
In Chapter 7, the change in body composition, muscle strength and physical performance 
from baseline assessment to six months post-transplantation was evaluated. Similar to 
previous studies, there was a significant increase in DXA fat mass and decline in DXA 
skeletal muscle mass. This corresponded to a high prevalence of ‘Sarcopenic obesity’. 
Despite an overall significant improvement in physical performance measures by six 
months, sarcopenic obesity patients were associated with inferior performance than the 
non-sarcopenic patients. No association was found with sarcopenic obesity and 
cardiometabolic risk. 
In conclusion, this thesis significantly contributes to the literature in several areas. Firstly, it 
provides important body composition data, both in health and a population with cirrhosis. It 
also provided evidence of the clinical utility of a comprehensive body composition 
assessment in patients with cirrhosis undergoing liver transplantation. Furthermore, a 
sarcopenia evaluation incorporating assessment of skeletal muscle mass, muscle strength 
and physical performance provides the optimal risk assessment for pre- and post-
transplant adverse events. Finally, this research identified that pre-transplant CT visceral 
adipose tissue is an independent risk factor for post-transplant metabolic syndrome. 
Identification of high-risk patients using the above techniques could assist risk stratification 
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Cirrhosis represents the end-stage of many diseases [Table 1-1] which result in chronic 
liver injury. Irrespective of the underlying aetiology, chronic liver injury leads to hepatic 
stellate cell activation and progressive fibrosis.1 Cirrhosis is the final stage, and is defined 
histopathologically as the transformation of the liver into regenerative parenchymal 
nodules divided by fibrous bands.1 This results in architectural distortion with a reduction in 
hepatocellular mass and function, and alterations in hepatic blood flow.1 With ongoing liver 
injury, there is a progressive increase in portal pressure and hepatocyte dysfunction which 
eventually results in decompensated disease.1 
Table 1-1 Aetiology of cirrhosis2 
Toxic Alcoholic liver disease Arsenic 
Autoimmune  
Autoimmune hepatitis 
Primary biliary cholangitis 







Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis 
Biliary 
Atresia 
Chronic biliary obstruction 




α1 Antitrypsin deficiency 
Cystic fibrosis 
Gaucher’s disease 
Glycogen storage disease 
Galactosemia 
Vascular 




Granulomatous liver disease 
Medications – Methotrexate; Vitamin A 
Coeliac disease 
Cryptogenic cirrhosis 
1.1.1 Pathogenesis of cirrhosis 
The hepatic stellate cell is a nonparenchymal cell within the perisinusoidal space of Disse 
which carries a central role in the development of hepatic fibrosis.2 Activation of quiescent 
stellate cells into contractile, proliferative and fibrogenic myofibroblasts results in collagen 
matrix deposition leading to hepatic fibrosis.2 Initially the predominate matrix produced is 
fibronectin, with other forms subsequently produced such as collagen type I and III.2, 3  
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Many pathways have been linked to activation of hepatic stellate cells and hepatic 
fibrogenesis including transforming growth factor-β, platelet-derived growth factor-β, 
vascular endothelial growth factor and integrins.3 Several surrounding cells lines are 
responsible for the secretion of these cytokines. Epithelial cell injury is proposed as the 
initiating process in most liver diseases.2 Hepatic macrophages (Kupffer cells), have also 
been identified as a key contributor.2 Finally, sinusoidal endothelial cells have been 
implicated in stellate cell activation via angiogenesis. Release of paracrine activating 
molecules by endothelial cells has been identified as one mechanism of stellate cell 
activation.2     
1.1.2 Financial burden of cirrhosis 
The burden of cirrhosis is increasing in Australia and worldwide.4 A systematic review by 
Mokdad et al. reported the number of global cirrhosis related deaths increased from 
676,000 in 1980 to over one million in 2010 (~2% of the global population).4 In Australia, 
the number of cirrhosis related deaths in 2012 was 7266 (0.03% population).5 
It is estimated that in 2012, chronic liver disease (including hepatitis A/B/C, non-alcoholic 
fatty liver disease, alcoholic liver disease, primary biliary cirrhosis, primary sclerosing 
cholangitis, hemochromatosis and hepatocellular carcinoma) affected more than six million 
(~26%) Australians.5 The total financial cost of liver disease was estimated as $5.4 billion 
in 2012, while the total cost including the burden of disease was $50.7 billion.5 
1.1.3 Natural history of cirrhosis 
Cirrhosis has traditionally been classified broadly as compensated or decompensated 
disease.2 More recently, Garcia-Tsao et al proposed a refined staging system for 
cirrhosis.6 This model describes four progressive clinical stages. Stage one cirrhosis is 
found in the absence of ascites and varices, while Stage two is present when varices 
develop in the absence of bleeding. Stage one and two are equivalent to ‘compensated 
cirrhosis’. With progressive liver injury, ‘decompensated cirrhosis’ develops, incorporating 
Stage three and Stage four cirrhosis. These two stages were not well defined, but it has 
been suggested that Stage four cirrhosis is characterised by recurrent variceal 




Prognosis of patients with compensated cirrhosis is significantly better than patients with 
decompensated cirrhosis. The median survival time of patients with compensated cirrhosis 
has been estimated as >12 years, with a one-year survival rate >95%.7 Transition of 
patients from compensated to decompensated cirrhosis occurs at a rate of approximately 
10% per annum.7 Once patients develop decompensated cirrhosis they have high 
mortality rates. The median survival time of patients with decompensated cirrhosis has 
been estimated as two years, while the one-year survival is approximately 60%.7 
Several prognostic models such as the Child-Pugh class [Appendix C] and Model for End-
stage Liver Disease (MELD) score [Appendix D] have been developed over the last 50 
years to help predict the mortality of an individual with cirrhosis.8 The Child-Turcotte score 
was one of the first models proposed in 1964, originally developed to predict outcomes 
after surgery for portal hypertension.9 It was subsequently modified to the Child-Pugh 
class in 1973, replacing a subjective nutritional assessment with the objective prothrombin 
time or International Normalised Ratio (INR).10  
More recently, the MELD score was developed by Malinchoc et al. to predict the prognosis 
of cirrhosis patients receiving a transjugular portosystemic intrahepatic shunt.11 It was 
subsequently adopted for liver transplant organ allocation in 2002. Its use in the setting of 
liver transplantation will be discussed further in Section 1.7.  
1.1.5 Complications of cirrhosis 
Patients with cirrhosis are at risk of several complications [Table 1-2], with the majority 
broadly related to the development of portal hypertension and liver insufficiency. Portal 
hypertension is the first and most important complication of cirrhosis to develop.6 It 
contributes to many of the clinical complications of cirrhosis, and the risk of such 
complications is proportional to the degree of portal hypertension. The hepatic venous 
pressure gradient (HVPG) is the most widely accepted indirect measure of portal pressure, 
and a level > 10 mmHg is considered “clinically significant portal hypertension” which is 
associated with developing varices and/or clinical decompensation.6  
Portal hypertension develops due to increased intrahepatic resistance (architectural 
distortion), increased portal blood flow and extrahepatic haemodynamic changes 
(splanchnic and systemic vasodilatation).6 Splanchnic and systemic vasodilatation induce 
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a hyperdynamic circulatory state that leads to other major complications such as ascites, 
hyponatraemia and hepatorenal syndrome. 
Table 1-2. Complications of cirrhosis2 
Portal hypertension 
 Varices ± haemorrhage 
 Splenomegaly, hypersplenism 
 Ascites 
Sepsis 
 Spontaneous bacterial peritonitis 
 Bacteraemia 
 Pneumonia; Urinary tract infections; cellulitis 
Renal disorders 
 Hepatorenal syndrome 
Neuropsychiatric disorders 
 Hepatic encephalopathy 
 Depression 
Cardiopulmonary disorders 
 Hepatopulmonary syndrome 
 Portopulmonary hypertension 
 Cardiomyopathy 








 Hepatocellular carcinoma 
Metabolic Disorders 




Another important complication of cirrhosis is hepatic encephalopathy. It incorporates a 
wide array of fluctuating neurological and psychiatric manifestations in patients with 
cirrhosis (and acute liver failure).2 The level of impairment can range from mild 
neurocognitive disturbances to overt coma. The most widely used clinical classification 
system is that of West-Haven [Table 1-3].12 More recently a new classification system 
SONIC (Spectrum of Neurocognitive Impairment in Cirrhosis) was proposed to improve the 
clinical classification of hepatic encephalopathy for research studies.13 Neurocognitive 
testing such as the Portosystemic Encephalopathy Syndrome test, the Inhibitory Control 
test and the Stroop test have been developed to improve the sensitivity and specificity of 




Table 1-3. Clinical stages of hepatic encephalopathy: The West Haven criteria.12 
Grade Clinical characteristics 
0 Normal 
1 Personality changes; attention deficits; irritability; depression 
2 Asterixis; speech abnormalities; changes in sleep-wake cycle, lethargy; cognitive dysfunction 
3 Altered level of consciousness; confusion; disorientation; amnesia 
4 Stupor and coma 
A number of factors have been attributed to the development of hepatic encephalopathy, 
including the production of neurotoxins (eg ammonia), increased permeability of the blood-
brain barrier and abnormal neurotransmission.2 
One of the cardinal features of advanced cirrhosis is loss of body cell mass, bone mass 
and/or fat mass.17 Patients with cirrhosis have alterations in lipid, carbohydrate and protein 
metabolism that contribute to these changes in body compartments.18 Furthermore, there 
are disturbances in fluid homeostasis and compartmentalisation in cirrhotic patients which 
make accurate assessment of body composition difficult.19 It has been reported that 
skeletal muscle mass is regularly overestimated in decompensated cirrhosis because 
prediction equations are rendered invalid with alterations in body water compartments.19 
Impairment in muscle strength, physical performance and cardiorespiratory fitness in 
advanced cirrhosis are also well documented and associated with adverse outcomes.20-23 
In the few studies these variables have been measured in combination, they appear to 
carry independent prognostic information.23-26 However, the methods utilised to measure 
these key variables are not standardised, and hence those with the best predictive validity 
have yet to be identified. 
Prior studies have described an association of sarcopenia with adverse outcomes in 
patients with cirrhosis [Section 1.7.1.2 below]. In most of these studies, ‘sarcopenia’ was 
defined as skeletal muscle mass depletion. However, several working groups recommend 
that the term ‘sarcopenia’ should be defined by impairment in muscle mass, muscle 
strength and/or physical performance.27, 28 
Finally, patients with ‘frailty’ have been associated with adverse outcomes. Lai et al. found 
that frail patients (Fried Frailty Index ≥3) were prevalent (17% of 294 cirrhosis patients) 
and associated with a higher risk of mortality (Hazard Ratio [HR] 1.45; 95% confidence 
interval [CI] 1.04–2.02; P = 0.03).29 The concept of frailty and its clinical implications will be 




Cirrhosis represents the end stage of chronic liver disease. After patients progress to 
decompensated cirrhosis, they are at risk of several complications associated with adverse 
outcomes. One such complication is loss of skeletal muscle mass. In the subsequent 
sections of this review, the impact of skeletal muscle loss in patients with cirrhosis will be 
reviewed.  
Prior to this, the difficulties in estimating body composition in patients with cirrhosis needs 
to be explored. In Section 1.2, the methods used to measure body composition will be 
reviewed in detail. The impact of abnormalities in fluid homeostasis which are present in 
patients with cirrhosis will be discussed in detail. 
Subsequently, the concepts of sarcopenia, frailty and cardiorespiratory fitness and their 
significance in cirrhosis will be explored.  
Finally, the management of decompensated cirrhosis including liver transplantation will be 
reviewed. The specific impact of sarcopenia and frailty will be discussed in the context of 
liver transplantation. 
1.2 Human body composition 
Assessment of human body composition requires the consideration of three inter-
connected areas: body composition rules and models; body composition methodology; 
and body composition variation.30 The body composition rules and models area considers 
body components and the links between them. The gold standard model used to study this 
area is the five level multi-compartment model in which body mass is considered as the 
sum of multiple components at each level [Figure 1-1].30 The five levels are: atomic, 
molecular, cellular, tissue-organ, and whole body.30 Definitions of some important cellular 




Figure 1-1 Basic two-compartment model and five-level multi-compartment model of body 
composition. [ECS - extracellular solids; ECF - extracellular fluid]31  
 
Table 1-4. Body composition terminology.30 
Term Definition 
Body cell mass  The cellular components of the body including intracellular water (lean body mass – extracellular water and solids) 
Lean body mass  Non-adipose tissue body mass (body cell mass + extracellular water + solids) 
Fat-free mass  Lean body mass + non-fat component of adipose tissue 
Body fat mass  Quantity of triglyceride fat in the body 
Adipose tissue mass Fat + supporting cellular and extracellular tissues 
Extracellular solids Total body mineral + fascia and cartilage 
Two-, three- and four-compartment models have been used in the study of human 
composition based on components of the five-level model.32 At the most basic level is the 
two-compartment model. In this model, the body is divided into fat mass and fat-free mass 
[Figure 1-1] with mathematical formulas subsequently used to calculate lean body mass, 
body cell mass or skeletal muscle mass. Two-compartment models have the advantage 
that they can be assessed accurately with bedside measures in healthy populations.30 
Three- and four-compartment models improve accuracy, but are increasingly resource and 
time intensive.30  
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The other key areas of body composition assessment include consideration of the 
methods available to measure body components (methodology area), and how body 
composition varies due to the impact of physiological or pathological conditions (variation 
area).30 
1.2.1 Biological influence on body composition 
Many biological factors influence body composition including genetics, age, ethnicity and 
sex. A brief overview of these factors will now be explored. 
1.2.1.1 Genetics 
Complex multifactorial traits whose mode of inheritance cannot be reduced to Mendelian 
patterns characterise human body composition phenotypes.30 These traits have been 
influenced by many domains, including social, behavioural, physiological, metabolic, 
cellular and molecular domains. The influence of genotype is often altered by 
environmental factors.30 
Further detail on the impact and study of genetics in human body composition is beyond 
the scope of this review and can be found in Human Body Composition, Chapter 16.30  
1.2.1.2 Age 
Human body composition change occurs progressively throughout an individual’s lifespan, 
from conception to death. Age related changes can be divided into three phases: growth 
and development; maturity and senescence.30 A brief overview of the fat and skeletal 
muscle changes seen through the maturity and senescence phases will now be explored.  
Fat mass is the variable with the most significant between-individual variability (6-60% 
body weight).30 Within-individual variability can also be significant but has a typical pattern 
of change related to ageing. In adulthood, total body fat increases slowly with age.30 Guo 
et al. estimated the rate of increase in fat mass to be 0.37kg/year in males, and 
0.41kg/year in females.33 During senescence (age >65 years), total fat mass declines.30 
The anatomical distribution of fat also has distinct patterns of age-related change. Visceral 
adipose tissue increases with age, particularly during middle age.30 In old age, visceral 
adipose tissue remains relatively stable, although the proportion may increase due to the 
decline in total fat mass mentioned previously.30 
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Skeletal muscle mass is relatively stable during adulthood up to the age of 45 years 
[Figure 1-2].30, 34 After this, there is a progressive decline in skeletal muscle mass.34 Rates 
of loss are greater for lower limb muscles compared to upper limb muscles.34 
 
Figure 1-2. Relationship between whole body skeletal muscle mass and age34 
1.2.1.3 Sex 
Sexual dimorphism in body composition is well documented. Multicomponent reference 
data from Ellis et al. demonstrated that white adult males have greater protein, mineral and 
water compartments than females.35 Estimated fat mass overlaps between the sexes 
across adulthood.35  
In addition, the abdominal distribution of adipose tissue and skeletal muscle varies 
between sexes.30 Most studies suggest that during adulthood, visceral adipose tissue 
increases with age in both sexes, although the rate of increase is typically greater in 
males.30 Subcutaneous adipose tissue also increases with age up until 60 years and then 
declines in both sexes.30 Adult males have a higher proportion of visceral adipose tissue 
than females.30 Subcutaneous adipose tissue shows overlap between the sexes, although 
females tend to have higher mean values throughout adulthood.30 
There are many other sex-specific variations in fat mass distribution that have been 
described, such as ‘fat patterning’ and differences in trunk-to-extremity distribution. Further 
detail can be found in Human Body Composition, Chapter 18.30 
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1.2.1.4 Race and ethnicity 
Population variability in body composition requires consideration of both race and ethnicity. 
Prior studies have classified groups according to geographic locations (eg European, 
African, Asian, etc), racial colour (eg White Americans, Black Americans, Hispanic 
Americans, etc), and according to specific countries in many Asian studies.30 
Variations in body composition measured by dual X-ray absorptiometry (DXA) highlight 
ethnic variation. Data from Ellis et al. show that American blacks have proportionally more 
appendicular skeletal muscle mass and bone mass compared with whites.36, 37 This ethnic 
variation is more prominent in the upper limbs.36, 37  
Data from Ishida et al. demonstrated that Japanese females (age 20-30 years) have lower 
ultrasound muscle thickness than white females.38 With regard to adipose tissue, Park et 
al. showed that Asian Americans have less overall adipose tissue and subcutaneous 
adipose tissue than American whites.39 Visceral adipose tissue differences varied 
according to sex, with Asian American males having less visceral adipose tissue, while 
females had more visceral adipose tissue than American whites.39  
Finally, there are ethnic specific differences in percent body fat levels according to body 
mass index.30 This is reflected in the World Health Organisation recommendation for lower 
body cell mass (BMI) cut-offs to diagnose obesity in Asian populations.40 
1.2.2 Body composition assessment in cirrhosis 
Analysing body composition in cirrhosis is challenging for several reasons already 
mentioned. At the core are disturbances in fluid homeostasis which alter the hydration of 
fat-free mass. As a consequence, two-compartment models have been reported as 
inaccurate in cirrhosis patients.41, 42  
Historically the accurate assessment of body composition in cirrhosis has been performed 
using molecular and cellular compartment models. Recently techniques have been 
developed which allow the direct measurement of functional tissues (e.g. skeletal muscle; 
adipose tissue) in the setting of cirrhosis.43, 44 The utility of available techniques to study 




Anthropometry is defined as ‘the scientific study of the measurements and proportions of 
the human body’.45 In body composition studies it refers to measures such as height, 
weight, waist circumference, and skinfold thickness (SFT) assessment. The skinfold 
thickness can be used to estimate body fat mass and fat-free mass using prediction 
equations derived in healthy populations. However, these estimates have been shown to 
be inaccurate in decompensated cirrhosis.19 
The mid-arm muscle circumference (MAMC) and mid-arm muscle area (MAMA) are 
estimates of upper arm muscle derived from the triceps skin fold thickness and the mid-
arm circumference. MAMC is calculated using the following equation19: 
MAMC = MAC - πTSF 
Furthermore, MAMA is calculated as per the equation below:19  
 
Both the MAMC and the MAMA have shown correlation with total skeletal muscle mass in 
healthy cohorts.19 Figueiredo and colleagues showed that MAMC only had a Pearson 
correlation coefficient of 0.55 with a body cell mass reference estimate in patients with 
cirrhosis.46  
1.2.2.2 Bioelectrical impedance analysis 
Bioelectrical impedance analysis (BIA) is a non-invasive bedside test which provides 
estimates of body compartments based on the different electrical conductance through 
tissues containing water versus those containing fat.30 It relies on several assumptions 
regarding the electrical properties of the body including tissue hydration and density. 
Formulas are subsequently applied to estimate fat-free mass, fat mass, body cell mass 
and skeletal muscle mass. BIA is well validated in healthy populations for estimating body 
composition.47 However sodium and water accumulation seen in cirrhotic patients leads to 
an overestimation of fat-free mass.41, 42, 48, 49 
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BIA was originally developed to assess impedance using a single current frequency 
(50Hz). However single-frequency analysers are limited in their ability to differentiate intra-
and extra-cellular water.50 Multi-frequency analysers offer the advantage of differentiating 
these water compartments with bioelectrical impedance spectroscopy (BIS) although the 
technique appears to still have accuracy issues in patients with cirrhosis.42 Despite these 
limitations, low skeletal muscle mass estimated by BIA has been shown to be an 
independent predictor of mortality (HR 4.85; 95%CI 2.09–11.79; P < 0.001) in cirrhosis 
patients who undergo liver transplantation.51  
Segmental bioelectrical impedance is a variation of BIS which involves changing the 
position of the electrodes to measure impedance through single segments (arm, leg and 
trunk). Studies utilising segmental BIS have shown good correlation to whole body fat-free 
mass in a healthy population.30 It remains to be seen if the accuracy of BIS can be 
improved in patients with decompensated cirrhosis by using segmental analysis. 
1.2.2.3 Dual-energy X-ray Absorptiometry 
Dual-energy X-ray absorptiometry (DXA) is a technique which measures the attenuation of 
low and high energy photons through bone, lean tissue, and fat.30 Most studies suggest it 
provides accurate and reproducible measurement of fat mass, fat-free mass and bone 
mass in healthy populations and those with cirrhosis.42, 47 However, estimates of lean body 
mass and skeletal muscle mass are less accurate in cirrhosis because DXA cannot 
separate intracellular and extracellular water (the two largest components of lean body 
mass). Therefore, accurate DXA derived lean body mass and skeletal muscle mass 
assessment in this population requires measurement of water compartments (total body 
water and extracellular water).41, 52  
Diagnosis of low skeletal muscle mass using DXA has historically focused on the 
appendicular lean mass adjusted for height (in metres) squared.27 This method has not 
been validated in patients with cirrhosis. With regard to cut-offs used to diagnose low 
skeletal muscle mass, there are several published values. The most widely accepted are 
those published by Baumgartner et al.53 Cut-offs of 7.26kg/m2 for males and 5.45kg/m2 for 
females were proposed, which represent the values two standard deviations below a 




Ultrasonography is developing into a promising bedside modality for the quantification of 
both skeletal muscle mass and fat mass. Ultrasound measurement of skeletal muscle 
thickness has been assessed in a variety of populations with excellent intra- and inter-
observer variability including observers with minimal training.54 Campbell et al. assessed 
the utility of ultrasound to estimate total skeletal muscle mass in a cohort of intensive care 
patients.44 They found that even in the presence of oedema, ultrasound maintained good 
correlation with values derived from DXA. They also found it was reliable in monitoring 
changes in skeletal muscle mass over time. There are no published studies to date 
assessing the validity of ultrasound for estimating body composition in patients with 
cirrhosis. It has been proposed by some authors as an alternative to anthropometry in 
patients with cirrhosis, as it provides a direct measurement of skeletal muscle and in 
theory less influenced by fluid disturbances.55 
1.2.2.5 Computed tomography and magnetic resonance imaging 
Cross sectional imaging modalities such as magnetic resonance imaging (MRI) and 
computed tomography (CT) are reliable and accurate methods for assessing body 
composition, however are limited by cost, availability and, in the case of CT, radiation 
exposure.30 With the increasing availability of CT for assessment of illness, the utilisation 
of this imaging modality to provide information on body composition has grown 
exponentially. In 2004, Shen et al. presented data that demonstrated skeletal muscle area 
and adipose tissue area on a single slice of cross-sectional imaging strongly correlates 
with total body skeletal muscle mass in a healthy population.43 They assessed the optimal 
level on a CT abdomen for estimating total skeletal muscle mass. The highest correlation 
between skeletal muscle area and total muscle volume was 5cm above the L4-L5 vertebral 
interspace (r = 0.924; P < 0.001).43 
Based on this principal, a variety of techniques have been developed to estimate skeletal 
muscle mass using CT. Table 1-5 provides a sample of the most commonly used 
methods, including landmarks, software and thresholds used. It is clear that there is 
significant heterogeneity in the methods used to analyse body composition using CT, and 
also the cut-offs used to define low skeletal muscle mass. 
One of the first studies to publish data measuring skeletal muscle area on CT was Prado 
and colleagues. They measured the skeletal muscle area at the level of the 3rd Lumbar 
Vertebrae and determined the gender specific skeletal muscle index (skeletal muscle area 
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corrected for height squared) cut-offs which were associated with mortality in a population 
of obese patients with cancer.56 Many subsequent studies have used these cut-offs values 
to define low skeletal muscle mass and have shown an impact on morbidity and mortality 
in different populations.57 
Table 1-5. Comparison of methods used to assess skeletal muscle using computed tomography. 
Author Skeletal muscle mass assessment method 
Level of 
CT Software Threshold values 
 Total skeletal muscle area assessment    
Mourtzakis et al. 58 Total Skeletal Muscle Area L3 Slice-O-Matic 
Muscle: -29 to +150 HU 
SAT: -190 to -30 HU 
VAT: -150 to -50 HU 
Tsien et al. 59 Total Skeletal Muscle Area L4 
Leonardo Workstation 
using Oncocare N/A 
Richards et al. 60 Total Skeletal Muscle Area L3 ImageJ 
Muscle: -29 to +150 HU 
Adipose: -190 to -30 HU 
 Psoas muscle assessment    
Durand et al. 61 Transverse Psoas Muscle Thickness Umbilicus Not stated N/A 
Englesbe et al. 62 Psoas Muscle Area L3 MATLAB N/A 
Valero et al. 63 Psoas Muscle Area & Volume L3 
TPA - ImageJ 
TPV - AW Workstation 
Volume Viewer 
Software 
Muscle: +30 to +110 HU 
CT – Computed tomography; HU – Hounsfield unit; SAT – Subcutaneous adipose tissue; VAT – Visceral adipose tissue; TPA – Total 
psoas area; TPV – Total psoas volume 
It should be recognised that expert sarcopenia committees suggest that the cut-offs for 
diagnosing low skeletal muscle mass be two standard deviations below the level of a 
young healthy population.27 Unfortunately, there is a paucity of normative CT data for 
skeletal muscle area. Hamaguchi et al. published data on 657 healthy Japanese liver 
transplant donors and found CT skeletal muscle index thresholds of 40.31cm2/m2 for 
males and 30.88cm2/m2 for females.64 However, Asian populations are well known to have 
smaller physiques than Caucasians, and it is likely that threshold values associated with 
adverse outcomes in patients with cirrhosis will show ethnic variation.40 Thus, further data 
are required to establish the ‘healthy’ distribution of CT skeletal muscle area in young 
populations of different ethnicities. 
There is indirect evidence to support the cut-offs proposed by Prado et al. Mourtzakis et al. 
compared 31 patients with advanced cancer who had paired CT and DXA data. They 
showed that in this population there was a strong correlation between CT skeletal muscle 
index and DXA appendicular lean mass. Using regression equations, the thresholds for 
skeletal muscle mass depletion of 55.4cm2/m2 for men and 38.9cm2/m2 corresponded to 
16 
 
the well-established DXA appendicular lean mass cut-offs published by Baumgartner et 
al.53, 58 
There is also a need to define the normal distribution of adipose tissue, given the potential 
impacts of this on cardio-metabolic health. In the Framingham Heart study, both visceral 
adipose tissue and subcutaneous adipose tissue on a single CT slice have been shown to 
strongly correlate with total body adipose tissue.65 However there is limited normative data 
to define extremes of visceral adipose tissue and subcutaneous adipose tissue. The Japan 
Society for the Study of Obesity has suggested that a visceral adipose tissue area 
>100cm2 be used to diagnose Visceral Obesity based on data from a Japanese cohort.66 
Caucasian data has suggested a visceral adipose tissue area >106cm2 is associated with 
metabolic complications in a female cohort while another study involving both males and 
females found a visceral adipose tissue area >130cm2 to carry the highest risk of 
metabolic complications.67, 68 
1.2.2.6 Total body potassium 
Estimation of total body potassium (TBK) with a whole-body counter has been validated as 
an accurate method of quantifying body cell mass in healthy populations.30, 69, 70 The 
whole-body counter detects the natural γ-ray emitted by the decay of 40potassium. 
Adjusting for patient weight allows the calculation of TBK. Mathematical models are used 
to then estimate fat-free mass, body cell mass and total skeletal muscle mass.71 This 
technique has the advantage that it does not expose patients to radiation. However, it 
requires specialised resources, limiting clinical utility.71 TBK counting has been considered 
by some authors as a reference method for assessment of body cell mass and skeletal 
muscle mass, even in patients with excess extracellular water.72 However, other authors 
have expressed concern regarding the accuracy of TBK counting for body composition 
evaluation in patients with cirrhosis due to disturbances in total body potassium and 
intracellular potassium concentration.19, 73, 74 In addition, it has been suggested that diuretic 
therapy, which is commonly prescribed in patients with cirrhosis, may affect the accuracy 
of TBK.19 
1.2.2.7 In-vivo neutron activation analysis 
In-vivo neutron activation analysis (IVNAA) is the only technique available for elemental 
body composition analysis. It utilises controlled neutron irradiation of the element under 
evaluation.32 This induces release of γ-rays from tissue nuclei which have element specific 
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detectable energies.32 By quantifying total body nitrogen it can provide an accurate (±3%) 
estimate of total body protein.19 
IVNAA is considered a gold standard for measuring body protein and is not affected by 
alterations in hydration seen in patients with cirrhosis.30 However, neutron activation 
systems are expensive, require experienced personnel and are limited to only a few 
centres in the world. IVNAA also carries a significant radiation exposure, although 
refinements in technique have reduced this to less than 0.3 millisieverts.19, 32  
1.2.2.8 Total body water 
Patients with cirrhosis have increased sodium and water accumulation even in early 
stages of disease, therefore estimation of total body water (TBW) and extracellular water 
(ECW) is essential in providing a reference assessment of body composition.52 
Measurement of TBW can be achieved with isotope dilution techniques. Several isotopes 
have been used such as the radioactive isotopes tritium (3H2O) and 18-oxygen (H218O).30 
However, the most commonly used isotope is non-radioactive deuterium (2H2O). Subjects 
drink tracer-labelled water, with the dose depending on the method used for tracer 
analysis. Higher doses are required when samples are analysed with Fourier transform 
infrared (FTIR) spectroscopy compared with mass spectroscopy.19 After a period of 
equilibration, a sample of saliva, urine or plasma is collected for analysis. In the setting of 
fluid retention, it has been suggested that the optimal equilibration time is 5-6 hours, 
although some authors have suggested longer times are required.19, 30 
1.2.2.9 Extracellular water 
Extracellular water can be measured by several tracer dilution tests; however, the sodium 
bromide dilution test is the most widely used.30 Subjects take an oral dose of sodium 
bromide (0.75mmol NaBr/kg body weight) in water and then have a plasma sample 
collected after an equilibration period. It is recommended that this period be 5-6 hours for 
patients with fluid overload, although delay in equilibration for up to 8.5-11.7 hours has 
also been suggested.30, 75 The tracer levels of bromide are measured with High 
Performance Liquid Chromatography.30 
1.2.2.10 Summary 
The difficulties in assessing body composition in patients with cirrhosis has been 
thoroughly explored. Traditional bedside body composition techniques and prediction 
equations are inaccurate in this patient population. Thus, there is a need for ongoing 
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research to identify accurate bedside body composition assessment techniques in patients 
with cirrhosis. A multi-compartment model which includes assessment of water 
compartments is recommended to provide a reference assessment of body composition.  
Loss of skeletal muscle mass is an integral component of sarcopenia. However, it is 
important to recognise that muscle strength and physical performance are also important 
components. The concept of sarcopenia, its prevalence in cirrhosis, and its clinical 
implications will now be reviewed. 
1.3 Sarcopenia 
‘Sarcopenia’ is a term that was originally proposed by Rosenberg in 1989, to describe the 
loss of muscle mass during normal ageing.76, 77 With recognition that muscle loss can 
occur in people of all ages, the term ‘Primary Sarcopenia’ was suggested for age-related 
impairment of muscle, while other causes should be referred to as ‘Secondary 
Sarcopenia’.27 
Secondary sarcopenia can be broadly classified as activity-related, disease-related or 
nutrition-related. The aetiology of sarcopenia is often multifactorial and it can be difficult to 
distinguish primary from secondary sarcopenia.27, 28 Expert panels recommend the use of 
the same diagnostic criteria, regardless of the aetiology.27, 28 As such, future reference of 
the term sarcopenia in this document will incorporate both primary and secondary 
sarcopenia. 
Over time there has been recognition of the importance of declining muscle function 
(strength and physical performance) and these components are now included in the 
definition of sarcopenia by multiple expert panels.27, 28, 78 The European Working Group on 
Sarcopenia in Older People (EWGSOP) defines sarcopenia as ‘a syndrome characterised 
by progressive and generalised loss of skeletal muscle mass and strength with a risk of 
adverse outcomes such as physical disability, poor quality of life and death’.27  
As people age, there is a disassociation between the loss of muscle mass, and muscle 
strength and power [Figure 1-3].79 It has been suggested that loss of muscle function is a 
better indicator of poor cardio-respiratory function, functional limitations and mortality than 




Figure 1-3 Dissociation of decline in muscle mass, strength and power with increasing age. Adapted 
from Barry et al.79 
This dissociation has not been examined in the setting of progressive chronic illness, 
including patients with cirrhosis.  
1.3.1 Pathogenesis of sarcopenia 
The pathogenesis of sarcopenia is multifactorial [Figure 1-4], with disturbances in protein 
synthesis, proteolysis, neuromuscular integrity and muscle fat content contributing to the 
onset and progression of sarcopenia.28 
 
 
Figure 1-4. Mechanisms leading to the development of sarcopenia.27 GH – growth hormone; IGF-1 – 




Research into age-related sarcopenia has identified several important factors leading to 
decline in muscle quantity and quality. Firstly, there is a progressive decline in anabolic 
hormones such as testosterone, oestrogen, growth hormone and insulin like growth factor-
1 with increasing age.81  
Another mechanism believed to contribute is oxidative stress in skeletal muscle and/or 
motor neurons. It has been hypothesised that with increasing age, there is a greater 
burden of free radicals which produce changes in deoxyribonucleic acid (DNA), lipids and 
proteins.81 
Several other mechanisms have been proposed as contributors to age-related sarcopenia, 
including excess pro-inflammatory cytokines (e.g. interleukin-6 and tumour necrosis factor-
α), increased myofiber apoptosis, change in mitochondrial function, and a decline in α-
motor neurons.81, 82  
Finally, age-associated reduction in physical activity along with inadequate nutrition are 
important factors in primary sarcopenia.81  
Secondary sarcopenia can occur at any age as a consequence of cachexia, malnutrition, 
disuse or endocrine disorders.28 Cachexia is a multifactorial syndrome characterised by 
severe wasting of body tissue compartments due to underlying disease.28 It has been 
defined as “a complex metabolic syndrome associated with underlying illness and 
characterised by loss of muscle, with or without loss of fat mass”.83 Several 
pathophysiological mechanisms contribute to the onset of cachexia. Systemic 
inflammation has been identified as a key component of cachexia, with several studies 
demonstrating that an imbalance between pro-inflammatory and anti-inflammatory 
cytokines plays a pivotal role.28 Other groups have identified that elevated interleukin-6 
and C-reactive protein correlate with loss of body weight.84  
In contrast, malnutrition is a ‘state of nutrition in which a deficiency (or excess) of energy, 
protein, and other nutrients causes measurable adverse effects on tissue composition and 
function’.28 The term ‘malnutrition’ is most frequently associated with ‘undernutrition’, which 
is a state of inadequate calories, protein or other nutrients needed for tissue maintenance 
and repair.85 However, by definition it also incorporates overnutrition and the impact of 
obesity on health.28 Undernutrition should be applied only to conditions that dramatically 
respond to feeding.86  
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In the context of cachexia, undernutrition may be a significant component in its 
pathogenesis.28 However, it is important to note that not all malnourished patients are 
cachectic.28 
A review of sarcopenia pathogenesis in patients with cirrhosis will follow in Section 1.3.4.2. 
1.3.2 Diagnosis of sarcopenia 
The criteria recommended by the EWGSOP for diagnosis of both primary and secondary 
sarcopenia are:27  
 Presence of low skeletal muscle mass AND either low muscle strength OR low 
physical performance. 
The recommended cut-off for deficiency is two standard deviations below the mean 
reference value for healthy young adults.27 
The EWGSOP also proposed a staging system as shown in Table 1-6.  
Table 1-6. European Working Group on Sarcopenia in Older People (EWGSOP) conceptual stages of 
sarcopenia 






1.3.3 Assessment of sarcopenia 
Assessment of sarcopenia, including quantifying muscle mass, muscle strength and 
physical performance, can be conducted by many methods.27 Table 1-7 provides a 
summary of the methods available to assess these variables in clinical practice and 
research. 
1.3.3.1 Skeletal muscle mass 
Assessment of skeletal muscle mass can be performed using several methods which have 
been reviewed in Section 1.2.2 above. In clinical practice, the most frequently used 
bedside methods are anthropometry and bioelectrical impedance analysis. Radiological 
assessment using dual energy X-ray absorptiometry (DXA) is an alternative, particularly 






assessment). DXA can provide an accurate assessment of body composition in addition to 
bone density assessment.  
Retrospective analysis of CT scans performed for other clinical indications is also a useful 
alternative and is becoming more frequently utilised in the research setting. However, 
translation from research to clinical practice is scarce. 
Table 1-7. Measurement of muscle mass, strength and physical performance in research and 
practice. Adapted from Cruz-Jentoft et al.27 
Criteria Clinical practice Research 







Total body potassium 
Ultrasound 
Muscle strength Handgrip strength Handgrip strength  
Knee flexion/extension 
Peak expiratory flow 
Physical performance SPPB 
Gait speed test 
Get-up-and-go test 
Stair climb power test 
Six-minute walk distance 
SPPB 
Gait speed test 
Get-up-and-go test 
Sit-to-stand test 
Six-minute walk distance 
BIA - Bioelectrical impedance analysis; CT – Computed tomography; DXA – Dual energy X-ray absorptiometry; IVNAA – 
In-vivo neutron activation analysis; MRI – Magnetic resonance imaging; SPPB - Short physical performance battery 
1.3.3.2 Muscle strength and power 
Muscle strength is defined as the force-producing capacity of muscle (i.e. maximal force), 
whereas muscle power is the ability to perform muscular work per unit of time (i.e. rapid 
force development).80 Muscle strength in its simplest form is expressed as an absolute 
figure given that it does not require other measurements.80  
Muscle strength is mainly determined by the size of the muscle, with a maximal contractile 
force of three to four kg/cm2 of cross-sectional area. Therefore, maximal resistance 
training which induces muscle hypertrophy will improve strength.87 Other factors which 
influence muscle strength include muscle orientation, ratio of fast-twitch to slow-twitch 
fibres, body weight, and body mass index.87, 88 
A systematic review by Mijnarends et al. assessed the validity and reliability of tools to 
measure muscle mass, strength and performance in older people.47 The leg press and 




Another important measure of functional state is muscle power. Several studies have 
identified that this may be more relevant than muscle strength for many tasks of daily 
living.80, 89 Muscle power is strongly associated with gait speed, balance and functional 
status.80  
There are a number of methods to measure muscle power, most of which require 
specialised equipment. However, several clinical tests have been developed to measure 
muscle power. One example that has been validated in the elderly population is the stair 
climb test.90 This involves measuring the time a subject takes to ascend 10 stairs. 
1.3.3.3 Physical performance 
There are several validated tools available for the assessment of physical performance in 
the elderly population. The meta-analysis by Mijnarends et al. found that the tests with the 
highest validity and reliability are gait speed, the Short Physical Performance Battery, the 
sit-to-stand test and the six-minute walk distance.47 
Most working groups define a gait speed less than 0.8 to 1 m/s as consistent with 
sarcopenia. There are several protocols published to assess gait speed. The most widely 
used is the six-minute walk distance, which is a submaximal test of exercise capacity.91 
When used with a standardised protocol the test is reliable across a number of different 
populations.92  
Gait speed is also assessed as a component of the Short Physical Performance Battery. 
Guralnik et al. developed the Short Physical Performance Battery as a battery of physical 
performance tests to objectively assess lower extremity function.93 It is comprised of three 
elements: 
1. Balance test – ability to hold three positions for 10 seconds 
2. Gait speed test – gait speed over four metres 
3. Chair stand test – time to complete five chair rises 
Reference values were derived from a study of 5,000 persons aged 71 years and older in 
three communities.93 The Short Physical Performance Battery has also been used to 
assess functional impairment and frailty in patients with cirrhosis, chronic kidney disease 
and advanced cancer.94, 95 
The sit-to-stand test was developed by Jones et al. to provide a reliable and valid field test 
to assess lower limb strength and physical performance.96 Subsequently Smith et al. 
24 
 
utilised anthropometric measures (body mass, femur length) to develop an equation to 
estimate lower limb power using the sit-to-stand test.97 
1.3.4 Sarcopenia in cirrhosis 
Cirrhosis is associated with complex changes in body compartments, one of which is loss 
of skeletal muscle mass cell mass and/or quality.17 These disturbances are consistently 
found to be proportional to the severity of cirrhosis.17, 98 Peng et al. showed that the mean 
protein index measured by neutron activation analysis was significantly lower in Child-
Pugh C patients than Child-Pugh B (P = 0.0002) and Child-Pugh A (P = 0.0001) patients.98 
Consistent with the general population, there were age- and sex-specific differences in 
patients with cirrhosis. 
The prevalence, pathogenesis and prognostic implications of sarcopenia in patients with 
cirrhosis will now be explored. 
1.3.4.1 Prevalence of sarcopenia 
There are no published studies in patients with cirrhosis using the complete EWGSOP 
definition of sarcopenia. However, several studies have examined the prevalence of 
deficiencies in the respective components included in the definition.20, 99-101  
It is important to note that the prevalence figures for sarcopenia in the different studies 
discussed below differ substantially due to differences in tests and thresholds employed to 
define impairment. 57 This makes it difficult to directly compare these publications with 
respect to clinical outcomes in patients with cirrhosis. 
1.3.4.1.1 Prevalence of skeletal muscle mass depletion 
Table 1-8 demonstrates the studies reporting the prevalence of skeletal muscle mass 
depletion according to the method of assessment and cut-offs used. As expected, there 
are sex-specific differences in prevalence, as well as proportional to the severity of liver 
disease. 
1.3.4.1.2 Prevalence of muscle weakness 
Prior publications have consistently shown a high prevalence of muscle weakness in 
patients with cirrhosis which is proportional to liver disease severity. Panzak et al. 
measured muscle strength using an isokinetic dynamometer in the upper and lower limbs. 
The results demonstrated that cirrhotic patients were significantly weaker than controls.102 
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Table 1-9 summarises the publications that have assessed muscle strength in cirrhosis 
patients undergoing liver transplantation. The most utilised measure of muscle strength in 
this population is handgrip strength. Figueiredo et al. identified that handgrip strength, 
when combined with mid-arm muscle circumference, was a sensitive predictor of body cell 
mass depletion.46 The same group also found reduced handgrip strength was associated 
with longer intensive care unit admission post-liver transplant.24 Subsequently Alvares-da-
Silva et al. demonstrated that reduced handgrip strength was associated with a significant 
increase in incidence of major complications of cirrhosis such as refractory ascites, 
spontaneous bacterial peritonitis, encephalopathy, variceal bleeding and hepatorenal 
syndrome.99 
1.3.4.1.3 Prevalence of physical performance impairment 
The prevalence of impaired physical performance also varies depending on the method of 
assessment [Table 1-10]. Lai et al. reported on a cohort of 294 cirrhosis patients listed for 
liver transplant and found the prevalence of impaired physical performance from the Short 
Physical Performance Battery was 31%.29 
The six-minute walk distance has been measured in several cohorts with cirrhosis. 
However, no prevalence figures for poor physical performance have been reported due to 
lack of an accepted cut-off for defining impairment. Lai et al. did show that ‘frail’ cirrhosis 
patients had a significantly lower six-minute walk distance (231m vs 338m; P < 0.001) 




Table 1-8. Prevalence of skeletal muscle mass depletion in cirrhosis. 
Author Year Patients Population Method Threshold Prevalence 
Anthropometry 
Lolli et al.104 1992 135 M  65 F Cirrhosis - mixed TSF; MAC <5
th percentile reference M 5-45% F 10-30% 
Akerman et al.105 1993 104 Cirrhosis – mixed TSF; MAC <5th percentile reference 45% 
Loguercio et al.106 1996 97 M  87 F Cirrhosis - mixed TSF; MAC 50-30% of control group 
CP A 8% 
CP B/C 26% 
Merli et al.107 1996 635 M 400 F Cirrhosis - mixed TSF; MAMA <5
th percentile reference M 38%  F 8% 
Caregaro et al.108 1996 82 M 38 F Cirrhosis – ALD & Viral TSF; MAMC <5
th percentile reference M 34% F 8% 
Sarin et al.109 1997 111 M Cirrhosis – ALD & non-ALD  TSF; MAMC <1 SD of the healthy control group 
Non-ALD 
68% 
ALD 54%  
Pirlich et al.110 2000 27 M 14 F Cirrhosis TSF; MAMA <25
th percentile reference 68.3% 
Alberino et al.111 2001 143 M 69 F Cirrhosis - inpatient TSF; MAMC <5
th percentile reference 
CP A 13% 
CP B 35% 
CP C 46% 
Roongpisuthipong et al.112 2001 33 M 27 F 
Cirrhosis – ALD & non-
ALD TSF <10
th percentile reference 38% 
Riggio et al.113 2003 50 M 24 F Cirrhosis - mixed TSF; MAMA <5
th percentile reference M 50% F 30% 
Guglielmi et al.114 2005 227 M 107 F Cirrhosis - mixed TSF; MAMA <5
th percentile reference 
CP A 16% 
CP B 25% 
CP C 44% 
Campillo et al.115 2006 580 M 295 F Cirrhosis - mixed TSF; MAMC <5
th percentile reference 
CP A 20% 
CP B 28% 
CP C 32% 
Carvalho et al.116 2006 226 M 74 F 
Cirrhosis – ALD & non-
ALD TSF; MAMC PCM score <80% 
M 37% 
F 42% 
Panagaria et al.117 2006 81 M Cirrhosis – ALD & non-ALD TSF; MAMA <5
th percentile reference M 86% 
Tai et al.118 2010 24 M 12 F 
Cirrhosis -
decompensated  TSF; MAMC <5
th percentile reference 50% 
de Carvalho et al.119 2010 41 M 15 F Cirrhosis – mixed MAMC/Albumin PCM score <80% 24% 
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Bioelectrical impedance analysis 
Lautz et al.120 1992 65 M 58 F Cirrhosis – mixed Single frequency BIA BCM <35% body weight 43% 
Selberg et al.121 1997 76 M 74 F Cirrhosis – mixed Single frequency BIA BCM <35% body weight 44% 
Kaido et al.51 2013 192 Cirrhosis – mixed Multi-frequency BIA SMM <90% of standard 24% 
Ruiz-Margain et al.122 2015 249 Cirrhosis – mixed BIA phase angle PhA <4.9° CP A 37% CP B/C 71% 
Maharshi et al.123 2015 201 M 46 F Cirrhosis - mixed Single frequency BIA <80% of ‘multi-compartment score’ 
CP A 37%  
CP B 64% 
CP C 80% 
Schutte et al.124 2015 44 M 7 F 
Cirrhosis (mixed) with 
HCC Single frequency BIA Not specified – ‘low BCM’ 24% 
Koo et al.125 2017 52 M 71 F 
NASH vs NAFLD vs 
control Multi-frequency BIA ASM/Wt <29% M & <22.9% F 35% NASH 
Petta et al.126  2017 141 M 84 F NAFLD Single frequency BIA ASM/Wt <37% M & < 28 F 44% 
Dual energy X-ray absorptiometry 
Figueiredo et al.24 2000 42 M 27 F Cirrhosis – mixed DXA, TBW, ECW BCM <sex-specific lowest quartile 26% 
Figueiredo et al.127 2006 52 M 27 F Cirrhosis - mixed DXA, TBW, ECW BCM/TBF <80% controls 
CP A 34% 
CP B 69% 
CP C 94% 
Giusto et al.128 2015 46 M 9 F Cirrhosis - mixed DXA ASMI M <7.26 kg/m²; F <5.45 kg/m²  
M 48% 
F 23% 
Augusti et al.129 2016 30 M 24 F Cirrhosis – mixed DXA ASMI M <7.26 kg/m²; F <5.45 kg/m²  
M 17% 
F 17% 
Belarmino et al.101 2017 129 M Cirrhosis – mixed  DXA ASMI + HGS DXA <7.26 kg/m2; HGS <30 kg 24% 




Montano-Loza et al.131 2012 78 M  34 F Cirrhosis – mixed CT SMI [L3 level] M <52.4cm
2/m2; F <38.5 cm2/m2 M 50% F 18% 
Tandon et al.20 2012 85 M  57 F Cirrhosis – mixed CT SMI [L3 level] M <52.4cm
2/m2; F <38.5 cm2/m2 M 54% F 21% 
Meza-Junco et al.132 2013 83 M  15 F Cirrhosis (mixed) & HCC CT SMI [L3 level] 
M <43cm2/m2; F <41cm2/m2 [BMI <25] 





Cruz et al.133  2013 157 M  77 F Cirrhosis - mixed CT SMI [L3/L4 disc] M <52.4cm
2/m2; F <38.5 cm2/m2 M 76% F 50% 
DiMartini et al.134 2013 223 M  115 F Cirrhosis – mixed CT SMI [L3/L4 disc] M <52.4cm
2/m2; F <38.5 cm2/m2 M 76%  F 51% 
Masuda et al.135 2014 103 M  101 F Cirrhosis - mixed CT PMA [L3 level] M <800cm
2; F <380cm2 M 47%  F 36% 
Hanai et al.136 2015 76 M  54 F Cirrhosis - mixed CT SMI [L3 level] M <52.4cm
2/m2; F <38.5 cm2/m2 M 82%  F 50% 
Montano-Loza et al.137  2016 457 M  221 F Cirrhosis - mixed CT SMI [L3 level] 
M <43cm2/m2; F <41cm2/m2 [BMI <25] 
M <53cm2/m2; F <41cm2/m2 [BMI ≥25] 
M 21%  
F 27% 
Sinclair et al.138 2016 145 M Cirrhosis - mixed CT SMI [L4 level] M <52.4 cm2/m2 M 70% 
Tandon et al.139 2016 89 M  70 F Cirrhosis - mixed CT SMI [L3 level] M <52.4 cm
2/m2; F <38.5 cm2/m2 M 57%  F 26% 
Hiraoka et al.140 2016 684 M  304 F Cirrhosis - mixed CT PMI [mid-L3 level] <2 SD of sex-specific controls 
CP A 24% 
CP B 38% 
CP C 37% 
Carey et al.141  2017 277 M  119 F Cirrhosis - mixed CT SMI [L3 level] M <50 cm
2/m2; F <39 cm2/m2 M 50% F 33% 
Begini et al.142 2017 65 M  27 F Cirrhosis (mixed) & HCC CT SMI [L3 level] 
M <43cm2/m2; F <41cm2/m2 [BMI <25] 
M <53cm2/m2; F <41cm2/m2 [BMI ≥25] 
M 54%  
F 46% 
Nardelli et al.143 2017 34 M  12 F Cirrhosis - mixed CT SMI [L3 level] M <52.4cm
2/m2; F <38.5 cm2/m2 57% 
Total body potassium 
Crawford et al.17 1994 23 M  34 F Cirrhosis - mixed 
Total body potassium 
index TBK Index <90% 60% 
In-vivo neutron activation analysis 
Peng et al.98 2007 179 M  98 F Cirrhosis - mixed Total body protein Protein index <0.82 
M 63%;  
F 28% 
Abbreviations: ALD – Alcoholic liver disease; ASMI – Appendicular skeletal muscle index; BCM – Body cell mass; BIA – Bioelectrical impedance analysis; CP – Child-Pugh; CT- Computed 
tomography; DXA – Dual energy X-ray absorptiometry; ECW - Extracellular water; F – Female; HGS – Handgrip strength; LTx – Liver transplant; M – Male; MAC – Mid-arm circumference; 
MAMA - Mid-arm muscle area; MAMC – Mid-arm muscle circumference; PCM – Protein calorie malnutrition; PhA – Phase angle; PNI- Protein nutritional index; SD – Standard deviations; SGA – 
Subjective global assessment; SMI – Skeletal muscle index; TBF - Total body fat; TBW – Total body water; TSF – Triceps skin fold 
 
Literature Search Method: PubMed, Medline and Web of Science were examined from study development until August 2017 with the search limited to the English language. The search term 
used was: (“sarcopenia” OR “malnutrition” OR “muscle loss”) AND (“cirrhosis” OR “chronic liver disease” OR “end-stage liver disease”). Reference lists of retrieved articles were examined to 
locate additional studies that potentially met the inclusion criteria. 
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Table 1-9. Published studies of muscle strength in pre-liver transplant patients. 
Author Year Population Tests Results Outcomes 
Panzak et al.102 1998 
Non-ALD (n=42) vs 
ALD (n=33) vs  
Control (n=31) 
IMS upper/lower limb 
(Nm) 
Significant reduction in strength CLD 
vs controls Not assessed 
Beyer et al.144 1999 
Cirrhosis (mixed)  
23 M; 15 F 
Pre- & Post-LTx 
IMS lower limb (Nm) 
Time-to-transfer (s) 
Time for 3 squats (s) 
6MWD (m) 
Significant improvement in strength, 
6MWD, squats, TT at 6 months post-
LTx 
Not assessed 
Figueiredo et al.46 2000 
Cirrhosis (mixed) 




HGS 53-66% of normal adjusted for 
height, age & sex Not assessed 
Figueiredo et al.24 2000 
Cirrhosis (mixed) 
31 M; 22 F 
Pre-LTx 
HGS (kg) 
 Mean not reported 
Longer ICU stay associated 
with lower HGS (P<0.01) 
Wiesinger et al.145 2001 
Cirrhosis (mixed) 
n=26 (M:F not reported) 
Pre-LTx 
IMS knee (Nm) 
HGS (kg) 
Significant reduction in Knee 





Cirrhosis (30 M; 20 F) 
Hypertensive controls (n= 46) 
Functional GI controls (n=49) 
HGS (kg)  
Reduced HGS (63%) vs controls 
(4%) 
Reduced HGS predicts 
major complications 
Pieber et al.146 2006 
Cirrhosis (mixed) 
10 M; 5 F 
Pre- & Post-LTx 
IMS knee (Nm) 
HGS (kg) 
No difference muscle strength before 
and 1-2 months post-LTx 
Does not predict 
complications 
Huisman et al.100 2011 Cirrhosis (mixed) 56 M; 28 F 
HGS (kg) 
Pinch Strength (N) HGS – 67% ‘malnourished’ 
HGS associated with 
increased risk HE, SBP, 
HRS 
Lai et al.29  2014 
Cirrhosis (mixed) 
194 M; 100 F 
Pre-LTx 
HGS (kg) Median 32 kg (IQR 23-39) Does not predict mortality 
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Mizuno et al.147 2016 Cirrhosis (mixed) 
6 M; 6 F 
Pre- & Post-LTx (1 month) 
IMS knee (kg) 
HGS (kg) 
Mean IMS knee 19.1 ± 5.4kg pre-LTx 
vs 13.5 ± 5.8 post-LTx 
Mean HGS 21.4 +/- 5.4 pre-LTx vs 
17.3 ± 5.9kg post-LTx 
Does not predict outcomes 
Wang et al.23 2016 Cirrhosis (mixed) 
193 M; 99 F  
Pre-LTx HGS (kg) 
Median 31 (IQR 23-39) 
Weak HGS 30% 
Predictor of waitlist mortality 
(multivariate analysis) 
HR 0.74 (95%CI 0.59-0.92) 
Lai et al.26 2017 Cirrhosis (mixed) 
316 M; 220 F 
Pre-LTx HGS (kg) Median 28 (IQR 21-37) 
Associated with mortality 
(univariate) 
HR 0.95 (95%CI 0.93-0.97) 
Sinclair et al.148 2017 
Cirrhosis (mixed) 
376 M; 211 F 
Pre-LTx 
HGS (kg) 
Median 28 kg (IQR 22-35) 
hospitalised 
Median 33 kg (IQR 25-41) non-
hospitalised 
Lower HGS in patients 
hospitalised within 12 
months (P<0.001) 
6MWD – Six-minute walk distance; ALD - Alcoholic liver disease; BMI - Body mass index; CI – Confidence interval; CLD – Chronic liver disease; CP – Child-Pugh score; HE – Hepatic 
encephalopathy; HGS – Handgrip strength; HRS – Hepatorenal syndrome; IMS - Isokinetic muscle strength; LTx – Liver transplant; PNI – Protein nutritional index; SBP – 
Spontaneous bacterial peritonitis; TT – Time to transfer 
Literature Search Method: PubMed, Medline and Web of Science were examined from study development until August 2017 with the search limited to the English language and adult 
patients. The search term used was: (“malnutrition” OR “muscle strength” OR “handgrip strength”) AND (“cirrhosis” OR “chronic liver disease” OR “end-stage liver disease”). Reference 




Table 1-10. Published studies of physical performance in pre-liver transplant patients. 
Author Year Population Tests Results Outcomes 
Beyer et al.144 1999 
Cirrhosis (mixed) 
23 M; 15 F 
Pre- & Post-LTx 
6MWD (m) 
Squat Time (sec) 
Transfer Time (sec) 
Mean 462 ± 25.5 m 
Mean 2.7 ± 0.35 sec 
Mean 5.5 ± 0.46 sec 
Not assessed 
Carey et al.21 2010 
Cirrhosis (mixed) 
77 M; 44 F 
Pre-LTx 
6MWD (m) Mean 369 +/- 122 Predictor of mortality HR 0.58 (95%CI 0.37-0.93) 
Lai et al.29 2014 
Cirrhosis (mixed) 
194 M; 100 F 
Pre-LTx 
SPPB Median SPPB score 11 (IQR 9-12) 31% ‘Impaired’ SPPB (score <9) 




Cirrhosis CP C (mixed) 
n=5 (M:F not reported) 3-minute Step Test 
Peak VO2 & anaerobic threshold 
similar to standard CPET Not assessed 
Yadav et al.150 2015 Cirrhosis (mixed) 129 M; 84 F 6MWD (m) 
Mean 371 ± 121 m 
8.5% M; 17% F <250 m 
6MWD <250 m associated 
with higher mortality (P<0.001) 
VanWagner et 
al.151 2016 
Chronic Liver Disease 
(32% cirrhosis - mixed) 
34 M; 28 F 
Pre-LTx vs Post-LTx vs control 
6MWD (m) Post-LTx 6MWD worse compared to CLD & control groups Not assessed 
Wang et al.23 2016 
Cirrhosis (mixed) 
193 M; 99 F 
Pre-LTx 
SPPB Median SPPB score 11 32% ‘impaired’ SPPB (score <9) 
Predictor of mortality (HR 0.89 
95%CI 0.82-0.97) 
Dunn et al.152 2016 
Cirrhosis (mixed) 
n=53 (M:F not reported) 
Pre-LTx 
Physical activity (METs) 
using SenseWear monitor 
Mean % sedentary time = 75.9% 
(reference 62%) 
% sedentary behaviour 
associated with mortality 
(P=0.004) 
Mizuno et al.147 2016 
Cirrhosis (mixed) 
6 M; 6 F 
Pre- & Post-LTx (1 month) 
6MWD (m) Mean 366 ± 141 m pre-LTX Mean 341 ± 140 m post-LTx 
6MWD negatively correlated 
with postoperative days of first 
walking (r = -0.593; P=0.042) 
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Lai et al.26 2017 
Cirrhosis (mixed) 





Median 0.4 chair stands/sec 
Median 1.2 m/s 
Median balance time 30 sec 
Gait speed, chair stands/sec & 
balance time predictors of 
mortality (univariate) 
Sinclair et al.148 2017 
Cirrhosis (mixed) 
376 M; 211 F 
Pre-LTx 
SPPB Median 11 (9-12) hospitalised Median 11 (10-12) non-hospitalised 
Lower SPPB score (and gait 
speed/chair stands/sec) in 
patients hospitalised within 12 
months (P<0.001) 
6MWD – Six-minute walk distance; ALD - Alcoholic liver disease; BMI - Body mass index; CI – Confidence interval; CLD – Chronic liver disease; CP – Child-Pugh score; HE – Hepatic 
encephalopathy; HGS – Handgrip strength; HRS – Hepatorenal syndrome; IMS - Isokinetic muscle strength; LTx – Liver transplant; METs - Metabolic equivalents of tasks; PNI – 
Protein nutritional index; SBP – Spontaneous bacterial peritonitis; TT – Time to transfer 
Literature Search Method: PubMed, Medline and Web of Science were examined from study development until August 2017 with the search limited to the English language. The 
search term used was: (“physical performance” OR “exercise capacity” OR “functional capacity”) AND (“cirrhosis” OR “chronic liver disease” OR “end-stage liver disease”) AND (“liver 
transplant”). Trials measuring cardiorespiratory fitness and frailty were not included. Reference lists of retrieved articles were examined to locate additional studies that potentially met 





1.3.4.2 Pathogenesis of sarcopenia in cirrhosis 
In patients with cirrhosis, the pathogenesis of sarcopenia is multifactorial, with several 
mechanisms leading to an imbalance between muscle anabolism and muscle 
catabolism.153 An overview of the aetiology of sarcopenia in cirrhosis is shown in Figure 
1-5.  
 
Figure 1-5. Aetiology of sarcopenia in patients with cirrhosis154 
Malnutrition plays a significant role in the development of sarcopenia in cirrhosis. Several 
factors have been reported to contribute to malnutrition, including hypermetabolism, 
malabsorption, anorexia, and altered macronutrient metabolism.153 Studies have shown 
that between 15-30% of cirrhotic patients have increased resting energy expenditure 
(hypermetabolism).98, 155 Malabsorption has also been described as an important factor. 
Patients with cirrhosis have impaired intestinal absorption of nutrients due to portosystemic 
shunting, altered intestinal motility and bile acid deficiency.18 Anorexia is a common issue 
in cirrhotic patients which impairs caloric intake. The causes include physical symptoms, 
early satiety due to ascites, hormonal alterations and taste disturbance.18 
Activation of the ubiquitin–proteasome pathway has also been identified as an important 
factor in the development of sarcopenia in cirrhosis.154, 156 The ubiquitin–proteasome 
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pathway is a major proteolytic pathway which involves protein conjugation with ubiquitin 
and then subsequent degradation by the 26S proteasome.154 Both inactivity and systemic 
inflammation activate the ubiquitin–proteasome pathway. Patients with cirrhosis have a 
pro-inflammatory state, with elevated levels of tumour necrosis factor-α, interleukin-6 and 
interleukin-1.157 Animal models have found a strong correlation between tumour necrosis 
factor-α and muscle ubiquitin levels, suggesting activation of the ubiquitin–proteasome 
pathway.156  
End stage liver disease patients have a disturbance in metabolism, characterised by an 
increased rate of gluconeogenesis and protein catabolism, with reduced glycogenolysis.158 
Owen et al. found that a key factor was diminished hepatic glycogen content, likely as a 
consequence of extensive hepatic fibrosis.159 With overnight fasting, hepatic glucose 
production was reduced due to low rates of glycogenolysis. As a consequence, hepatic 
gluconeogenesis and ketogenesis are increased leading to muscle catabolism.159  
Another mechanism of muscle loss in cirrhosis patients is a disturbance in several major 
muscle growth regulatory proteins, including myostatin, testosterone and insulin-like 
growth factor-1. Myostatin is a potent inhibitor of muscle protein synthesis and satellite cell 
function. Garcia et al. showed that serum levels of myostatin in patients with cirrhosis are 
higher than controls.160 At the molecular level, Tsien et al. demonstrated an increase in 
myostatin expression in muscle biopsy samples from patients with compensated 
cirrhosis.161 The aetiology of raised myostatin in cirrhosis is uncertain, although some 
authors have proposed elevated serum ammonia as a mechanism.162 Qiu et al. 
demonstrated that in murine model, administration of ammonia stimulated myostatin 
expression.162  
Both insulin-like growth factor-1 and testosterone act to supress myostatin expression. 
Patients with end-stage cirrhosis also have deficiencies of insulin-like growth factor-1 and 
testosterone which may contribute towards the development and progression of 
sarcopenia.20, 163, 164 Prior studies have suggested that due to disturbances in the 
hypothalamic-pituitary-testicular axis, up to 90% of cirrhotic patients have testosterone 
deficiency.165, 166 
1.3.4.3 Prognostic significance of sarcopenia 
The impact of skeletal muscle impairment on clinical outcomes in cirrhosis has been 
evaluated using a diverse range of methods and has long been recognised as an 
important complication of cirrhosis.99, 100, 167 A comprehensive review of the prognostic 
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significance of sarcopenia will be performed in Section 1.7.1 in the context of liver 
transplantation. 
1.4 Frailty 
Another important concept related to sarcopenia is that of frailty. Frailty is defined as ‘a 
medical syndrome with multiple causes and contributors that is characterized by 
diminished strength, endurance, and reduced physiologic function that increases an 
individual’s vulnerability for developing increased dependency and/or death’.168 Multiple 
frailty assessment tools have been developed, with most using the five core phenotypic 
domains of frailty: slow walking speed, weakness, inactivity, exhaustion and weight loss 
[Table 1-11].168, 169 















Physical frailty phenotype  Yes Yes  No  No  Yes  No  
Deficit accumulation index  Yes No  Yes  Yes  No  Yes  
Gill frailty measure  Yes  No  No  No  No  No  
Frailty/Vigor assessment  Yes Yes  Yes  No  No  Yes  
Clinical frailty scale  Yes  Yes  No  Yes  No  Yes  
Brief frailty instrument  Yes No  Yes  Yes  No  No  
Vulnerable elders survey  Yes No  No  No  No  Yes  
FRAIL scale  Yes  No  No  Yes  Yes  No  
Winograd screening 
instrument  Yes No  Yes  Yes  No  Yes  
Frailty is highly prevalent in the elderly and is associated with increased risk for adverse 
health outcomes, including institutionalization, falls, hospitalisation and death.170, 171 It has 
been recommended that physicians perform frailty screening on all patients over the age 
of 70, and those with significant weight loss (≥5%) due to chronic disease.168 Individuals 
with chronic diseases such as cirrhosis and heart failure can develop frailty at an early 
age.168 
The most widely used measure of frailty is the Fried Frailty Index.169 This Index combines 
an assessment of frailty across the five physical domains above. Table 1-12 outlines the 
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cut-offs used to define impairment in each of these domains. A score of ≥3 is used to 
define frailty and is associated with mortality and morbidity in patients with cirrhosis.29, 148  
Table 1-12. Fried Frailty Index components172 
Component Threshold 
Weight loss 10 lbs (4.5 kg) lost unintentionally in prior year 
Weakness Grip strength: lowest 20% by gender, body mass index 
Exhaustion Self-reported 
Walking time (15 ft/4.5m) Slowest 20% by gender, height 
Kcals/week lowest 20% [males 383 Kcals/week; females 270 Kcals/week] 
 
Lai et al. were one of the first to explore the prevalence of frailty and its impact on 
outcomes. In this study, frailty was defined as a Fried Frailty Index ≥3 and found a 
prevalence of 17% in 294 cirrhosis patients listed for liver transplant. The risk of mortality 
was significantly higher in those classified as frail (HR 1.45; 95%CI 1.04–2.02; P = 0.03).29 
Thus, each 1-point increase in the Fried Frailty score was associated with a 45% increase 
risk of liver transplant waitlist mortality (P = 0.01).29 Sinclair et al. found that the Fried 
Frailty score was an independent predictor of hospitalisation (HR 1.21; 95%CI 1.02-1.44; P 
= 0.03) for patients on the liver transplant waiting list.148 
However, applying this Index to patients with cirrhosis is difficult since weight is 
confounded by fluid retention and exhaustion is a common symptom of cirrhosis. Given 
these limitations, Lai et al. sought to determine if objective measures of physical 
performance were associated with frailty and thus could be used as an alternative for 
frailty evaluation in cirrhosis patients. They found that in cirrhosis patients, five tests of 
physical performance (six-minute walk distance, sit-to-stand test, isometric knee 
extension, unipedal stance time and maximal step length) were independently associated 
with physical frailty (as defined by the Fried Frailty Index).103 
Using this principle, a novel frailty index was developed based on handgrip strength, chair 
stands (30 second sit-to-stand test) and balance (ability to balance in three positions for 10 
seconds each.26 The proposed Frailty Index was: 
Frailty Index = (-0.330 * gender-adjusted grip strength) + (-2.529 * number of chair 
stands per second) + (-0.040 * balance time) + 6  
This Frailty Index was found to enhance risk prediction for liver transplant waitlist mortality 




1.5 Cardiorespiratory fitness 
Cardiorespiratory fitness relates to the ability of an individual to transport oxygen from the 
atmosphere to the mitochondria in order to perform physical work.173 It provides an 
objective measurement of the functional capacity of an individual and has been shown to 
be an independent predictor of mortality and adverse outcome across a broad range of 
populations.173 
The cardiopulmonary exercise test is considered the gold standard for measurement of 
cardiorespiratory fitness. It provides ‘a global assessment of the integrative exercise 
response involving the pulmonary, cardiovascular, hematopoietic, neuropsychologic, and 
skeletal muscle systems that is not adequately reﬂected through the measurement of 
individual organ system function’.174 The cardiopulmonary exercise test can provide an 
estimate of cardiorespiratory fitness via maximal oxygen uptake (V̇O2max) or submaximal 
measurements such as the ventilatory threshold. 
The impact of cardiorespiratory fitness on transplant free survival has been evaluated in a 
large King’s College study.22 Bernal et al. found that ventilatory threshold was an 
independent predictor of reduced one-year transplant-free survival (HR 0.90; 95%CI 0.83-
0.98); P = 0.02).22 
Further discussion on the impact of cardiorespiratory fitness on liver transplantation 
outcomes will be covered in Section 1.7.1.4 below. 
1.6 Management of decompensated cirrhosis 
Once patients progress to decompensated cirrhosis, they develop a systemic disease, with 
multi-organ dysfunction and a poor prognosis [see Section 1.1.4].  
The management of decompensated cirrhosis involves two approaches. Firstly, the 
underlying aetiological factor(s) should be addressed if possible. For example, studies 
have shown that patients with alcoholic liver disease can have significant improvement in 
liver function with abstinence, and in some cases “re-compensation”.175 Similarly, 
treatment of chronic hepatitis B and chronic hepatitis C can result in improvement in liver 
function in some patients.176, 177 The effect of addressing the underlying aetiology in other 
liver diseases is less clear.178  
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The second approach involves evidence-based management of decompensated cirrhosis 
complications. Further discussion of the optimal management of these complications is 
beyond the scope of this review. A summary can be found in the European Association for 
the Study of the Liver Clinical Practice Guidelines for the management of patients with 
decompensated cirrhosis.178 
One complication of cirrhosis that does warrant further discussion is the management of 
sarcopenia. Several therapies have been explored, including dietary, exercise and 
hormonal interventions.  
Given undernutrition is a common cause of sarcopenia in cirrhosis, it would seem logical 
that dietary interventions are likely to improve outcomes. However, a Cochrane review of 
nutritional support for liver disease concluded there was insufficient evidence to support 
the routine use of nutritional interventions in patients with liver disease.179 The reviewers 
considered all but one of the 37 trials identified were at high risk of bias.179  
It has been highlighted in Section 1.3.1 that patients with cirrhosis rapidly switch to 
gluconeogenesis for energy supplies with short periods of fasting. Thus, the introduction of 
a late-evening protein snack has been recommended by several organisations. A meta-
analysis by Tsein et al. reviewed substrate utilisation studies and concluded that the 
published studies suggest that a late-evening snack reverses this early utilisation of 
gluconeogenesis lipids as a source of energy.180 Review of longer term clinical studies 
identified only one randomised controlled trial by Plank et al., which demonstrated that a 
late-evening snack (Ensure Plus/Diabetic Resource) improved total body protein and fat-
free mass over a 12-month period.181 Other non-randomised trials have had conflicting 
results.180  
Another therapy which theoretically should improve most aspects of sarcopenia is exercise 
therapy. There is moderate quality evidence that exercise interventions improve muscle 
strength and physical performance in the elderly.182 However, the impact on patients with 
cirrhosis is relatively unexplored. This is largely due to concerns raised in 1996 regarding 
the safety of exercise therapy in patients with cirrhosis and portal hypertension.183 A study 
by Zenith et al. in 2014 began to re-explore this therapeutic option.55 They performed a 
randomised controlled trial of aerobic exercise therapy in patients with compensated 
cirrhosis and found it was not associated with any adverse events.55 Further studies are 




Several potential pharmacological interventions for sarcopenia are also under evaluation. 
One such therapy is testosterone replacement in male patients. Sinclair et al. conducted a 
randomised control trial of intramuscular testosterone replacement and found a significant 
improvement in appendicular lean mass and bone mineral density compared to placebo.184 
Larger scale studies are required to evaluate the impact of testosterone replacement on 
transplant-free mortality, as well as liver transplant outcomes. 
Other therapeutic options that have been proposed for future studies include myostatin 
antagonists, leucine and insulin-like growth factor-1 supplementation. Further review of 
these therapies can be found elsewhere.153, 154 
Whilst therapies addressing the complications of cirrhosis can improve outcomes, these 
patients still experience a limited survival. In patients with no improvement in liver function 
with treatment of the underlying aetiology, liver transplantation can significantly improve 
outcomes.  
1.7 Liver transplant 
Liver transplantation was introduced as a treatment for end-stage liver disease in the 
1960s by Thomas Starzl, and is now performed routinely worldwide. Survival has improved 
significantly from a 30% one-year survival in the 1970s to around 90% one-year survival 
today.1, 185 Several factors have contributed to the improvement in survival including 
refinements in operative technique; organ procurement and preservation; and advances in 
immunosuppressive therapy, patient selection and stratification.185 
Early results of liver transplantation for patients with unresectable hepatocellular 
carcinoma (HCC) were unfavourable. However in 1996, Mazzaferro et al. established that 
deceased-donor liver transplantation was a viable option for the treatment of early HCC.186 
Patients transplanted using the Milan criteria (three lesions < 3 cm or single lesion < 5 cm) 
developed by Mazzaferro et al. have similar survival rates to patients transplanted for end-
stage liver disease.187  
In Australia, orthotopic liver transplantation started in January 1985 with the Queensland 
Liver Transplant Service, pioneered by Professor Russell Strong. Subsequently, other 
state-based services were established. Nationwide, approximately 270 transplants take 
place per year.188 As at the start of 2015, the overall one-year survival rate was 
approximately 94%, with a median survival of approximately 20 years.188  
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From 2010 to 2015, the Queensland Liver Transplant Service has performed between 27 
and 46 adult liver transplants per annum. In 2015, 45% of liver transplant recipients had a 
diagnosis of chronic hepatitis C, while alcoholic liver disease was present in 29%. 
Approximately 34% had hepatocellular carcinoma as the indication for transplantation. 
Patients were predominately Caucasian (87%) and of male sex (76%).  
1.7.1 Predictors of outcomes in liver transplantation 
The gold standard for assessing the severity of end-stage cirrhosis and predicting waiting 
list mortality is the model for end-stage liver disease (MELD) score.189 It was introduced in 
the United States of America in 2002 to allocate deceased donor organ livers for 
transplantation. Its introduction has resulted in a decrease in median waiting time to 
transplant and the number of deaths on the liver transplant waiting list.190, 191 
However, it has been demonstrated that the predictive accuracy of MELD is reduced 
towards the lower end of scores (MELD score ≤14).192 In these patients, other variables 
such as the hepatic venous pressure gradient (HVPG), and serum sodium have been 
shown to be independent predictors of mortality.193, 194 Routine assessment of portal 
pressures with HVPG is not practical since it requires an invasive procedure. However, the 
incorporation of serum sodium in the MELD (MELD-Na) improves predictive accuracy.195 
Despite these improvements, further prognostic factors are required to risk stratify patients 
on the waiting list for liver transplant. 
Predictors of post-transplant outcomes can be broadly classified as recipient variables and 
donor variables. Burroughs et al. used a large European database to analyse predictors of 
post-liver transplantation mortality. They found that increased 3-month mortality was 
associated with acute liver failure (adjusted odds ratio [OR] 1.61), donor age >60 years 
(OR 1.16), incompatible donor-recipient blood group (OR 2.07), older recipient age (OR 
1.12 per 5 years), split or reduced graft (OR 1.96) and total ischaemia time > 13 hours (OR 
1.38). In addition, several variables were associated with improved early outcomes 
including recipients with a diagnosis of hepatocellular carcinoma, alcoholic liver disease, 
chronic hepatitis C or primary biliary cholangitis, donor age < 40 years, and larger size of 
the transplant centre (>70 per annum).196  
In other studies, several intraoperative variables have been shown to predict post-liver 
transplant outcomes including operation time; blood product use >15 units; cold ischaemic 
time >13 hours; and donation after circulatory death.197, 198  
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Establishing other independent predictors of post-transplant adverse events is important 
for improving current risk stratification models, and potentially identify patients for 
interventions. Prior literature has identified several variables which have encouraging 
preliminary data as predictors of adverse liver transplant outcomes and warrant further 
evaluation. These include sarcopenia, frailty, cardiorespiratory fitness and visceral adipose 
tissue. These risk factors will now be discussed in detail. 
1.7.1.1 Low skeletal muscle mass 
Low skeletal muscle mass defined objectively by anthropometry, computed tomography 
(CT) or dual energy X-ray absorptiometry (DXA) has consistently shown to have an impact 
on liver transplant morbidity and mortality [Table 1-13]. 
A large study by Alberino and colleagues used anthropometry to diagnose low skeletal 
muscle mass and found that patients below the 5th percentile had lower transplant-free 
survival rates.111 
The use of CT to diagnose low skeletal muscle mass has increased exponentially in the 
last five years.57 In 2012, Montano-Loza et al. measured the skeletal muscle area on a 
single transverse CT image and found a significant, independent risk of mortality with 
muscle wasting (HR 2.21; 95%CI 1.23-3.95; P = 0.008).131 Since then, multiple studies 
have been published showing a correlation between skeletal muscle area and survival, 
both before and after liver transplant.20, 133, 134, 199 A meta-analysis by van Vugt et al. found 
that skeletal muscle mass depletion measured on CT had a trend towards reduced 
survival for cirrhosis patients awaiting liver transplant (HR 1.72; 95%CI 0.99 – 3.00; P = 
0.05).20 If further validation studies confirm these findings, CT skeletal muscle assessment 





Table 1-13. Prognostic significance of skeletal muscle mass depletion in liver transplant patients 
Author Year Patients SMM assessment method Threshold Outcome 
Anthropometry 
Alberino et al.111 2001 143 M 69 F TSF; MAMC 
<5th percentile - severe 
<10th percentile - moderate 
Moderate-severe depletion associated with 
significantly lower survival at 6, 12 and 24 
months post-LTx (P<0.001) 
Bioelectrical Impedance Analysis 
Selberg et al.121 1997 76 M 74 F Single frequency BIA BCM <35% Body Weight 
“Trend” towards lower survival post-LTx 
(P=0.08) 
Kaido et al.51 2013 192 Multi-frequency BIA SMM <90% of standard Independently associated with post-LTx mortality HR 4.85 (95%CI 2.09-11.79) 
Dual Energy X-ray Absorptiometry 
Figueiredo et al.24 2000 31 M 22 F DXA, TBW, ECW 
LBM and BCM used as continuous 
variables 
Lower LBM associated with post-LTx ICU stay 
>4 days (P=0.05) 
BCM not associated with outcomes 
Giusto et al.128 2015 46 M 9 F 
MAMC 
DXA FFM Index 
CT SMI [L3 level] 
Variables assessed as continuous 
variables  
MAMC (HR 1.05; P<0.001) and DXA FFMI (HR 
1.12; P<0.001) associated with mortality on 
univariate analysis 
Lindqvist et al.130 2017 68 M 38 F DXA FFM Index 
FFM Index assessed as continuous 
variable 
DXA FFMI associated with independent risk of 
infection post-LTx (HR 0.67; 95%CI 0.45-0.99) 
Computed Tomography 
Montano-Loza et al.131 2012 78 M  34 F CT SMI [L3 level] M <52.4cm
2; F <38.5 cm2 ‘Sarcopenia’ independent risk for mortality pre-LTx (HR 2.21; CI not reported; P=0.008) 
Tandon et al.20 2012 85 M  57 F CT SMI [L3 level] M <52.4cm
2; F <38.5 cm2 
‘Sarcopenia’ independent predictor of pre-LTx 
mortality (HR 2.36, 95%CI 1.23-4.53) after 
adjustments for age and MELD scores. 
Meza-Junco et al.132 2013 83 M  15 F CT SMI [L3 level] 
M <43cm2/m2; F <41cm2/m2 [BMI <25] 
M <53cm2/m2; F <41cm2/m2 [BMI ≥25] 
‘Sarcopenia’ (HR 2.53; 95%CI 1.35-4.73; 
P=0.004) was independently associated with 
mortality pre-LTx 
Cruz et al.133  2013 157 M  77 F CT SMI [L3/L4 disc] 
CT SMI evaluated as continuous 
variable 
CT SMI independently associated with post-LTx 
survival (HR 0.97; 95%CI 0.94-0.99; P=0.04) 
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DiMartini et al.134 2013 223 M  115 F CT SMI [L3/L4 disc] 
CT SMI evaluated as continuous 
variable 
CT SMI independently associated with mortality 
post-LTX in males (HR 0.95 95%CI not 
reported) but NOT females (HR 0.98; P=0.55) 
CT SMI also a predictor of ICU length of stay, 
total length of stay, and days of intubation 
Durand et al.61 2014 455 M  107 F 
CT TPMT/height 
[Umbilicus] 
CT TPMT/height assessed as 
continuous variable 
TPMT/height independently associated with pre-
LTx mortality (HR 0.86; 95%CI 0.79–0.95; 
P=0.001) 
Masuda et al.135 2014 103 M  101 F CT PMA [L3 level] M <800cm
2; F <380cm2 
‘Sarcopenia’ was independent predictor of post-
LTx survival (HR 2.06 95%CI 1.01-4.20) and 
postoperative sepsis (HR 5.31 95%CI 1.53-
18.4) 
Montano-Loza et al.137  2016 457 M  221 F CT SMI [L3 level] 
M <43cm2/m2; F <41cm2/m2 [BMI <25] 
M <53cm2/m2; F <41cm2/m2 [BMI ≥25] 
‘Sarcopenia’ independently associated with 
transplant free survival (HR 2.00 95%CI 1.44–
2.77) 
Sinclair et al.138 2016 145 M CT SMI [L4 level] M <52.4 cm2/m2 
‘Sarcopenia’ NOT associated with pre-LTx 
mortality when assessed in multivariate model 
(HR 0.96 95%CI 0.92-1.01) 
Carey et al.141  2017 277 M  119 F CT SMI [L3 level] 
CT SMI evaluated as continuous 
variable 
SMI independently associated with waiting list 
mortality (HR, 0.95; 95%CI 0.93-0.98). 
Kalafateli et al.25 2017 162 M  70 F CT PMI [L3 level] 
CT PMI assessed as continuous 
variable 
PMI independently associated with 1-year post-
LTx mortality HR 0.996 95%CI 0.992–0.999). 
ALD – Alcoholic liver disease; ASMI – Appendicular skeletal muscle index; BCM – Body cell mass; BIA – Bioelectrical impedance analysis; CP – Child-Pugh; CT- Computed 
tomography; DXA – Dual energy X-ray absorptiometry; ECW - Extracellular water; F – Female; HGS – Handgrip strength; LTx – Liver transplant; M – Male; MAC – Mid-arm 
circumference; MAMA - Mid-arm muscle area; MAMC – Mid-arm muscle circumference; PCM – Protein calorie malnutrition; PhA – Phase angle; PNI- Protein nutritional index; SGA – 
Subjective global assessment; SMI – Skeletal muscle index; TBF - Total body fat; TBW – Total body water; TSF – Triceps skin fold 
 95% Confidence intervals not reported 
 
Literature Search Method: PubMed, Medline and Web of Science were examined from study development until August 2017 with the search limited to the English language. The 
search term used was: (“sarcopenia” OR “malnutrition” OR “muscle loss”) AND (“cirrhosis” OR “chronic liver disease” OR “end-stage liver disease”). Reference lists of retrieved articles 




The presence of depleted skeletal muscle mass has also been associated with increased 
morbidity and mortality post-liver transplant.62, 133, 134 Englesbe et al. found in a study of 
163 patients that peri-transplant reduced psoas muscle cross-sectional area on CT was 
associated with increased post-transplant mortality.62 Montano-Loza et al. used a different 
technique of assessing the total skeletal muscle area on cross-sectional imaging at the L3 
vertebral level. The authors found that low skeletal muscle area was associated with an 
increased risk of post-operative infections and length of stay, but not mortality.199 
Subsequent studies have also assessed the impact of muscle loss on post-transplant 
outcomes. On systematic review, depletion of skeletal muscle mass assessed on CT was 
associated with an increased risk of post-transplant mortality (HR 1.84; 95%CI 1.11–3.05; 
P = 0.02).57 
1.7.1.2 Muscle weakness 
Loss of muscle strength has predominately been defined in cirrhosis cohorts by using 
handgrip strength [Table 1-9 above]. Two of the largest studies using handgrip strength 
found muscle weakness was associated with an increased frequency of major cirrhosis 
complications including variceal haemorrhage, hepatic encephalopathy, ascites, SBP and 
HRS.99, 100 A larger study by Wang et al. involving 292 patients found an association of 
reduced handgrip strength with waiting list mortality (HR 0.74; 95%CI 0.59–0.92; P = 
0.008).23 
The impact of pre-transplant low muscle strength on post-transplant outcomes has also 
been assessed. In a study of 53 patients undergoing liver transplant, Figueiredo et al. 
found that low handgrip strength was associated with an intensive care unit stay greater 
than four days (P = 0.01).24 
1.7.1.3 Impaired physical performance 
Impaired physical performance is gaining recognition as an important prognostic factor in 
cirrhosis patients [Table 1-10 above]. Lai and colleagues found that mortality increased for 
each 1-unit decrease in the Short Physical Performance Battery (P < 0.001).29 Wang et al. 
also found impairment of the Short Physical Performance Battery was associated with 
waitlist mortality (HR 0.89; 95%CI 0.82-0.97; P = 0.01) in a large single centre study.23 
The six-minute walk distance has also demonstrated prognostic utility in patients with 
cirrhosis. Carey and colleagues found for every 100m reduction in the six-minute walk 
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distance, there was an increased risk of mortality (P < 0.001).21 A six-minute walk distance 
less than 250m was associated with an increased risk of waitlist death.21 
There is limited data on the impact of physical performance impairment on post-transplant 
outcomes. 
1.7.1.4 Impaired cardiorespiratory fitness 
Pre-transplant impairment in cardiorespiratory fitness has been associated with increased 
post-liver transplant morbidity and mortality.22, 200, 201 Prentis et al. evaluated the predictive 
value of cardiopulmonary exercise testing on 182 patients undergoing liver transplant.201 
They found that the mean ventilatory threshold was significantly different between 
survivors and non-survivors at 90 days post-transplantation (P < 0.001). Ventilatory 
threshold remained a significant predictor of mortality after multivariate logistic regression 
analysis (OR 3.84; 95%CI 1.17-12.58; P = 0.02).201 Additionally, they found that a 
ventilatory threshold <11ml/kg/min was associated with an increased length of critical care 
stay (P < 0.001). 
1.7.1.5 Obesity and visceral adipose tissue 
Prior studies have failed to demonstrate obesity as a risk for waiting list morbidity and 
mortality, with the exception of Class 3 (body mass index >40) obesity.202-204 However, 
post-transplant obesity is more prevalent than in the general population and is 
independently associated with post-transplant metabolic syndrome (PTMS) and 
cardiovascular disease.205, 206 Post-transplant cardiovascular disease is a significant 
problem, as highlighted by D'Avola et al. who found it was the fourth highest cause of 5-
year mortality in a large cohort of Spanish liver transplant recipients.206 Early diagnosis 
and intervention of cardio-metabolic risk factors post-transplant has been proposed to 
counteract the risk of cardiovascular disease.207 
To help predict post-transplant metabolic complications, some authors have examined pre-
transplant variables and found the presence of pre-transplant obesity to be a strong 
predictor of PTMS, along with diabetes and dyslipidaemia.208, 209 However, the prognostic 
utility of pre-transplant body composition to predict PTMS, such as excess visceral 
adipose tissue (VAT), is currently unknown. Prior studies have identified that as visceral 
adipose tissue increases, there is a progressive risk of derangement in metabolic risk 
factors.67, 68 This risk appears to increase significantly beyond a visceral adipose tissue 
surface area of 130cm2 (measured on CT).67, 68 Furthermore, the combination of high 
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visceral adipose tissue with low subcutaneous adipose tissue (SAT) has been proposed to 
be a more potent risk factor for the subsequent development of metabolic syndrome than 
increased visceral adipose tissue alone.210 
1.7.1.6 Sarcopenic obesity 
Post-liver transplantation body composition studies suggest that most patients experience 
an increase in fat mass and decline in skeletal muscle mass in the first 12 months.59, 211, 212 
Following an initial dramatic decline in both fat mass and skeletal muscle mass in the first 
30 days after liver transplantation, there is typically an increase in both compartments 
although this is more pronounced for fat mass.213, 214 This discordant change in fat mass 
and skeletal muscle mass is likely to increase the risk of developing ‘Sarcopenic Obesity’. 
Sarcopenic obesity is defined as the co-presence of both low skeletal muscle mass and 
excess fat mass, and has been linked with a higher risk of cardio-metabolic complications 
than obesity alone.215-218 It is hypothesised that the loss of skeletal muscle mass 
accentuates the insulin resistance associated with excess adipose tissue.219 
Choudhary et al. used bioelectrical impedance analysis to diagnose sarcopenic obesity in 
a cohort of Indian liver transplant recipients and found a prevalence of 88%.211 Patients 
with sarcopenic obesity also had a significantly higher prevalence of post-transplant 
metabolic syndrome compared to those without sarcopenic obesity. However, no 
significant differences were found for the individual cardio-metabolic variables that 
comprise the metabolic syndrome. There are several restrictions in generalising this study 
to liver transplantation patients. Firstly, the method of body composition using bioelectrical 
impedance analysis has limitations in the assessment of body composition in patients with 
cirrhosis highlighted previously in Section 1.2.2. Secondly, Asian populations have a 
higher proportion of body fat content compared to Caucasian and other populations as 
highlighted in Section 1.2.1.4.  
Another consequence of sarcopenic obesity in the elderly population is the association 
with physical performance impairment.220, 221 Baumgartner and colleagues demonstrated 
that patients with sarcopenic obesity had a higher prevalence of disturbances in physical 
performance.221 Subsequently, it was shown that the presence of sarcopenic obesity was 
a risk factor for the development of de novo physical performance impairment.220 Given 
that the presence of the metabolic syndrome has been associated with poor physical 
performance, further studies are necessary to examine the relationship of these variables, 
both at the population level and in the post-liver transplant setting. 
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1.7.2 Persistence of sarcopenia post-liver transplant 
Several studies suggest that skeletal muscle mass depletion can persist for up to 12 
months in a significant proportion of liver transplant recipients.59, 213 In addition, de novo 
sarcopenia post-transplant has also been reported. Tsien et al. found that 75% of patients 
who did not have muscle depletion pre-transplant developed it post-transplant.59 Again, all 
of these studies have defined sarcopenia according to skeletal muscle mass depletion 
alone. Some studies have assessed changes in muscle strength and cardiorespiratory 
fitness post-transplant, but none have assessed the three core features of sarcopenia 
together.144, 146 
Some of the key factors thought to contribute to post-transplant sarcopenia include 
immunosuppression; recurrent hospitalisations; recurrent infections and chronic renal 
impairment.212 
There are few data on the consequences of post-transplant sarcopenia and frailty. Some 
authors have hypothesised that post-transplant sarcopenia may contribute to the 
development of the metabolic syndrome and impaired quality of life after liver 
transplantation.59 Tsien and colleagues found an increased risk of diabetes mellitus and a 
trend towards increased mortality in patients with post-transplant skeletal muscle mass 






Due to limitations in our current organ allocation system, there is a need to identify 
independent predictors of poor outcomes in patients undergoing liver transplant. 
This literature review has explored multiple potential predictors of outcomes pre- and post-
liver transplantation. Two such predictors are skeletal muscle area and adipose tissue 
area measured on CT. However, there is limited normative body composition data using 
this technique, and thus we begin with a study (Chapter 3) which explores the distribution 
of muscle and adipose tissue on abdominal CT in a healthy Caucasian cohort. 
It has already been highlighted that skeletal muscle mass can be estimated using multiple 
techniques in patients with cirrhosis, although the accuracy of many methods is poor due 
to assumptions regarding the hydration fraction of fat-free mass. In Chapter 4 we provide 
an investigation into the relationship of several skeletal muscle mass estimation 
techniques, both traditional and novel, compared to a body cell mass reference model. 
Low skeletal muscle mass, muscle weakness and impaired physical performance have all 
been individually identified as risk factors for adverse events on the liver transplant waiting 
list. However, sarcopenia evaluation should incorporate assessment of each of these 
domains. Few studies have explored the significance of each of these variables in a single 
cohort. Chapter 5 is an investigation into the association of these variables with pre- and 
post-transplant outcomes 
Visceral distribution of adipose tissue has been associated with metabolic syndrome and 
cardiovascular disease in the general population. There are limited data on the risk this 
carries in the transplant population. Chapter 6 explores the risk of post-transplant 
metabolic syndrome associated with visceral adipose tissue. 
Finally, sarcopenic obesity has been linked with a higher risk of physical performance 
impairment and metabolic syndrome in the elderly. The association of these variables has 




1.9 Aims and hypotheses 
The specific aims and hypotheses of the studies are: 
1. To characterise the distribution of skeletal muscle area, visceral adipose tissue 
and subcutaneous adipose tissue measured by CT in a healthy cohort to provide 
reference data. 
2. To assess if conventional bedside measures of skeletal muscle mass (MAMC 
and BIA/BIS) correlate with a reference measurement of body cell mass. We 
hypothesise that anthropometric studies and BIA/BIS have limitations in 
accuracy in patients with cirrhosis. 
3. To assess if a novel bedside measure of skeletal muscle mass (US muscle 
thickness) is reliable and has a strong correlation to a body cell mass reference 
measurement. We hypothesise that US muscle thickness is reliable and has a 
strong correlation to body cell mass in patients with cirrhosis. 
4. To assess if sarcopenia (including skeletal muscle mass; muscle strength and 
physical performance assessment), adipose tissue or cardiorespiratory fitness 
predict outcomes pre- and post-liver transplantation. We hypothesise that 
sarcopenia and cardiorespiratory measures will provide independent prognostic 
information pre- and post-liver transplantation. 
5. To assess the changes in body composition and physical performance that 
occur from baseline pre-transplant assessment to six months post-transplant. 
We hypothesise that a significant proportion of patients develop sarcopenic 








In this Chapter, the study design will be described, along with the methodology used for 
the assessment of body composition, muscle strength and physical performance. Other 
methodology, including statistical analysis, will be described in the subsequent individual 
Chapters.  
2.1 Study design 
The studies performed as part of this thesis have arisen through careful planning and 
utilising limited resources.  
Chapters three and six were retrospective studies conducted with an exemption of consent 
from the Metro South Hospital and Health Service Ethics Committee. Consent for Chapter 
3 was also provided by the Princess Alexandra Hospital Department of Nephrology. 
The projects that comprise Chapters 4, 5 and 7 were performed prospectively after 
approval from the Metro South Hospital and Health Service Ethics Committee and 
conducted according to the Declaration of Helsinki. Recruitment for these chapters was 
conducted by the candidate approaching patients referred to the Queensland Liver 
Transplant Service. A consort diagram is shown in Figure 2-1 which outlines the 
recruitment outcome. 
The most common reason for declining participation was a ‘lack of time’ and ‘already 
having too many investigations’.  
During the period of recruitment, from July 2014 to February 2017, there was one waiting 
list death, and seven post-transplant deaths. Of the cohort studied, there were no waiting 
list deaths and two post-transplant deaths as at August 2017.  
Of the 16 patients who received testing but not transplanted, six were listed for transplant 
but subsequently delisted due to HCC progression (n = 2), improvement in MELD score (n 
= 2), resolution of lesion which had prior features of a HCC (n = 1) and one patient with 
detectable serum alcohol on routine screening (n = 1). Ten patients participating in the 
study were never listed for the following reasons: excluded due to medical co-morbidities 
(n = 2); HCC progressing outside criteria during assessment (n = 1) and seven patients 




Figure 2-1. Consort diagram of patient recruitment for Chapters 4, 5 and 7. 
2.2 Body composition methodology 
2.2.1 Anthropometrics 
Body weight and height were measured by a single observer (AW) to the nearest 0.1 kg 
and 0.01 cm using standardised equipment and procedures.  
Mid-upper arm circumference (MAC) and triceps skinfold (TSF) measurements were taken 
on the right side at the mid-acromiale-radiale point. Three measurements were performed 
by an experienced observer (MW) with International Society for the Advancement of 
Kinanthropometry (ISAK) accreditation. The average value for all measurements was 
calculated for the analysis. The mid-arm muscle circumference (MAMC) was calculated 
according to the following formula:  
MAMC (cm) = MAC – TSF  




2.2.2 Bioelectrical impedance spectroscopy  
Whole body bioelectrical impedance spectroscopy (BIS) was performed using a Bioimp 
SFB7 impedance spectrometer (Impedimed, Brisbane, Australia) as described 
previously.223 Single-tab Ag-AgCl adhesive gel electrodes were placed on the right side of 
the body, with the subject in supine position. The voltage (sense) electrodes were placed 
so that the distal edge of the electrode was lying along the skin crease on the dorsal 
surface of the wrist and the ankle at the level of the styloid process and medial malleolus, 
respectively. Current source electrodes were placed on the palmar surface of the hand 
and plantar surface of the foot at the distal ends of the metacarpals and metatarsals, 
respectively. To prevent a potential short circuit of the electrical pathway, care was taken 
to ensure that there was no contact between the skin of the subject’s limbs and other parts 
of the body. A minimum of five impedance readings were taken at one second intervals 
using the automated repeat reading mode of the instrument. The subject was observed 
during this time to ensure that there was no movement, that there was no skin to skin 
contact and that leads remained connected. Acceptability of the data was confirmed by 
inspecting the Cole plots of the data on the SFB7 display immediately after data collection. 
Minimal scattering of data points and the presence of a well-fitted Cole plot indicated a 
valid measurement.  
Prediction of body composition (fat mass and fat-free mass) was performed by fitting the 
impedance data to the Cole model to obtain resistance at zero and infinite frequencies 
using manufacturer’s software (Bioimp Version 4.12). These data were then used to 
calculate total body water, extracellular water, fat-free mass and fat mass according to 
mixture theory using the Bioimp program. 
2.2.3 Ultrasound muscle thickness 
Ultrasound (US) estimation of skeletal muscle mass was performed using a Phillips EPIQ 
Ultrasound Scanner (Phillips, Andover, MA, USA) with a linear transducer 12-5 MHz by 
two blinded observers (AW and Mr Scott King [SK]). The primary observer was an 
experienced sonographer (SK) while the other was an inexperienced observer (AW) who 
received basic sonography training.  Three muscle thickness measurements were taken at 
the mid forearm, mid upper arm anteriorly and mid-thigh on the dominant side of the body 





Figure 2-2. Ultrasound muscle thickness of the right mid-thigh. 
Three muscle thickness measurements were taken at each of the following sites on the 
dominant side of the body:  
1. Mid Forearm - With the elbow extended and the forearm supinated, a point was 
marked midway between the antecubital skin crease and the ulnar styloid. The thickness 
of the flexor compartment was measured at this level anteriorly between the superficial fat-
muscle interface and the interosseous membrane. 
2. Mid Upper Arm Anteriorly - With the elbow extended, the mid-acromiale-radiale 
point was marked on the skin. Then with the subject supine, the elbow extended and the 
forearm supinated, the thickness of the flexor compartment was measured at this level, 
over the biceps, between the superficial fat-muscle interface and the humerus.  
3. Mid Thigh - With the subject supine and the knee extended, the midway point 
between the anterior superior iliac spine and the upper pole of the patella was identified 
and the thickness of the quadriceps muscle group between the superficial fat-muscle 
interface and the femur was measured anteriorly. 
Observers applied probe pressure as light as possible to minimise compression of the 





2.2.4 Computed tomography body composition analysis 
Computed tomography (CT) of the abdomen is performed as a routine pre-transplant 
assessment and these scans were available for reanalysis using ImageJ (National 
Institutes of Health, Bethesda, Maryland, USA) to assess skeletal muscle and adipose 
tissue. An example is shown in Figure 2-3.  
After ethical approval was granted from the Metro South Hospital and Health Services 
District and The University of Queensland’s Human Research Ethics Committees, CT 
scans were located for each patient via the Princess Alexandra Hospital Picture Archiving 
and Communication System (PACS). Using coronial and sagittal reconstructions to assist, 
the CT slice closest to the mid L3 vertebrae was selected and a Digital Imaging and 
Communication in Medicine (DICOM) file downloaded for further analysis.  
CT scans were assessed for quality as previously described.224 CT scans were excluded if 
they had incomplete views of the abdominal skeletal muscles, as well as artifact due to 
patient movement and metallic foreign bodies (eg cardiac leads, spinal fixation; bullet 
fragments).224 
Data were obtained from a single transverse CT image at the mid third lumbar vertebrae. 
Tissue segmentation was performed using Hounsfield unit thresholds of -29 to +150 for 
muscle and -190 to -30 for adipose tissue.224, 225 Cross-sectional area of subcutaneous 
adipose tissue (SAT), visceral adipose tissue (VAT) and skeletal muscle was measured. 
Skeletal muscle area was normalized for stature (cm2/m2), and described as the skeletal 
muscle index (SMI) as previously reported.58  
  
Figure 2-3. ImageJ analysis of adipose tissue and skeletal muscle area using computed tomography. 
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2.2.5 Dual-energy X-ray absorptiometry 
A whole body DXA scan was performed using a GE Prodigy Scanner (GE Healthcare 
Lunar, Madison, WI, USA). The precision (CV) of the GE Prodigy has been estimated at 
0.8% for lean tissue, 2.5% for fat mass, and 1.3% for bone mass in healthy cohorts.226 
DXA fat mass, fat-free mass, bone mass and appendicular lean mass (ALM) were 
measured as per the manufacturer’s guidelines by the duty radiologist. ALM was used to 
calculate the DXA Skeletal Muscle Index (SMI) according the following equation: DXA SMI 
(kg/m2) = DXA ALM/Height2.27 
2.2.6 Total body potassium  
Total body potassium counting was performed to provide an assessment of body cell mass 
(BCM) using a shadow-shield whole-body counter (Accuscan, Canberra Industries, 
Boston, MA) containing three sodium iodide crystal scintillation detectors arranged over a 
scanning bed. Each subject underwent two 20-minute measurements and the average 
was used for analysis. The CV for this machine is 7.1%.  
Body cell mass was calculated from the TBK measurements using the following equation 
from Wang et al.70:  
 BCM (kg) = (TBKx9.20)/39.1 
2.2.7 Body water assessment 
Assessment of water compartments was performed using deuterium (D2O) and bromide 
(Br) dilution tests. Venous blood was drawn immediately before the oral intake of a cocktail 
containing approximately 1g D2O/kg body weight of a solution of 99.9% D2O and 0.75 
mmol Br/kg body weight. Further samples of venous blood were collected following a four-
hour and six-hour equilibration period during which the patient remained fasting. 
Deuterium and bromide assays were performed using Fourier transform infra-red 
spectroscopy (Shimadzu Corp., Kyoto, Japan) and high performance liquid 
chromatography respectively.223 Analytical precision using these methods has been 
estimated at <2%.227 
Total body water (TBW) was calculated from the quantity of deuterium administered and 
the measured increase in tracer concentration over the time course of the study, and 
compared with baseline plasma concentration as described previously.227 Extracellular 
water (ECW) volume was calculated as the corrected bromide space as described 
previously.227 The bromide dilution space was converted into ECW by correcting for the 
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fraction of water in plasma (0.94), the Donnan equilibrium factor for bromide (0.95), and 
the fraction of bromide dose that is retained and assumed to remain extracellular (0.90).223 
Intracellular water (ICW) was calculated as the difference between TBW and ECW and the 
percentage hydration of fat-free mass was calculated as the ratio of TBW to DXA fat-free 
mass. 
2.3 Assessment of muscle strength  
2.3.1 Isometric handgrip strength 
Upper limb muscle strength was assessed by measuring isometric handgrip strength 
based on the protocol by Roberts et al.228  
A single observer (AW) measured isometric handgrip strength on the non-dominant side 
using a hand dynamometre (Mentone, Melbourne, Australia).  
Participants performed three trials in a standing position, with three minutes of rest 
between attempts. The average value for all trials was calculated for the analysis.  
Further details on the protocol used for handgrip strength measurement can be found in 
Appendix F. 
2.3.2 Global muscular strength 
Global muscular strength was assessed with a Mid-Thigh Pull (MTP) using a Portable 
Force Platform 400-series (Fitness Technology, Adelaide, Australia). Three attempts were 
provided; the trial with the greatest peak force value was analysed. Peak force was 
measured offline with a customised Matlab script (The Mathworks Inc., USA). 
2.4 Assessment of physical performance 
2.4.1 Sit-to-stand test  
The sit-to-stand test was performed as per the protocol described by Jones et al.96  
The test was administered using a standard chair without arms. The test began with the 
participant seated in the middle of the chair, back straight, feet approximately shoulder-
width apart and placed on the floor at an angle slightly back from the knees, with one foot 
slightly in front of the other to help maintain balance when standing. Arms were crossed at 
the wrists and held against the chest.  
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At the signal "Go", the participant rose to a full stand (body erect and straight) and then 
returned back to the initial seated position. The participant was encouraged to complete as 
many full stands as possible within a 30 second time limit and was instructed to be fully 
seated between each stand. While monitoring the participant's performance to assure 
proper form, the tester silently counted the completion of each correct stand. Following a 
demonstration by the tester, a practice trial of one repetition was given to check proper 
form, followed by the 30 second test trial. The score was the total number of stands 
executed correctly within 30 seconds (more than halfway up at the end of 30 seconds 
counted as a full stand). Incorrectly executed stands were not counted. 
2.4.2 Short Physical Performance Battery 
The Short Physical Performance Battery (SPPB) was conducted as described by Guralnik 
et al.93 Assessment of balance, gait speed and chair stands was performed according to 
the following protocol. 
Balance 
Tests of standing balance included tandem, semi-tandem, and side-by-side stands. For 
each stand, the interviewer first demonstrated the task, then supported one arm while 
participants positioned their feet, asked if they were ready, then released the support and 
began timing. The timing was stopped when participants moved their feet or grasped the 
interviewer for support, or when 10 seconds had elapsed. Each participant began with the 
semi-tandem stand, in which the heel of one foot was placed to the side of the first toe of 
the other foot, with the participant choosing which foot to place forward. Those unable to 
hold the semi-tandem position for 10 seconds were evaluated with the feet in the side by-
side position. Those able to maintain the semi-tandem position for 10 seconds were further 
evaluated with the feet in full tandem position, with the heel of one foot directly in front of 
the toes of the other foot.  
Gait Speed Test 
To test walking speed, a four-metre walking course was used with no obstructions for an 
additional one-metre at either end. Participants were instructed to: "walk to the other end 
of the course at your usual speed, just as if you were walking down the street to go to the 
store". Participants could use assistive devices if needed, and each participant was timed 




Chair Stand Test 
To test the ability to rise from a chair (termed the chair stand), a straight-backed chair was 
placed next to a wall; participants were asked to fold their arms across their chest and to 
stand up from the chair one time. If successful, participants were asked to stand up and sit 
down five times as quickly as possible, and were timed from the initial sitting position to the 
final standing position at the end of the fifth stand.  
Overall score 
Categories of performance were created for each set of performance measures to permit 
analyses that included those unable to perform a task. Participants who could not 
complete the four-metre walk and repeated chair stands were assigned a score of 0. 
Those completing the task were assigned scores of one to four, corresponding to the 
quartiles of time needed to complete the task, with the fastest times scored as four. The 
three tests of standing balance were considered as hierarchical in difficulty in assigning a 
single score of zero to four for standing balance. A summary performance scale was 
created by summing the category scores for the walking, chair stand, and balance tests. 
2.4.3 Six-minute walk distance 
The six-minute walk distance was performed according to the protocol of Coombes et al.91 
Patients were tested using the Princess Alexandra Hospital Department of Respiratory 
walking course. The walking course is 25 metres in length so that one lap (out and back) is 
50 metres. This course has pre-existing markers at one-metre intervals. 
A single observer (AW) conducted the test as follows: 
1. Patients were asked to walk as far as possible for six minutes. They were advised 
to pivot briskly around the cones and continue back the other way without 
hesitation. They were permitted to slow down, to stop, and to rest as necessary.  
2. The distance walked was recorded on a data sheet each time a lap was completed.  
3. If the participant stopped to rest, the stopwatch kept running.   
4. When the six minutes elapsed, the exact point on the floor where the participant 
finished was noted. 
5. The total distance walked was recorded.  
Further details on the protocol for the six-minute walk test can be found in Appendix F. 
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2.4.4 Stair climb test 
A stair climb test was performed according to the protocol by Bean et al.229 A summary of 
the protocol is as follows: 
1. A single observer (AW) stood with the subject at the base of a well-lighted, 10-stair 
flight of stairs. 
2. Subjects were instructed to safely ascend the stairs as fast as they could.  
3. They were further instructed that they could use the handrail if they thought it was 
necessary for safety purposes 
4. The observer started the test by saying: “Ready, set, go.”  
5. Timing began after the examiner said “Go”.  
6. When both feet of a subject reached the top step, the timing stopped.  
Time was recorded to the nearest 0.01 second, and the best of three trials was taken. 
2.5 Assessment of cardiorespiratory fitness 
Cardiopulmonary exercise testing was performed in accordance with recommendations by 
the American Thoracic Society/American College of Chest Physicians.174 The primary 
cardiopulmonary exercise test-derived variable included in the studies was the ventilatory 
threshold, which is a submaximal marker of cardiorespiratory fitness.174 Ventilatory 
threshold was determined using the modified V-slope method incorporated into the 
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The interest in using computed tomography (CT) images to provide body composition data 
has grown in recent years. Despite this, the availability of normative data is limited. 
Therefore, this study provides normative cross-sectional CT skeletal muscle and adipose 





Introduction: The analysis of Computerised Tomography (CT) images to provide body 
composition data has grown exponentially. Despite this, there remains limited published 
data defining the normal range of skeletal muscle area and adipose tissue area using CT. 
The aim of this study was to determine age- and sex-specific body composition data using 
CT at the level of the 3rd Lumbar vertebrae, in a Caucasian population with a healthy body 
mass index. In addition, we sought to explore the CT data for relationships between age, 
sex and body composition variables, as well as to develop cut-off values for low skeletal 
muscle mass. 
Patients and methods: We included 107 healthy Caucasian patients (46 males; 61 
females) with a healthy body mass index (18 - 26 kg/m2) for analysis. Body composition 
data were obtained from a single transverse CT image at the mid third lumbar vertebrae 
using ImageJ software. Tissue segmentation was performed using Hounsfield unit 
thresholds of -29 to +150 for muscle and -190 to -30 for adipose tissue. 
Results: The mean age of the study cohort was 47.8±11.0 years (range 21 to 73) with a 
median body mass index of 23.7 kg/m2 (interquartile range [IQR] 22.3–24.8). Visceral 
adipose tissue (VAT) area was significantly higher in men (92.9 cm2 [IQR 59.3–133.3) vs 
42.2 cm2 (IQR 28.3 – 68.4); P<0.001), while women had higher subcutaneous adipose 
tissue (SAT) area (156.7 ± 52.1 cm2 vs 113.9 ± 47.0 cm2; P<0.001). Skeletal muscle Index 
(SMI) was significantly higher in men (53.6 ± 6.4 cm2/m2 vs 42.3 ± 5.6 cm2/m2; P<0.001). 
Patients were sub-divided into age above or below 50 years. Cut-offs for low skeletal 
muscle mass, representing two standard deviations below the young healthy population 
mean values, were 43.5cm2/m2 for men and 30.0cm2/m2 for women. 
Conclusion: Our data provides an insight into the distribution of skeletal muscle and 
adipose tissue surface area values measured on CT from a healthy Caucasian population. 
Our CT derived cut-offs for low skeletal muscle mass, based on international guidelines, 





Loss of skeletal muscle mass and/or function has a significant impact on health outcomes 
across a broad range of populations.27, 57, 230, 231 With the increasing availability of 
computed tomography (CT) for assessment of illness, the utilisation of this imaging 
modality to provide information on body composition has grown exponentially. In 2004, 
Shen et al. presented data from a healthy cohort that demonstrated skeletal muscle and 
adipose tissue surface area on a single slice of cross-sectional magnetic resonance 
imaging (MRI) strongly correlates with total body MRI muscle and fat stores.43 
In 2008, Prado et al. measured skeletal muscle area at the level of the 3rd lumbar 
vertebrae and corrected for height (in metres) squared, to provide the skeletal muscle 
index (SMI). Sex-specific low SMI cut-offs associated with mortality were published in a 
population of obese patients with cancer.56 Subsequently many researchers have used 
these thresholds to define low skeletal muscle mass in studies examining the relationship 
of skeletal muscle mass to morbidity and mortality in different populations.57 
However, normative data using CT are scarce to confirm that these thresholds are in 
accordance with guidelines which define ‘sarcopenia’ as two standard deviations below the 
age and sex-specific mean value.53  
There is also a need to define the distribution of adipose tissue in healthy populations. The 
Japan Society for the Study of Obesity has suggested that a visceral adipose tissue (VAT) 
area >100cm2 be used to diagnose ‘visceral obesity’ based on data from a healthy 
Japanese cohort.66 However, it is well recognised that there is significant ethnic variation in 
adipose and muscle stores. 
The aim of this study was to determine age- and sex-specific body composition values 
using CT at the level of the 3rd lumbar vertebrae, in a healthy Caucasian population with 
normal body mass index. In addition, we sought to explore the CT data for relationships 
between age, sex and body composition variables, as well as develop cut-off values for 
low skeletal muscle mass. 
3.4 PATIENTS AND METHODS 
Ethics approval was granted from the Metro South Human Research Ethics Committee 
(HREC/14/QPAH/23). We included 107 healthy self-identified Caucasian patients (46 
males; 61 females) with a healthy body mass index (18 - 26 kg/m2) for analysis. Patients 
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having a CT abdomen for trauma evaluation (n = 17), or as part of a living donor renal 
transplant assessment (n = 90) were included. The clinical records were evaluated and 
patients excluded if they had illnesses (pre-existing malignancy (n = 4); unexplained iron 
deficiency anaemia (n = 1)), medications (hormonal therapy (n = 6); angiotensin inhibitors 
(n = 4); statins (n = 3)) or a CT not suitable for analysis (n = 24).232 
CT scans were analysed using a single transverse CT image at the mid third lumbar 
vertebrae using ImageJ software (National Institute of Health, Bethesda, MD, USA) as 
described in Section 2.2.4. The cross-sectional area of subcutaneous adipose tissue 
(SAT), VAT and muscle were measured and normalized for stature (cm2/m2), and 
described as subcutaneous adipose tissue index (SATI), visceral adipose tissue index 
(VATI) and skeletal muscle index (SMI) as previously reported.58 Twenty subjects had a 
CT with only partial SAT area and were classified as missing data. 
All images were analysed by a single trained observer (AW). Intra-observer variability was 
assessed by re-analysing 10 randomly selected scans after a minimum 6-month interval. 
The intraclass correlation coefficient (ICC) for skeletal muscle area was 1.00 (95%CI 0.99 
- 1.00), VAT 0.99 (95%CI 0.98 - 1.00) and SAT was 1.00 (95%CI 1.00 – 1.00), while the 
coefficients of variation were 0.7%, 6.5% and 2.4% respectively. Variation in software was 
assessed by re-analysing 10 scans with Slice-O-Matic (Tomovision, Montreal, QC, 
Canada). This analysis showed ICCs of 0.99 (95%CI 0.97 – 1.00), 0.99 (95%CI 0.97 - 
1.00) and 1.00 (95%CI 1.00 - 1.00) for skeletal muscle area, VAT and SAT respectively. 
Using 10 randomly selected scans, inter-observer variability was assessed by a blinded 
second trained analyst (SK). The ICC for skeletal muscle area, VAT and SAT for this 
comparison were 1.00 (95%CI 0.99 – 1.00), 1.00 (95%CI 1.00 – 1.00) and 1.00 (95%CI 
1.00 – 1.00) respectively. 
3.5 STATISTICAL ANALYSIS 
Statistical analyses were performed using SPSS (Version 24; IBM, New York, USA). Two-
tailed (P = 0.05) tests of significance were used. Continuous data were assessed for 
normality using a Shapiro-Wilk test and are presented as means ± standard deviation 
(SD), or medians and interquartile range (IQR), depending on distribution of the data. Non-
normally distributed data were transformed where possible for statistical analysis. 
Comparison of continuous variables was examined using independent t-tests (normal 
distribution) or Mann-Whitney U tests (non-normal distribution). Correlation was assessed 
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using Pearson’s or Spearman’s test of correlation depending on the distribution of data. 
For interpretation of correlation coefficients, Cohen's levels were used.233 
Patients were divided into sex- and age-specific groups since these two variables are 
known to have significant impact on body composition variables.30 To provide a ‘young’ 
reference data set, an age cut-off of less than 50 years was used. This age cut-off has 
been used in other studies to define ‘young cohorts’, and provided an even distribution of 
data in our cohort.59, 234 Prior population level studies have demonstrated that decline in 
skeletal muscle mass does not occur until approximately 45 years of age.34  
The median age of our young healthy males and females was 39.8 years (IQR 27.4 – 
46.0) and 45.5 years (IQR 40.5 – 47.9) respectively. Comparison of age- and sex-specific 
groups was performed using one-way ANOVA analysis and Tukey’s post hoc test (normal 
distribution) or Kruskal Wallis analysis and Dunn’s post hoc test (non-normal distribution). 
3.6 RESULTS 
The mean age of the study cohort was 47.8 ± 11.0 years (range 21 to 73) with a median 
body mass index of 23.7 kg/m2 (IQR 22.3 – 24.8). Sex-specific patient characteristics are 
shown in Table 3-1. There was no significant sex-specific difference in age or body mass 
index. As expected, there were sex-specific significant differences in height, weight, SMI, 
SAT and VAT. 
Table 3-1. Patient characteristics (n = 107) 
Variable Male  (n = 46) 
Female  
(n = 61) P Value 
Age (yr)  45.8 ± 13.1 49.2 ± 8.9 0.139 
Height (m)  1.78 ± 0.07 1.64 ± 0.07  <0.001 
Weight (kg)  75.6 ± 8.2 62.9 ± 6.2 <0.001 
BMI (kg/m2)  24.4 (22.4 – 25.3) 23.4 (22.2 – 24.7) 0.109 
VAT (cm2) 92.9 (59.3 – 133.3) 42.2 (28.3 – 68.4) <0.001 
SAT (cm2)  113.9 ± 47.0 156.7 ± 52.1 <0.001 
SMA (cm2)  170.2 ± 20.4 113.6 ± 15.7 <0.001 
VATI (cm2/m2) 28.7 (18.5 – 39.4) 15.6 (10.7 – 25.3) <0.001 
SATI (cm2/m2) 35.8 ± 14.5 58.8 ± 20.7 <0.001 
SMI (cm2/m2) 53.6 ± 6.4 42.3 ± 5.6 <0.001 
Values presented as mean ± SD, or median (interquartile range) where data were not normally distributed.  
BMI = Body mass index; VAT = Visceral adipose tissue area; SAT = Subcutaneous adipose tissue area; SMA = Skeletal muscle area; 
VATI = Visceral adipose tissue index; SATI = Subcutaneous adipose tissue index; SMI = Skeletal muscle index 
The relationship of body mass index to other body composition variables was explored. 
Body mass index was found to be moderately correlated with SMI (rho = 0.423; P < 0.01), 
VATI (rho = 0.382; P < 0.01) and SATI (rho = 0.315; P < 0.01). 
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There were no significant associations of SMI (men: r = -0.176, P = 0.243; women:             
r = -0.29, P = 0.822) or SAT (men: r = 0.274, P = 0.079; women: r = 0.08, P = 0.602) with 
age. There was, however, a moderate association of VAT with increasing age in men (r = 
0.504; P < 0.01) but not women (r = 0.194; P = 0.133). 
Patients were sub-divided into age above or below 50 years to provide a ‘young healthy’ 
reference cohort. CT body composition results are shown in their sex- and age-specific 
groups in Table 3-2 and Table 3-3.  
Sex- and age-specific differences in body composition were explored. One-way ANOVA 
analysis showed a significant difference in mean SMI between groups (F = 31.29; P < 
0.001). Tukey’s post hoc test showed that young males had a significantly higher mean 
SMI than both female groups (P < 0.001); however, there was no difference compared to 
older males (P = 0.798) [Figure 3-1]. There was also no significant difference in mean SMI 
between the two female groups (P = 0.980). 
Between group comparison of SAT, using one-way ANOVA, demonstrated similar findings, 
with significant sex-differences (higher SAT in females) but not age [Figure 3-2]. Analysis 
of VAT also showed sex-specific differences in groups, with both male cohorts having 
higher VAT compared to females [Figure 3-3]. However, there was also a significant 
difference between the two male cohorts (P = 0.025), with older males having higher VAT. 
Figure 3-4 provides a three-dimensional representation of the distribution of skeletal 
muscle area, VAT and SAT measurements in the study cohort, highlighting the sex-
specific differences described. 
Cut-offs for low skeletal muscle mass recommended by the European Working Group on 
Sarcopenia in Older People (EWGSOP) are two standard deviations below the mean of 
sex-specific healthy young adults.27 Based on our data, the cut-offs for CT SMI were 




Table 3-2. Age and sex-specific CT body composition surface area values. 
 Males <50 years Females <50 years Males ≥50 years Females ≥50 years  
SMA (cm2) VAT (cm2) SAT (cm2) SMA (cm2) VAT (cm2) SAT (cm2) SMA (cm2) VAT (cm2) SAT cm2) SMA (cm2) VAT (cm2) SAT (cm2) 
Number 26 26 24 33 33 25 20 20 18 28 28 20 
Mean 173.7 80.9 107.1 116.0 45.2  147.7 165.7 119.1 123.0 110.8 49.5 168.0 
Std deviation 19.2 40.7 43.6 17.0 25.0 54.1 21.6 56.8 51.0 13.8 29.5-81.8§ 48.4 
Minimum 126.5 11.7 11.9 87.7 10.3 60.5 126.2 36.3 43.9 78.0 18.0 54.9 
Maximum 203.8 160.7 188.3 152.1 105.6 235.5 220.0 221.8 226.9 142.5 155.5 242.5 
5th Percentile 132.8 14.4 18.9 91.8 12.0 61.8 127.0 36.7 43.9 82.4 19.3 57.1 
20th Percentile 157.5 35.3 76.5 102.6 19.5 95.8 152.0 59.9 79.9 100.1 26.8 122.9 
80th Percentile 193.3 117.1 152.4 134.5 72.0 213.3 182.8 176.3 172.5 119.8 85.8 216.9 
95th Percentile 201.8 158.6 188.3 148.5 94.4 234.3 219.0 220.9 226.9 139.9 142.9 242.1 
CT – Computed tomography; VAT - Visceral adipose tissue area; SAT - Subcutaneous adipose tissue area; SMA - Skeletal muscle area 
 Median § IQR 
Table 3-3. Age and sex-specific CT body composition index values. 
 

























Number 26 26 24 33 33 25 20 20 18 28 28 20 
Mean 54.3 25.0 33.4 42.6 13.8 53.6 52.7 37.8 39.0 42.0 18.7 65.3 
Std deviation 5.4 12.1 13.6 6.3 9.7-23.9§ 20.1 7.6 18.2 15.6 4.8 10.9-27.9§ 20.0 
Minimum 42.7 3.7 3.8 29.2 3.8 21.9 41.6 11.4 13.8 31.6 6.1 21.4 
Maximum 61.5 49.4 60.1 57.4 44.5 88.2 67.6 74.7 68.5 51.1 66.4 100.9 
5th Percentile 42.9 4.8 6.3 31.1 4.5 22.5 41.7 11.6 13.8 32.1 6.8 22.2 
20th Percentile 49.0 11.6 23.8 38.1 7.6 35.2 44.9 19.1 25.8 38.6 10.4 45.7 
80th Percentile 60.2 35.7 47.0 47.7 27.4 75.7 61.6 57.9 4.6 47.2 29.9 78.2 
95th Percentile 61.3 49.3 59.6 53.8 35.7 87.9 67.4 74.0 68.5 50.3 60.4 100.7 
CT – Computed tomography; VATI - Visceral adipose tissue index; SATI - Subcutaneous adipose tissue index; SMI - Skeletal muscle index 




Figure 3-1. (a) Comparison of computed tomography (CT) skeletal muscle index [SMI] in age- and 
sex-specific groups (b) Tukey’s multiple comparison graph for SMI. **** Significant at 0.0001 level 
 
Figure 3-2. (a) Comparison of computed tomography (CT) subcutaneous adipose tissue [SAT] area in 
age and sex-specific groups (b) Tukey’s multiple comparison graph for SAT area. *** Significant at 
0.001 level * Significant at 0.05 level 
 
Figure 3-3. (a) Comparison of computed tomography (CT) visceral adipose tissue (VAT) area in age 
and sex-specific groups (b) Tukey’s multiple comparison graph for VAT area. **** Significant at 




Figure 3-4. Cluster graph showing skeletal muscle area and adipose tissue area distribution. VAT – 
Visceral Adipose Tissue; SAT – Subcutaneous adipose tissue. All values in centimetres squared. 
3.7 DISCUSSION 
The use of cross-sectional imaging for clinical care is expanding and can provide important 
body composition information on patients. Multiple methods have been reported to quantify 
skeletal muscle on CT, however the most common method is the measurement of total 
skeletal muscle area on a single transverse image. There is a paucity of normative CT 
data using this technique. Our aim was to provide age- and sex-specific body composition 
values using CT at the level of the 3rd lumbar vertebrae, in a healthy Caucasian 
population. 
These data provide a reference which can be used to define stages of skeletal muscle loss 
and adipose tissue excess in Caucasian cohorts. Conditions such as sarcopenia and 
sarcopenic obesity can be more specifically defined, even in patients with fluid retention. 
To date, the most frequently used CT skeletal muscle cut-offs defining low skeletal muscle 
mass have been derived using optimal stratiﬁcation to predict mortality in cohorts with 
cancer.56, 235 The mean CT SMI in our sex-specific groups of healthy subjects approached 
the previously utilised cut-offs from Prado et al. (52.4cm2/m2 for men and 38.5cm2/m2 for 
women).56 These cut-offs were derived from a population with a body mass index >30 and 
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it is likely that a proportion of this cohort had higher lean mass contributing to their 
increased body mass index. Subsequently Martin et al. published data from a cohort of 
cancer patients which suggested lower cut-offs are associated with mortality in those 
patients with normal body mass index (<43 cm2/m2 for men and <41 cm2/m2 for 
women).235 
Our low skeletal muscle mass cut-offs were similar to those published by Hamaguchi et al. 
from a large Japanese population.64 CT muscle and adipose surface area values at the 
level of the 3rd lumbar vertebrae were collected on 657 healthy Japanese liver transplant 
donors. Their thresholds for low skeletal muscle mass were 40.31cm2/m2 for males and 
30.88cm2/m2 for females.64 
The normative data from our study and Hamaguchi et al. suggest that the previously 
widely used cut-offs from Prado et al. may not be representative of low skeletal muscle 
mass according to the EWGSOP definition. However, these cut-offs have been linked to 
morbidity and mortality in many different cohorts suggesting that less marked degrees of 
muscle loss are likely to be clinically significant.56, 235 We propose that stages of skeletal 
muscle mass loss should be considered in future studies using CT, similar to what was 
suggested by Janssen et al. for studies using BIA.236 Thus, patients more than one 
standard deviation below the healthy population mean (48.9cm2/m2 for males and 
36.3cm2/m2 for females) would be classified as ‘Class I skeletal muscle mass depletion’ 
while those more than two standard deviations would have ‘Class II skeletal muscle mass 
depletion’ [  Table 3-4]. 
  Table 3-4. Proposed thresholds to define stages of skeletal muscle loss 
 Males Females 
Class I skeletal muscle mass depletion  48.9cm2/m2 36.3cm2/m2 
Class II skeletal muscle mass depletion  43.5cm2/m2 30.0cm2/m2 
We have not provided a cut-off for adipose tissue for several reasons. Firstly, VAT did not 
have a normal distribution in the female cohort. Secondly, metabolic derangements are 
known to start with a VAT area >100cm2 and become generalised at a VAT area 
>130cm2.67, 68 We feel that these thresholds would be more appropriate than cut-offs 
derived from our normative data. 
There are several limitations to this study. Firstly, our skeletal muscle data is limited to the 
most common technique for estimating muscle mass on CT, with many alternatives which 
have not been measured. Secondly, our young reference population included patients up 
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to 50 years of age compared to an upper limit of 40 years of age used by Baumgartner et 
al.53 The median age of our ‘young healthy’ population was 39.8 years (IQR 27.4 – 46.0) 
and 45.5 years (IQR 40.5 – 47.9) in males and females respectively. Finally, our cohort is 
ethnically limited to Caucasian subjects. Further studies are required to build on the 
normative data presented here, both in Caucasian populations as well as other ethnic 
groups. 
To conclude, our data provides an insight into the distribution of skeletal muscle and 
adipose tissue surface area values on CT, in a healthy Caucasian population at the level 
of the 3rd lumbar vertebrae. The cut-offs for skeletal muscle mass depletion, which 
represent two standard deviations below the sex-specific healthy population mean values, 
are much lower than those frequently used in the literature. We propose the use of a multi-
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Whilst muscle wasting is a recognised complication of cirrhosis, prior studies have found 
that bedside techniques used to estimate skeletal muscle mass suffer from accuracy 
issues in patients with cirrhosis. Therefore, we sought to assess if the latest bioelectrical 
impedance technology could improve skeletal muscle mass estimation, as well as a novel 
method of assessing skeletal muscle mass using ultrasound. We also sought to evaluate 
the relationship of radiological skeletal muscle mass estimates (DXA appendicular lean 





Introduction: Loss of skeletal muscle mass is a well-recognised complication of cirrhosis. 
Bedside methods including anthropometrics and bioelectrical impedance analysis (BIA) 
have been described as inaccurate in this population and thus there is a need to identify 
alternatives. There is also a paucity of data on the accuracy of commonly used radiological 
methods such as dual X-ray absorptiometry (DXA) appendicular lean mass (ALM) and 
computed tomography (CT) skeletal muscle area in patients with cirrhosis. The aim of this 
study was to evaluate several methods of skeletal muscle mass estimation compared to a 
reference model in patients with cirrhosis.  
Patients and methods: A cross-sectional, single centre study was performed by 
prospectively recruiting patients with cirrhosis referred to the Queensland Liver Transplant 
Service. Patients underwent assessment of skeletal muscle mass using bedside 
techniques (mid-arm muscle circumference (MAMC), bioelectrical impedance 
spectroscopy (BIS), ultrasound muscle thickness (USMT)) and radiological methods (DXA 
ALM, CT skeletal muscle area). These were compared to a reference measurement of 
body cell mass derived using a multi-compartment model using isotope dilution tests and 
DXA.  
Results: Forty-two patients (age 56 years, interquartile range 48-60, 86% male) were 
recruited. Bedside skeletal muscle mass estimation techniques were strongly correlated to 
the body cell mass reference, with BIS estimation having the strongest correlation 
coefficients (r=0.782–0.792; P<0.01). A novel technique measuring USMT offered no 
advantage over traditional bedside techniques. Of the radiological methods, DXA ALM had 
the strongest correlation coefficient (r=0.781; P<0.01). Weaker correlation coefficients 
were observed in patients with ascites, except the MAMC.  
BIS estimates of fat mass, fat-free mass, total body water and extracellular water 
demonstrated strong correlation coefficients compared to reference values, however there 
were wide limits of agreement present. 
Conclusion: These results confirm the difficulties in assessing skeletal muscle mass in 
patients with cirrhosis, in particular those with ascites. Of all the techniques evaluated, 
DXA ALM and BIS measurements provided the best estimate of body cell mass and 
therefore skeletal muscle mass. We suggest DXA ALM for estimation of skeletal muscle 
mass in patients with cirrhosis as there are established thresholds for skeletal muscle 
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mass depletion, and an accurate assessment of bone mass and density can also be 
provided. The use of USMT over other bedside skeletal muscle mass estimates was not 
supported by our results. Further studies evaluating novel bedside skeletal muscle mass 





Loss of skeletal muscle mass is a well-recognised complication of cirrhosis which is 
associated with morbidity and mortality. In 2001, Alberino et al. used anthropometry (mid-
arm muscle circumference [MAMC]) to demonstrate that skeletal muscle mass depletion 
was an independent risk factor for mortality.111 
Since then, there have been many publications exploring the implications of skeletal 
muscle mass depletion. Many of these studies have used body composition techniques 
based on a two-compartment model and used prediction equations to estimate skeletal 
muscle mass. However, patients with cirrhosis have alterations in the hydration fraction 
and density of fat-free mass even in early stages of disease, and prediction equations 
have been reported as inaccurate in these patients.41, 42 
Over time there have been refinements in some techniques, such as bioelectrical 
impedance analysis (BIA). Original analysers used a single frequency (50kHz) to provide 
body composition estimates. However, single-frequency BIA (SFBIA) is limited in its ability 
to differentiate intra- (ICW) and extra-cellular water (ECW).50 With the introduction of multi-
frequency analysers, it was proposed that differentiation of these water compartments 
using bioelectrical impedance spectroscopy (BIS) was possible.50 Pirlich et al. evaluated 
the accuracy of anthropometrics and multi-frequency BIA (MFBIA), for estimation of body 
cell mass in patients with cirrhosis.110 They found MFBIA to be superior to anthropometrics 
when compared to a total body potassium (TBK) reference. However, a study by Strauss 
et al. suggested that MFBIA also has accuracy issues in patients with cirrhosis when 
compared to a gold standard four-compartment model.42 
More recently, cross-sectional imaging, such as computed tomography (CT), has allowed 
the direct measurement of skeletal muscle mass and adipose tissue using a single 
abdominal image. In theory, this would counteract many of the inaccuracies associated 
with prediction equations. However, this is yet to be validated in patients with cirrhosis. 
Some authors have expressed concerns regarding the accuracy of skeletal muscle mass 
assessment using abdominal CT in the setting of ascites.237 
Another technique that offers direct assessment of skeletal muscle mass at the tissue level 
is the use of ultrasound (US). Campbell et al. described a novel skeletal muscle mass 
estimation technique involving measuring the skeletal muscle thickness (MT) at three 
appendicular sites (upper arm, forearm, and thigh).44 Zenith et al. used a variation of this 
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technique in patients with cirrhosis to monitor the impact of exercise training.55 However 
the accuracy of this method in patients with cirrhosis is yet to be evaluated. 
Prior studies in patients with cirrhosis that have evaluated the accuracy of body 
composition methods against a reference model have suggested that dual energy X-ray 
absorptiometry (DXA) has superior results to most other two-compartment techniques. A 
study by Strauss et al. found that DXA was the most accurate two-compartment method of 
measuring fat mass and fat-free mass in patients with cirrhosis, compared to total body 
protein measurement using in-vivo neutron activation analysis (IVNAA).42 Likewise, 
Morgan et al. found that DXA had superior accuracy than bedside techniques for 
estimating fat mass and fat-free mass.41 It has been proposed that DXA appendicular lean 
mass (ALM) is not affected by ascites and is therefore the preferred method to assess 
skeletal muscle mass.101 However, DXA ALM has not been assessed compared to a 
reference model in patients with cirrhosis. 
The ‘gold standard’ for measurement of whole body skeletal muscle mass is MRI, or a 
multi-compartment model as described in Section 1.2. Unfortunately, several reference 
techniques, including MRI and densitometry, were not available for this study due to 
financial and/or logistical constraints. As such, a multi-compartment reference estimate of 
body cell mass was performed using DXA and tracer dilution testing.  
Body cell mass has previously been used as a surrogate of whole body skeletal muscle 
mass in healthy cohorts and patients with cirrhosis.30, 46 Body cell mass is defined as ‘the 
working energy metabolising portion of the human body’, and is comprised of the non-fat 
tissues (including intracellular water), such as skeletal muscle, viscera and blood [Section 
1.2].70, 238 Skeletal muscle mass represents the dominant cell mass of body cell mass, 
estimated in healthy individuals to be 60% of body cell mass in males and 55% in 
females.71 Body cell mass can be calculated using a multi-compartment model, which by 
definition excludes the extracellular water compartment, and in theory provides an 
estimate of skeletal muscle mass without the confounder of extracellular water excess. It is 
important to emphasise that this model, like many others used in the literature, has not 
been validated in patients with cirrhosis. 
The aim of this study was to examine the relationship of traditional and novel bedside 
skeletal muscle mass estimation techniques (MAMC, BIS, USMT) and radiological 
techniques (DXA, CT) to a multi-compartment reference body cell mass measurement in 
patients with cirrhosis. In addition, we sought to establish the accuracy of BIS in estimating 
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fat mass, total body water (TBW) and extracellular water (ECW) compared to reference 
values. 
4.4 PATIENTS AND METHODS 
A cross-sectional cohort study was performed by recruiting patients with cirrhosis who 
were referred to the Queensland Liver Transplant Service between May 2014 and January 
2017. Ethical approval was granted from the Metro South Hospital and Health Services 
District and The University of Queensland’s Human Research Ethics Committees 
(Approval numbers: HREC/14/QPAH/23; 2014000254). Written informed consent was 
obtained prior to participation. Patients were excluded if they were less than 18 years of 
age and/or had previously received a liver transplant. Forty-two patients were included in 
the analysis. 
Patients were assessed in the outpatient department following an overnight fast. Clinical 
data was collected including patient demographics, medical history, surgical history and 
prescribed medications. Biochemical results were recorded including bilirubin, albumin, 
international normalised ratio (INR), creatinine, and sodium. 
Anthropometrics 
Body weight and height were measured by a single observer (AW) to the nearest 0.1 kg 
and 0.01 cm using standardised equipment and procedures. Mid-upper arm circumference 
(MAC) and triceps skinfold (TSF) measurements were taken on the right side and used to 
calculate the mid-arm muscle circumference (MAMC) as described in Section 2.2.1. Three 
patients did not have a TSF measurement performed due to logistical issues. 
Bioelectrical impedance spectroscopy 
Right side whole body bioelectrical impedance spectroscopy (BIS) was performed using a 
Bioimp SFB7 (Impedimed, Brisbane, Australia) as described in Section 2.2.2.  
Equations to estimate skeletal muscle mass in healthy populations using bioelectrical 
impedance data have been developed by several groups. These have not been evaluated 
in patients with cirrhosis previously. Skeletal muscle mass was predicted from the 
impedance data using the published equations from Kyle et al., Janssen et al. and 




BIA appendicular skeletal muscle mass using the equation of Kyle et al.239:  
SMMKyle =  -4.211 + (0.267*Ht2 /R) + (0.095*W) + (1.909*sex [M = 1, F = 0]) + 
(-0.012*Age) + (0.058*Xc) 
BIA whole body skeletal muscle mass was estimated using the equation from Janssen et 
al.240: 
SMMJanssen (kg): [(Ht2/R*0.401) + (sex [M = 1, F = 0]*3.825) + (age*-0.071)] + 5.102 
Where Ht = height, R = Resistance, W = weight; M = male, F = female and Xc = 
reactance. R and Xc at 50kHz were extracted from the BIS data.  
BIS whole body skeletal muscle mass using the equation from Tengvall et al.241: 
SMMTengvall = -24.05 + (0.365*Ht) + (-0.005*Ri) + (-0.012*Re) +  
(-1.337*sex (M=0, F=1)) 
Where Ri = intracellular resistance; Re = extracellular resistance. 
Appendicular skeletal muscle index (SMI) and whole body SMI were calculated by 
adjusting for height, squared. Thresholds for diagnosis of appendicular skeletal muscle 
mass depletion were a SMI less than 7.26kg/m2 for men and 5.45kg/m2 for women.27 Low 
whole body SMI was defined as less than ≤8.50 kg/m2 for men and ≤5.75 kg/m2 for 
women.242 
Ultrasound muscle thickness 
Ultrasound (US) estimation of skeletal muscle mass was performed using a Phillips EPIQ 
Ultrasound Scanner (Phillips, Andover, MA, USA) as described in Section 2.2.3.  
Inter-observer variability was assessed on 10 patients by a second observer (AW) 
performing a blinded examination on the same day. The intraclass correlation coefficient 
(ICC) was 0.97 (95%CI 0.87-0.99). It was planned to assess intra-observer variability by 
re-examining 10 patients within four weeks by the same observer (SK). However, due to 
logistical constraints, results were only obtained in four patients precluding ICC analysis. 
Ultrasound muscle thickness (USMT) testing was initiated after the inception of the study, 




Computed tomography  
Computed Tomography (CT) of the abdomen was analysed as described in Section 2.2.4. 
Using the data from Chapter 3, thresholds for low CT skeletal muscle index (Class I 
skeletal muscle mass depletion) were less than 48.9cm2/m2 for males and 36.3cm2/m2 for 
females. These thresholds represent values one standard deviation from the ‘young 
healthy’ reference and are similar to the cut-offs used by Prado et al. which have 
prognostic significance in patients with cirrhosis. 
All images were analysed by a single trained observer (AW). Intra-observer variability was 
assessed by re-analysing 10 randomly selected scans after a six-month interval. The ICC 
for skeletal muscle area was 0.99 (95%CI 0.98 – 0.99), while VAT was 1.00 (95%CI 0.99 - 
1.00) and SAT was 1.00 (95%CI 1.00 – 1.00). Coefficient of variation (CV) values were 
2.0%, 1.7% and 0.9% respectively. To examine potential variation in image analysis 
software, the same scans were analysed using Slice-O-Matic (Tomovision, Montreal, QC, 
Canada), providing an ICC of 0.99 (95%CI 0.95 – 0.99), 1.00 (95%CI 0.99 - 1.00) and 1.00 
(95%CI 1.00 - 1.00) for skeletal muscle area, VAT and SAT, respectively. Inter-observer 
variability was determined by a radiologist (JR) using ImageJ who was blinded to the 
analysis. The ICC was 0.99 (95%CI 0.97 - 1.00), 1.00 (95%CI 0.99 - 1.00) and 0.99 
(95%CI 0.99 - 1.00) for skeletal muscle area, VAT and SAT, respectively. 
The time interval between the CT scan and other body composition assessments was 
recorded. CT data was excluded if the time between the two assessments was greater 
than three months, leaving 35 patients with data for inclusion. One patient did not have a 
pre-transplant CT available for analysis. 
Dual-energy X-ray absorptiometry 
A whole body DXA scan was performed using a GE Prodigy Scanner (GE Healthcare 
Lunar, Madison, WI, USA) as described in Section 2.2.5. Depletion of skeletal muscle 
mass was defined as a DXA SMI less than 7.26kg/m2 for men and 5.45kg/m2 for women.27 
Total body potassium  
Total body potassium counting was performed using a shadow-shield whole-body counter 
(Accuscan, Canberra Industries, Boston, MA) as described in Section 2.2.6.  
Body cell mass was calculated using the following equation from Wang et al.70:  
BCMTBK (kg) = (TBK (g) x 9.20)/39.1. 
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Two patients did not have a TBK scan for logistical reasons. 
Body water assessment 
Assessment of water compartments was performed using deuterium (D2O) and bromide 
(Br) dilution tests as described in Section 2.2.7 above.  
Body cell mass reference model 
A multi-compartment ‘reference’ measurement of body cell mass was calculated as 
described by Wang et al. for comparison with skeletal muscle mass estimates.70 Wang et 
al. described a body cell mass model as follows:70  
BCM (kg) = FFMDXA (kg) – extracellular solids (ECS) (kg) –  
extracellular fluid (ECF) (kg) 
Where ECS = 1.732 x DXA bone mass/0.9582 and ECF = ECW/b where b is the fraction 
of ECF that consists of ECW. b has been estimated at 0.98.70 
4.5 STATISTICAL ANALYSIS 
Statistical analyses were performed using MedCalc Statistical Software (Version 17.9.7; 
Ostend, Belgium). Continuous data were assessed for normality using a Shapiro-Wilk test 
and are presented as means ± SD (for normally distributed data), or medians and IQR (for 
non-normally distributed data). Non-normally distributed data were transformed 
(logarithmic, square or exponential) where possible for statistical analysis. 
The relationship between skeletal muscle mass estimates and the body cell mass 
reference was assessed using Pearson’s (rp) correlation. 
Agreement between reference body composition values and estimates of fat mass, fat-free 
mass, TBW and ECW was assessed using Pearson’s (rp) and concordance correlation (rc) 
as well as by limits of agreement analysis according to the method of Bland and Altman.243 
For interpretation of Pearson correlation coefficients, Cohen's levels were used.233 
A receiver-operator characteristic (ROC) curve was used to evaluate the utility of USMT 
for the diagnoses of skeletal muscle mass depletion in male patients using the DXA 
threshold of Baumgartner et al. as the reference.53 The area under the ROC (AUROC) 
value is presented. The value with the highest sensitivity and specificity for predicting 




Forty-two patients (36 men, 6 women) with a median age of 56 years (interquartile range 
[IQR] 48–60) were included in the analysis. Patient clinical characteristics are shown in 
Table 4-1. 
Body composition results are shown in Table 4-2. The cohort had a mean weight of 82.5 ± 
16.1 kg, with a median DXA fat mass of 21.0 kg (IQR 15.1-27.6) and mean DXA fat-free 
mass of 60.2 ± 10.5 kg. The mean reference body cell mass (BCMDXA/Br) was 34.3 ± 7.2 
kg. Bland and Altman analysis of body cell mass measured by total body potassium 
counting was compared to the reference body cell mass measurement (BCMDXA/Br). 
Compared to the BCMDXA/Br, the BCMTBK had a significant mean bias of 14.9 kg (P < 0.001) 
with LOA ±11.4 kg.  
Table 4-1. Patient characteristics 
Characteristic Result 
Number of patients 42 
Age 56 (48-60) 
Sex: male [n (%)] 36 (86%) 
Ethnicity [n (%)]  
Caucasian 37 (88%) 
Asian 3 (7%) 
Indigenous 1 (2%) 
Other  1 (2%) 
Aetiology of liver disease [n (%)]  
Chronic hepatitis C 26 (62%) 
Alcohol 5 (12%) 
Primary sclerosing cholangitis 3 (7%) 
Other 8 (19%) 
Hepatocellular carcinoma [n (%)] 22 (52%) 
Laboratory values  
Bilirubin (µmol/L) 37 (22-61) 
Albumin (g/L) 31 ± 6 
INR 1.4 (1.2-1.6) 
Creatinine (µmol/L) 69 (58-86) 
Sodium (mmol/L) 136 ± 3 
MELD score 14 ± 5 
Child-Pugh class [n (%)]  
A 15 (36%) 
B 15 (36%) 
C 12 (29%) 
Ascites [n (%)]  
None 21 (50%) 
Mild/diuretic controlled 15 (36%) 
Moderate/severe 6 (14%) 
Values presented as mean (± SD), or median (interquartile range) where data were not normally distributed, and number and 
percentage. MELD - Model for end-stage liver disease; INR – International normalised ratio 




Table 4-2. Body composition measurements 
Characteristic Men N = 36 
Women 
N = 6 Overall 
Anthropometrics    
Height (m) 1.77 ± 0.07 1.64 ± 0.05 1.75 ± 0.08 
Weight (kg) 84.7 ± 15.4 69.3 ± 14.4 82.5 ± 16.1 
BMI (mg/kg2) 27.2 ± 4.7 25.6 ± 5.0 26.9 ± 4.7 
MAMC (cm) 26.3 ± 2.4 22.8 ± 3.9 30.2 ± 3.9 
Ultrasound     
US MT upper arm (cm) 2.87 ± 0.31 2.13 ± 0.47 2.72 ± 0.46 
US MT forearm (cm) 3.57 (3.21-3.74) 2.90 (2.58-3.12) 3.52 (3.10-3.63) 
US MT thigh (cm) 4.15 ± 0.64 3.66 ± 0.73 4.05 ± 0.67 
US MT total (cm) 10.52 ± 0.73 8.60 ± 1.25 10.13 ± 1.15 
Dual energy X-ray absorptiometry     
Fat mass (kg) 20.6 (13.6-27.4) 21.8 (18.8-29.8) 21.0 (15.1-27.6) 
Fat-free mass (kg) 62.7 ± 8.7 45.5 ± 8.6 60.2 ± 10.5 
Bone mass (kg) 3.09 ± 0.52 2.32 ± 0.33 2.98 ± 0.57 
Appendicular lean mass (kg) 24.9 ± 4.0 17.7 ± 4.2 23.9 ± 4.8 
Appendicular SMI (kg/m2) 7.99 ± 1.13 6.52 ± 1.49 7.78 ± 1.28 
Deuterium and bromide body water     
Total body water [D2O] (L) 50.4 ± 8.0 38.0 ± 7.9 48.6 ± 9.0 
Extracellular water [Br] (L) 20.9 ± 5.8 15.4 ± 5.9 20.1 ± 6.1 
Intracellular water (L) 29.5 ± 5.9 22.6 ± 8.0 28.5 ± 6.6 
Hydration of fat-free mass 79.6% (77.3-81.7) 84.1% (80.7-86.8) 80.1% (77.3-83.0) 
Total body potassium counting    
TBK (g) 96.4 ± 14.9 70.4 ± 9.0 93.2 ± 16.7 
Bioelectrical impedance spectroscopy      
Fat mass (kg) 18.0 (12.1-27.9) 21.8 (19.5-27.2) 18.2 (13.3-27.6) 
Fat-free mass (kg) 66.0 ± 11.8 45.7 ± 9.9 62.5 ± 12.7 
Appendicular SMM (kg) [Kyle] 26.7 ± 4.3 18.1 ± 3.8 25.5 ± 5.2 
Whole body SMM (kg) [Janssen] 33.7 ± 5.0 21.9 ± 4.9 32.1 ± 6.5 
Whole body SMM (kg) [Tengvall] 27.5 ± 3.2 17.1 ± 6.1 27.6 (23.9-29.3) 
Total body water (L) 47.5 ± 8.3 34.9 ± 8.0 45.7 ± 9.3 
Extracellular water (L) 21.7 ± 3.7 15.4 ± 3.6 20.8 ± 4.2 
Computed tomography    
Skeletal muscle area (cm2) 168.4 ± 27.9 117.4 ± 12.3 160.9 ± 31.8 
VAT area (cm2) 112.3 (75.6-191.7) 66.4 (49.6-88.0) 104.9 (69.0-160.0) 
SAT area (cm2) 151.7 (92.3-207.3) 185.7 (95.9-260.3) 152.6 (97.2-211.3) 
Body cell mass estimates    
BCMDXA/Br (kg) 35.8 ± 6.0 25.6 ± 8.5 34.3 ± 7.2 
BCMTBK (kg) 22.7 ± 3.5 16.6 ± 2.1 21.9 ± 3.9 
Values presented as mean (± SD), or median (interquartile range) where data were not normally distributed, and number and 
percentage.  
BMI - Body mass index; MAMC – Mid-arm muscle circumference; US MT – Ultrasound muscle thickness; D2O – Deuterium; Br – 
Bromide; TBK – Total body potassium; BCM - Body cell mass; SMA – Skeletal muscle area; SMI – Skeletal muscle index; SMM; 
Skeletal muscle mass; VAT - Visceral adipose tissue area; SAT - Subcutaneous adipose tissue area. 
 USMT Male n = 23; Female n = 6 
 
Skeletal muscle mass estimation 
Comparison of skeletal muscle mass estimation techniques with reference body cell mass 




Table 4-3. Comparison of skeletal muscle mass estimates to a body cell mass reference  
 Men Women Overall 
 r P Value r P Value r P Value 
MAMC (cm) § 0.442 0.011 0.898 0.015 0.665 <0.001 
BIAKyle (kg) 0.702 <0.001 0.814 0.048 0.792 <0.001 
BIAJanssen (kg) 0.698 <0.001 0.714 0.111 0.782 <0.001 
BISTengvall (kg) 0.702 <0.001 0.713 0.112 0.782 <0.001 
US MT biceps (cm) 0.218 0.319 0.829 0.042 0.636 <0.001 
US MT forearm (cm) ‡ 0.299 0.165 0.467 0.350 0.555 0.002 
US MT thigh (cm)  0.355 0.096 0.438 0.385 0.464 0.011 
US MT total (cm)  0.500 0.015 0.600 0.208 0.737 <0.001 
US MT arm# (cm) ‡ 0.379 0.074 0.738 0.094 0.645 <0.001 
DXA ALM (kg) 0.699 <0.001 0.714 0.111 0.781 <0.001 
CT SMA (cm2) Δ 0.595 <0.001 0.943 0.005 0.752 <0.001 
# US MT Arm = US MT biceps + forearm  n = 29 § n = 37 Δ n = 30 ‡ Analysis performed with transformed data 
BCM - Body cell mass; TBK – Total body potassium; DXA – Dual energy X-ray absorptiometry; MAMC – Mid-arm muscle 
circumference; BIA – Bioelectrical impedance analysis; BIS – Bioelectrical impedance spectroscopy; US MT – Ultrasound muscle 
thickness; ALM – Appendicular lean mass; CT – Computed tomography; SMA – Skeletal muscle area 
Traditional bedside measurements (MAMC, BIA, BIS) correlated strongly with the 
reference body cell mass measurement. Upper limb ultrasound muscle thickness 
measurements also strongly correlated to the body cell mass reference, however thigh 
measurements had at best moderate correlation (rp = 0.464). Total US muscle thickness 
results had strong correlation to the reference methods. Isolating upper limb muscle 
thickness measurements (USMT arm) did not improve the correlation coefficients. CT 
skeletal muscle area and DXA SMI were both strongly correlated to body cell mass. BIA 
and DXA ALM measurements had the highest correlation coefficients compared to the 
body cell mass reference. 
Effect of ascites on skeletal muscle mass measurements 
To evaluate the impact of overt ECW excess on skeletal muscle mass estimation, results 
were re-analysed after patients were divided according to presence or absence of ascites 
on clinical examination. There were 21 patients with and 21 without clinically detected 
ascites. 
Comparison of skeletal muscle mass estimates to the body cell mass reference was 
performed using Pearson correlation coefficients and is shown in Table 4-4 and Table 4-5. 
All skeletal muscle mass estimates except the MAMC had stronger correlation coefficients 
in patients without ascites. 
In patients without ascites, traditional bedside skeletal muscle mass estimates had inferior 
correlation coefficients to DXA ALM. 
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Table 4-4. Pearson correlation coefficients comparing skeletal muscle mass estimates to reference 
body cell mass in patients without ascites (n = 21; men = 18, women = 3) 
 Men Overall 
 r P Value r P Value 
MAMC (cm) § 0.308 0.230 0.524 0.018 
BIAKyle (kg) 0.747 <0.001 0.811 <0.001 
BIAJanssen (kg) 0.751 <0.001 0.816 <0.001 
BISTengvall (kg) 0.806 <0.001 0.858 <0.001 
US MT biceps (cm) 0.580 0.061 0.808 <0.001 
US MT forearm (cm)  0.117 0.731 0.514 0.060 
US MT thigh (cm)  0.544 0.083 0.291 0.312 
US MT total (cm)  0.696 0.017 0.782 0.001 
US MT arm# (cm)  0.523 0.099 0.784 0.001 
DXA ALM (kg) 0.828 <0.001 0.877 <0.001 
CT SMA (cm2) Δ 0.718 <0.001 0.835 <0.001 
# US MT Arm = US MT biceps + forearm § n = 20  n = 14 (Men = 11; Women = 3) Δ n = 18 
BCM - Body cell mass; TBK – Total body potassium; DXA – Dual energy X-ray absorptiometry; MAMC – Mid-arm muscle 
circumference; BIA – Bioelectrical impedance analysis; BIS – Bioelectrical impedance spectroscopy; US MT – Ultrasound muscle 
thickness; ALM – Appendicular lean mass; CT – Computed tomography; SMA – Skeletal muscle area 
Note: insufficient numbers for isolated analysis of female patients  
Table 4-5. Pearson correlation coefficients comparing skeletal muscle mass estimates to reference 
body cell mass in patients with ascites (n = 21; men = 18, women = 3) 
 Men Overall 
 r P Value r P Value 
MAMC (cm) § 0.614 0.015 0.802 <0.001 
BIAKyle (kg) 0.718 0.001 0.800 <0.001 
BIAJanssen (kg) 0.691 0.002 0.775 <0.001 
BISTengvall (kg) 0.657 0.003 0.765 <0.001 
US MT biceps (cm) -0.199 0.536 0.465 0.095 
US MT forearm (cm) ‡ 0.426 0.167 0.604 0.017 
US MT thigh (cm)  0.217 0.497 0.618 0.014 
US MT total (cm) ‡ 0.282 0.123 0.697 0.004 
US MT arm# (cm) ‡ 0.156 0.628 0.481 0.070 
DXA ALM (kg) 0.571 0.013 0.694 0.001 
CT SMA (cm2) Δ ‡ 0.486 0.048 0.649 0.002 
# US MT Arm = US MT biceps + forearm § n = 18  n = 15 (men = 12; women = 3)  Δ n = 20  ‡ Analysis performed with transformed data 
BCM - Body cell mass; TBK – Total body potassium; DXA – Dual energy X-ray absorptiometry; MAMC – Mid-arm muscle 
circumference; BIA – Bioelectrical impedance analysis; BIS – Bioelectrical impedance spectroscopy; US MT – Ultrasound muscle 
thickness; ALM – Appendicular lean mass; CT – Computed tomography; SMA – Skeletal muscle area 
Note: insufficient numbers for isolated analysis of female patients  
Evaluation of skeletal muscle mass estimates in patients with ascites showed that DXA 
appendicular lean mass, CT skeletal muscle area, mid-arm muscle circumference and 
bioelectrical impedance were strongly correlated with the body cell mass reference. US 
muscle thickness measurements had inferior correlation coefficients, and in some 
instances, there was no significant relationship to the body cell mass reference. 
Bioelectrical impedance spectroscopy fat-free mass estimation 
Comparison of fat-free mass measured by DXA and BIS was performed [Figure 4-1]. 
Pearson correlation showed a strong relationship (rp = 0.931; P < 0.001), while 
concordance correlation coefficient (rc = 0.899) suggested a minor deviation from the line 
of identity. Limits of agreement (LOA) analysis demonstrated a significant mean 
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systematic bias of -2.2 kg (P = 0.005) with large limits of agreement (± 9.5 kg). There was 
a significant weak inverse correlation (rp = -0.192; P = 0.003) between the difference in 
DXA-measured and BIS predicted fat-free mass and the mean fat-free mass. Thus, BIS 
overpredicted fat-free mass with increasing mean fat-free mass values.  
Sex-specific differences in fat-free mass are shown in supplementary Figure 4-6. 
  
Figure 4-1. Comparison of total body fat-free mass measured by dual energy X-ray absorptiometry 
(DXA) and bioelectrical impedance spectroscopy (BIS). (a) Scatter plot of DXA and BIS fat-free mass. 
Solid line - regression line; dashed line - 95% confidence interval; dotted line - line of identity. ** 
Significant at 0.01 level. (b) Limits of agreement analysis for total body fat mass measured by DXA 
and BIS. Blue dashed line - regression line with 95% confidence intervals; solid line - mean bias; 
dashed line - limits of agreement; dotted line - zero reference. ** Significant at 0.01 level 
Bioelectrical impedance spectroscopy estimation of fat mass 
Estimation of fat mass by BIS was compared to DXA fat mass using concordance 
correlation and LOA analysis [Figure 4-2]. Pearson correlation demonstrated a strong 
relationship (rp = 0.865; P < 0.001), while the concordance correlation coefficient (rc = 
0.842) suggested only a minor deviation from the line of identity. However, LOA analysis 
showed a significant systematic negative bias of 2.1 kg (P = 0.005) with large LOA (± 9.2 
kg). There was a weak but significant positive correlation (rp = 0.212; P = 0.016) between 
the difference in DXA-measured and BIS predicted fat mass and the mean fat mass of the 
two methods. Thus, with increasing fat mass, BIS underpredicted fat mass. In those 
subjects with moderate-severe ascites, BIS overpredicted fat mass in most cases.  
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Figure 4-2. Comparison of total body fat mass measured by dual energy X-ray absorptiometry (DXA) 
and bioelectrical impedance spectroscopy (BIS). (a) Scatter plot of DXA and BIS fat mass. Solid line - 
regression line; dashed line - 95% confidence interval; dotted line - line of identity. ** Significant at 
0.01 level. (b) Limits of agreement analysis for total body fat mass measured by DXA and BIS. Blue 
dashed line - regression line with 95% confidence intervals; solid line - mean bias; dashed line - 
limits of agreement; dotted line - zero reference. * Significant at 0.05 level 
Bioelectrical impedance spectroscopy body water estimation 
Comparison of TBW measured by isotope (deuterium) dilution was compared to BIS 
predicted TBW [Figure 4-3]. The Pearson correlation coefficient revealed a strong 
relationship (rp = 0.889; P < 0.001), while the concordance correlation coefficient (rc = 
0.832) again suggested a minor deviation from the line of identity. LOA analysis found a 
significant systematic bias of 2.9 L (P < 0.01) with large limits of agreement of ±8.0 L. 
Patients with moderate-severe ascites were associated with an underestimation of TBW. 
  
Figure 4-3. Comparison of total body water (TBW) measured by deuterium and bioelectrical 
impedance spectroscopy (BIS). (a) Scatter plot of deuterium and BIS total body water. Solid line - 
regression line; dashed line - 95% confidence interval; dotted line - line of identity. ** Significant at 
0.01 level. (b) Limits of agreement analysis for total body water measured by deuterium and BIS. Blue 
dashed line - regression line with 95% confidence intervals; solid line - mean bias; dashed line - 
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Analysis of ECW measurements showed a considerably lower Pearson correlation 
coefficient (rp = 0.631), while the concordance correlation coefficient (rc = 0.590) 
suggested a large deviation from the line of identity [Figure 4-4]. LOA analysis found a 
non-significant mean negative bias of 0.7 L (P = 0.350), but large limits of agreement (± 
9.3 L). BIS consistently underestimated ECW in patients with moderate-severe ascites. 
Sex-specific differences in body water are shown in supplementary Figure 4-8 and Figure 
4-9. 
  
Figure 4-4. Comparison of extracellular water (ECW) measured by bromide dilution and bioelectrical 
impedance spectroscopy (BIS). (a) Scatter plot of Bromide and BIS ECW. Solid line - regression line; 
dashed line - 95% confidence interval; dotted line - line of identity. ** Significant at 0.01 level. (b) 
Limits of agreement analysis for Bromide and BIS ECW. Blue dashed line - regression line with 95% 
confidence intervals; solid line - mean bias; dashed line - limits of agreement; dotted line - zero 
reference. ** Significant at 0.01 level 
Comparison of skeletal muscle mass techniques at diagnosing skeletal muscle 
mass depletion. 
A complete body composition data set was available in 30 patients and used to assess the 
diagnosis of sarcopenia per modality. Previously published thresholds for diagnosis of 
skeletal muscle mass depletion were used for MAMC, BIA, BIS, DXA and CT. A 
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Figure 4-5. Frequency of skeletal muscle mass depletion diagnosis according to modality (n = 30) 
MAMC, BISTengvall and CT SMI all diagnosed skeletal muscle mass depletion in 8 patients 
(27%), while 7 patients were classified as having low skeletal muscle mass using DXA 
SMI. BIAKyle skeletal muscle mass depletion frequency (10%) was significantly lower (P = 
0.009) compared to DXA SMI. Using BIAJanssen no patients were classified as having 
skeletal muscle mass depletion. 
However, when compared with a diagnosis of skeletal muscle mass depletion using DXA 
SMI, MAMC misclassified 5 patients, CT SMI misclassified 7 patients, and BISTengvall 
misclassified 5 patients. 
There are no published thresholds for skeletal muscle mass depletion using US muscle 
thickness. A sensitivity and specificity analysis was performed in male patients to assess 
the ability USMT Total (corrected for height squared) to diagnose DXA SMI defined 
skeletal muscle mass depletion. There was a non-significant AUROC of 0.759 (95%CI 
0.536-0.983). The optimal threshold for diagnosis of skeletal muscle mass depletion was 
3.24 cm/m2 (Sn 67%, Sp 78%). 
4.7 DISCUSSION 
The primary aim of this study was to evaluate the utility of techniques used to estimate 
skeletal muscle mass in patients with cirrhosis, including traditional bedside methods 
(MAMC, BIA/BIS) and novel techniques (US muscle thickness). When compared to a body 
cell mass reference, the BIS, mid-arm muscle circumference, DXA and CT skeletal muscle 
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mass estimates had strong correlation coefficients. For all modalities except the mid-arm 
muscle circumference, the relationships were weaker in patients with ascites. This 
highlights the accuracy issues of two-compartment body composition models in patients 
with cirrhosis, and is consistent with several prior publications. In a study of 198 patients 
with cirrhosis, Strauss et al. found anthropometry and BIA to be inaccurate at estimating 
fat-free mass compared to a gold standard model.42 Morgan et al. also found that 
anthropometry, BIA, near-infrared interactance, and creatinine excretion were inaccurate 
compared to a fat-free mass reference derived from a four-component model.41 
US muscle thickness has been proposed as a novel technique to estimate skeletal muscle 
mass in patients with fluid retention, however our results do not support its use over 
BIA/BIS or the MAMC. US muscle thickness had inferior correlation coefficients to the 
body cell mass reference, particularly in patients with ascites. Further refinement in 
technology and technique are required to improve its ability to estimate skeletal muscle 
mass before use in the clinical setting. 
Despite the overall strong correlation coefficients observed with anthropometry and BIS 
assessments of skeletal muscle mass, these techniques have well documented limitations. 
Anthropometry has known issues with intra- and inter-observer variability, and requires 
specialised training and equipment.19 BIA/BIS is associated with less observer variability, 
but also requires specialised equipment, and current prediction equations still assume a 
normal hydration fraction of fat-free mass.239-241 In addition, there are discrepancies in the 
diagnosis of skeletal muscle mass depletion when using standard thresholds. For 
example, use of BIS and BIA (BIAKyle and BIAJanssen) prediction equations and previously 
published thresholds for diagnosis of skeletal muscle mass depletion resulted in a 
significant under-diagnosis compared to DXA skeletal muscle index. Whilst other 
modalities resulted in a similar frequency of skeletal muscle mass depletion diagnosis, up 
to 8 patients per modality were misdiagnosed. This highlights the difficulty in comparing 
sarcopenia studies given the heterogeneity in skeletal muscle mass assessment 
modalities and thresholds used. If any of the bedside methods are used for estimation of 
skeletal muscle mass, the results should be interpreted with caution, particularly for 
patients with overt fluid overload. 
In this study, the relationship of DXA appendicular lean mass and CT skeletal muscle area 
to a body cell mass reference was also examined. Both DXA appendicular lean mass and 
CT skeletal muscle area have been advocated as accurate measures of skeletal muscle 
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mass in the cirrhosis population.101, 128 DXA appendicular lean mass provided the 
strongest overall correlation coefficients to the reference body cell mass measurement. 
However, these coefficients are much lower than those observed when DXA appendicular 
lean mass was compared to whole body skeletal muscle mass in a healthy population (rp = 
0.950; P < 0.01).244  
CT skeletal muscle area on a single abdominal slice has also been validated as an 
accurate predictor of total skeletal muscle mass in a healthy population.43 However, some 
authors have expressed concern regarding a lack of validation of CT estimation in patients 
with ascites. Our results in patients with ascites supports this concern. The strength of 
correlation to the body cell mass reference declined in patients with ascites, and in male 
patients, there was no significant relationship detected. One explanation for the poor 
relationship is that muscle, ascites and oedema can have similar radiodensities and 
therefore cause interference with the image analysis software. 
This is the first study, to the author’s knowledge, to compare CT skeletal muscle area or 
DXA appendicular lean mass to a multi-compartment body cell reference in patients with 
cirrhosis. However, it is important to note that this model, like most body composition 
models, has not been validated in patients with cirrhosis. With the multi-compartment 
model chosen, we believe the body cell mass measurement provides a suitable estimate 
of skeletal muscle mass which takes into account body water compartments. Lack of a 
reference method which provided a direct measurement of total body protein or whole-
body skeletal muscle mass (e.g in-vivo neutron activation analysis and MRI respectively) is 
a limitation of this study. This prevented a limits of agreement analysis for the skeletal 
muscle mass estimates. Measurement of body density would also have allowed 
calculation of a four-compartment model. However, the use of tracer dilution tests to 
measure body water compartments and DXA to measure fat mass, fat-free mass and bone 
mass were considered a suitable alternative in patients with cirrhosis given the limited 
resources available at the initiation of this study.41, 42 This model relies on the assumption 
that DXA is an accurate method of measuring fat mass and fat-free mass in patients with 
cirrhosis. This was supported by the Strauss et al. study.42 However, Morgan et al. found 
that DXA estimates can be affected by the altered hydration fraction of the fat-free mass, 
with errors of up 6% in percentage body fat and 3.7 kg in fat-free mass compared to a gold 
standard four-compartment model.41 Both studies used high quality multi-compartment 
models, although each differed in the modalities used, as well as the type of DXA scanner. 
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Total body counting was utilised in our study and has been considered by some centres as 
a reference method for assessment of body cell mass and skeletal muscle mass, even in 
patients with excess ECW.72 Other authors have expressed concern regarding the 
accuracy of TBK counting for body composition evaluation in patients with cirrhosis due to 
disturbances in total body potassium and intracellular potassium concentration.73, 74 The 
TBK estimates of body cell mass in our study were significantly lower (P < 0.001) than the 
reference body cell mass measurement. This is consistent with the study by Strauss et al., 
which demonstrated a significant fat-free mass underestimation with TBK counting of 4.3 
kg with wide LOA (±11.7 kg).42 
A secondary aim of this study was to evaluate the utility of the latest BIS hardware and 
resistivity coefficients to assess fat mass, fat-free mass, TBW and ECW in patients with 
cirrhosis. Compared to reference measurements, the BIS results showed stronger 
correlation coefficients for fat mass, fat-free mass and TBW than the skeletal muscle mass 
measurements, although the limits of agreement remained large for all variables. The 
largest source of error appeared to be the BIS estimates of ECW, with a concordance 
correlation coefficient of 0.586 and large limits of agreement of ±9.3 L. BIS underestimated 
ECW with increasing ECW levels. Therefore, BIS currently has limited utility in patients 
with increased ECW, such as decompensated cirrhosis. However, technology 
advancements may be able to improve estimation of body water compartments, and allow 
the development of prediction equations which account for disturbances in hydration 
status.  
Assessment for skeletal muscle mass depletion is an essential component of the 
evaluation of a patient with cirrhosis, since it has been consistently associated with 
adverse outcomes. Intervention with nutritional, pharmacological or exercise based 
therapies has the potential to improve outcomes, although further studies are required to 
address this question. Despite the limitations of the body cell mass reference model, the 
study provides an important evaluation of skeletal muscle mass estimation techniques, 
both traditional and novel in patients with cirrhosis. We recommend assessment of skeletal 
muscle mass using DXA appendicular lean mass where feasible and evaluation for low 
skeletal muscle mass using the thresholds of Baumgartner et al.53 In our study, DXA 
appendicular lean mass had one of the strongest relationships to the body cell mass 
reference model. In addition, prior studies have demonstrated that is has excellent 
reproducibility in healthy adults.226, 245 DXA can also provide an accurate assessment of 
bone mass and density, even in patients with a disturbance in hydration status.246 
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However, use of DXA lean mass does have limitations in patients with cirrhosis, in 
particular its assumptions regarding the hydration of fat-free mass.41, 42 Use of the 
appendicular lean mass will minimise the impact of ascites on skeletal muscle mass 
estimation and has established depletion thresholds which are associated with adverse 
outcomes.101 CT assessment of skeletal muscle mass is a reasonable alternative, 
although only in patients who have had this imaging for an alternative indication.  
Perhaps of even greater importance is that assessment of skeletal muscle mass forms 
part of a global assessment of sarcopenia, including assessment of muscle strength and 
physical performance. In the setting of cirrhosis, each of these components have 
previously been associated with adverse outcomes as described in Chapter 1. The 
comprehensive assessment of sarcopenia is the theme of Chapter 5. 
To conclude, these results confirm the difficulties in assessing skeletal muscle mass in 
patients with cirrhosis, in particular those with significant fluid overload. We suggest the 
use of DXA for evaluation of skeletal muscle mass in research and clinical practice where 
feasible. BIA, BIS and anthropometrics also had strong relationships to the reference body 
cell mass and could be used as an alternative. However, they have significant known 
limitations and did result in misdiagnosis of skeletal muscle mass depletion compared to 
the DXA skeletal muscle index. Further refinement of established techniques or 
development of novel bedside techniques to measure skeletal muscle mass in patients 
with cirrhosis is required. Identification of high-risk patients may improve outcomes if 





Figure 4-6. Sex-specific comparison of total body fat-free mass measured by dual energy X-ray 
absorptiometry (DXA) and bioelectrical impedance spectroscopy (BIS). (a) Scatter plot of DXA and 
BIS fat-free mass. Solid line - regression line; dashed line - 95% confidence interval; dotted line - line 
of identity. ** Significant at 0.01 level. (b) Limits of agreement analysis for total body fat mass 
measured by DXA and BIS. Blue dashed line - regression line with 95% confidence intervals; solid 




Figure 4-7. Sex-specific comparison of total body fat mass measured by dual energy X-ray 
absorptiometry (DXA) and bioelectrical impedance spectroscopy (BIS). (a) Scatter plot of DXA and 
BIS fat mass. Solid line - regression line; dashed line - 95% confidence interval; dotted line - line of 
identity. ** Significant at 0.01 level. (b) Limits of agreement analysis for total body fat mass measured 
by DXA and BIS. Blue dashed line - regression line with 95% confidence intervals; solid line - mean 
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Figure 4-8. Sex-specific comparison of total body water (TBW) measured by deuterium and 
bioelectrical impedance spectroscopy (BIS). (a) Scatter plot of deuterium and BIS total body water. 
Solid line - regression line; dashed line - 95% confidence interval; dotted line - line of identity. ** 
Significant at 0.01 level. (b) Limits of agreement analysis for total body water measured by deuterium 
and BIS. Blue dashed line - regression line with 95% confidence intervals; solid line - mean bias; 
dashed line - limits of agreement; dotted line - zero reference 
 
  
Figure 4-9. Sex-specific comparison of extracellular water (ECW) measured by bromide dilution and 
bioelectrical impedance spectroscopy (BIS). (a) Scatter plot of Bromide and BIS ECW. Solid line - 
regression line; dashed line - 95% confidence interval; dotted line - line of identity. ** Significant at 
0.01 level. (b) Limits of agreement analysis for Bromide and BIS ECW. Blue dashed line - regression 
line with 95% confidence intervals; solid line - mean bias; dashed line - limits of agreement; dotted 
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 COMPREHENSIVE ASSESSMENT OF 
SARCOPENIA AND ITS CLINICAL SIGNIFICANCE IN PATIENTS 





The European Working Group on Sarcopenia in Older Persons (EWGSOP) has 
recommended that assessment of sarcopenia should include evaluation of skeletal muscle 
mass, muscle strength and physical performance. Low skeletal muscle mass, muscle 
weakness and impaired physical performance have all been associated with inferior 
outcomes in patients undergoing liver transplantation. However, few of these studies have 
included an evaluation of all three components of sarcopenia. Therefore, in this study we 
performed a comprehensive assessment of sarcopenia in order to determine its impact on 





Introduction: Sarcopenia has been associated with an increased risk of pre- and post-liver 
transplant morbidity and mortality in patients with cirrhosis. It is recommended that 
assessment of sarcopenia should involve measuring skeletal muscle mass, muscle 
strength and physical performance using standardised criteria such as the European 
Working Group on Sarcopenia in Older People (EWGSOP) guidelines. The aim of this 
investigation was to examine the prevalence of EWGSOP sarcopenia and explore the 
prognostic utility of each component in patients undergoing liver transplantation. 
Patients and methods: We prospectively recruited patients with cirrhosis referred to the 
Queensland Liver Transplant Service. Assessment of sarcopenia was performed 
according to the guidelines of the EWGSOP, including measurement of skeletal muscle 
mass using dual energy X-ray absorptiometry (DXA), muscle strength and physical 
performance. Clinical outcome data were collected pre-transplant and within 90 days post-
liver transplantation. 
Results: Sixty-eight patients (age 55 years, interquartile range 46-60, 82% male) 
completed baseline testing, of which 48 were listed for liver transplant and 44 received a 
liver transplant. In male patients, lower DXA skeletal muscle index (SMI) had a trend 
towards an association with delayed extubation (P=0.051), sepsis (P=0.068) and any 
major complication (P=0.071) post-liver transplant. Handgrip strength did not have any 
significant association with the adverse outcome variables assessed. Lower sit-to-stand 
test score was independently associated with pre-transplant sepsis (P=0.008) and hepatic 
encephalopathy admission (P=0.045). Impaired Short Physical Performance Battery 
(P=0.025) was an independent predictor of post-transplant sepsis, while an impaired six-
minute walk distance was a predictor of prolonged hospital stay (P=0.038).  
Conclusion: Measures of skeletal muscle mass and physical performance demonstrated 
significant associations with pre- and post-transplant outcomes including sepsis, any 
cirrhosis complication and prolonged hospital stay. The multi-component assessment of 
sarcopenia provides different prognostic information in patients with cirrhosis undergoing 
liver transplantation. Comprehensive assessment of sarcopenia as recommended by the 





Sarcopenia is a significant complication of cirrhosis, regardless of underlying aetiology. It 
has been associated with an increased risk of cirrhosis related complications such as 
variceal haemorrhage, hepatic encephalopathy, ascites, spontaneous bacterial peritonitis 
(SBP) and hepatorenal syndrome (HRS).99, 100 Several studies have also shown an 
association with increased risk of mortality, both pre- and post-liver transplant.57, 62 
One of the issues with the study of sarcopenia is the heterogeneity in diagnostic testing 
and thresholds used. The European Working Group on Sarcopenia in Older Persons 
(EWGSOP) has published guidelines on the assessment of sarcopenia with the aim of 
reducing the variability in sarcopenia assessment. These guidelines suggest that 
sarcopenia should encompass an assessment of skeletal muscle mass, muscle strength 
and physical performance.27 
Assessment of skeletal muscle mass in patients with cirrhosis is associated with error due 
to disturbances in body compartments as previously noted.41 In Chapter 4 computed 
tomography (CT) and dual energy X-ray absorptiometry (DXA) based methods were 
shown to have a strong association with a reference body cell mass measurement.  
Muscle strength assessed by handgrip strength is widely accepted as an accurate and 
reproducible assessment of whole body strength.47 Limited alternatives have been 
explored for these reasons, as well as its ease of use and extensive available normative 
data. 
The importance of physical performance evaluation in patients with cirrhosis has been 
highlighted in several recent studies using the Short Physical Performance Battery and six-
minute walk distance.21, 29, 148 Several other measures of physical performance have been 
used in the elderly population such as the sit-to-stand test and the stair climb test.96, 229 
The clinical utility of these tests has not been evaluated in patients with cirrhosis and there 
is also limited data on the reproducibility of these tests in this population. 
The aim of this study was to complete a comprehensive evaluation of sarcopenia in 
patients with cirrhosis and explore the relationship between measures of skeletal muscle 
mass, muscle strength and physical performance, as well as explore their clinical 
significance in predicting pre- and post-liver transplant complications. 
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5.4 PATIENTS AND METHODS 
A prospective cohort study was performed by recruiting patients with cirrhosis who were 
referred to the Queensland Liver Transplant Service between May 2014 and January 
2017. Ethical approval was granted from the Metro South Hospital and Health Services 
District and The University of Queensland’s Human Research Ethics Committees 
(Approval numbers: HREC/14/QPAH/23; 2014000254). Written informed consent was 
obtained prior to participation. Patients were excluded if they were less than 18 years of 
age; and/or had previously received a liver transplant. Sixty-eight patients consented to 
participation and received baseline assessment. Eighteen patients were excluded from the 
transplant outcome analysis due to either not meeting criteria for transplant listing (n = 12) 
or participation in an exercise training intervention (n = 8). Thus, 48 patients were included 
in the transplant waiting list analysis. Data were collected from transplant listing until 
delisting (n = 4) or transplantation. Forty-four patients were included in the post-transplant 
analysis. Data were collected from transplant until 90 days post-transplantation. 
Baseline clinical data were collected pre-transplant, including patient demographics, 
medical history, surgical history and prescribed medications. Biochemical results were 
recorded including bilirubin, albumin, international normalised ratio (INR), creatinine, and 
sodium. Assessment for hepatic encephalopathy (HE) was performed by a single 
experienced observer (AW) according to the West Haven criteria and patients were not 
tested if they had evidence of overt HE (greater than or equal to West Haven Grade 2 
HE).12 Patients were also screened for co-morbidities which would impair their muscle 
strength and physical performance, such as arthritis, neuropathy and myopathy. 
Anthropometric data including height, weight and waist circumference was collected by a 
single observer (AW) using standard procedures. Dry body weight was estimated by 
subtracting the volume of ascites removed at transplant or therapeutic paracentesis. Body 
mass index was calculated using the dry body weight. 
Assessment of sarcopenia was performed according the guidelines of the EWGSOP.27 
Body composition assessment 
Skeletal muscle mass was assessed using DXA and analysis of pre-existing CT scans. 
The median time between DXA and CT scans was 39 days (IQR 14-88).  
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Subjects underwent a whole body DXA scan (GE Prodigy Scanner; GE Healthcare Lunar, 
Madison, WI, USA) as described in Section 2.2.5. DXA appendicular lean mass (ALM) was 
used to calculate the DXA skeletal muscle index (SMI) according to the following equation: 
DXA SMI (kg/m2) = DXA ALM/Height2.27 Depletion of skeletal muscle mass was defined as 
a DXA SMI less than 7.26kg/m2 for men and 5.45kg/m2 for women.27 
CT abdomen images were analysed as described in Section 2.2.4. Thresholds for low 
skeletal muscle index were less than 48.9cm2/m2 for males and 36.3cm2/m2 for females as 
described in Chapter 3. 
Muscle strength 
Upper limb muscle strength was assessed by measuring isometric handgrip strength on 
the non-dominant side as described in Section 2.3.1. Impairment in muscle strength was 
defined as a handgrip strength less than the EWGSOP recommended sex and body mass 
index specific cut-offs.27 
Global muscular strength was assessed in sub-group of 37 patients with a Mid-Thigh Pull 
(MTP) as described in Section 2.3.2.  
Physical performance 
Physical performance was examined with the sit-to-stand test, Short Physical Performance 
Battery, six-minute walk distance, and the stair climb test as described in Section 2.4.21, 90, 
93, 96, 247  
Impairment of physical performance was classified as a Short Physical Performance 
Battery less than 10 points.89, 93 Cut-off for low six-minute walk distance was calculated 
using the equation by Enright et al.248 Impairment in sit-to-stand test was defined as less 
than 14 chair rises for men and less than 12 for women.96 
All bedside measures of muscle strength and physical performance were assessed for 
reliability and reproducibility. Intra-observer variability was determined by repeating the 
assessment on ten patients within 4 weeks. Inter-observer variability was measured by 
repeating the assessment on 10 patients by a trained blinded assessor (MW) on the same 




Table 5-1. Intraclass correlation coefficient values for bedside measures of strength and physical 
performance 
 
Intra-observer ICC (95% CI) Inter-observer ICC (95% CI) 
Handgrip strength 0.99 (0.97–1.00) 0.99 (0.95-1.00) 
Sit-to-stand test 0.70 (0.17-0.92) 0.94 (0.77-0.98) 
SPPB total score 0.70 (0.17-0.92) 0.45 (-0.21-0.83) 
Six-minute walk distance 0.92 (0.70-0.98) 0.98 (0.92-1.00) 
Stair climb test 0.86 (0.53-0.98) 0.98 (0.91-0.99) 
ICC – intraclass correlation coefficient 
Cardiorespiratory fitness 
Cardiopulmonary exercise testing was performed as described in Section 2.5. Impaired 
ventilatory threshold was defined as ≤ 9 mL/kg/min as described previously.22, 201 
Clinical outcomes 
Clinical outcomes were collected pre-, peri-, and post-liver transplant. Sepsis was defined 
according to international guidelines during a hospital admission.249 Episodes of 
cholangitis in patients with primary sclerosing cholangitis were not included in the waiting 
list analysis and thus was referred to as ‘non-cholestatic sepsis’. ‘Any cirrhosis 
complication’ included any of the following: sepsis; encephalopathy requiring admission; 
gastrointestinal haemorrhage; spontaneous bacterial peritonitis; and/or hepatorenal 
syndrome.  
‘Massive blood transfusion’ was defined as ≥10 units of Red Blood Cells (RBC).250 
‘Delayed extubation’ was defined as >8 hours post completion of procedure.251, 252 ‘Acute 
rejection’ was diagnosed based on histopathology. ‘Re-operation’ included any repeat 
laparotomy at the index transplant admission. The post-transplant category of ‘any major 
complication’ included any of the following: acute renal impairment requiring dialysis; re-
operation; hepatic artery thrombosis; sepsis and acute rejection. 
Survival data was collected. One patient died within 48 hours of liver transplantation due to 
multi-organ failure. There were no waiting list deaths from the cohort studied. Thus, there 
were insufficient events for meaningful survival analysis.  
5.5 STATISTICAL ANALYSIS 
Statistical analyses were performed using SPSS (Version 24; IBM, New York, USA). 
Continuous data was assessed for normality using a Shapiro-Wilk test and are presented 
as means ± SD (for normally distributed data), or medians and IQR (for non-normally 
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distributed data). Non-normally distributed data were transformed (logarithmic or square 
root) where possible to reduce skewness for statistical analysis. 
Continuous variable relationships were explored using Pearson correlation coefficients 
(normal distribution) or Spearman correlation coefficients (non-normal distribution). For 
interpretation of correlation coefficients, Cohen's levels were used.233 
Independent t-tests (normal distribution) or Mann-Whitney U tests (non-normal distribution) 
were used to compare continuous variables between two groups. Categorical variables 
were compared using the Pearson Chi Squared test or the Fisher Exact test when 
appropriate. Comparison between Child-Pugh classes was conducted using one-way 
ANOVA analysis and Tukey’s post hoc test (normal distribution), or Kruskal Wallis analysis 
and Dunn’s post hoc test (non-normal distribution). 
Univariate binary logistic regression was performed for all binary outcomes to test the 
relationship with potential predictors. To identify independent predictors, backward 
stepwise multiple logistic regression was performed. Variables with a P value <0.2 were 
considered for inclusion in all multivariate analyses. Multicollinearity was assessed with 
variance inﬂation factor (VIF) and considered in all multivariate models. Odd ratios and 
95% confidence intervals are reported. 
5.6 RESULTS 
Sixty-eight patients underwent baseline testing and had a median age of 55 years 
(interquartile range (IQR) 46 – 60). The cohort was predominately male (82%) and of 
Caucasian ethnicity (90%). Baseline patient characteristics are shown in Table 5-2. 
Using the EWGSOP recommended cut-offs, 15 patients had low DXA SMI, 11 had low 
handgrip strength and nine patients had an impairment in physical performance defined by 
the Short Physical Performance Battery. According to the overall sarcopenia classification 
system, no patients had ‘severe sarcopenia’, seven patients had ‘sarcopenia’ and eight 
had ‘pre-sarcopenia’ [Table 5-3].  
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Table 5-2. Baseline patient characteristics 
Characteristic Men Women Overall Liver transplant recipients 
Number of patients 56 12 68 44 
Age 56 (47-60) 51 (44-58) 55 (46–60) 57 (47-60) 
Sex [n]     
Male/female - - 56/12 37/7 
Ethnicity [n (%)]     
Caucasian 49 (88%) 12 (100%) 61 (90%) 38 (86%) 
Asian  4 (7%) 0 4 (6%) 4 (9%) 
Indigenous 2 (3%) 0 2 (3%) 2 (5%) 
Other  1 (2%) 0 1 (1%) 0 (0%) 
Aetiology of cirrhosis [n (%)]     
Hepatitis C 35 1 36 (53%) 25 (57%) 
Alcohol 4 5 9 (13%) 6 (14%) 
PSC  2 3 5 (7%) 3 (7%) 
Other 15 3 18 (20%) 10 (23%) 
HCC [n (%)] 30 (54%) 2 (17%) 32 (47%) 21 (48%) 
Laboratory values     
Bilirubin (µmol/L) 38 (21-60) 40 (24-124) 38 (24-69) 44 (24-73) 
Albumin (g/L) 31 ± 6 30 ± 7 31 ± 6 31 ± 6 
INR 1.3 (1.2-1.6) 1.5 (1.3-1.7) 1.4 (1.2-1.6) 1.5 (1.2-1.7) 
Creatinine (µmol/L) 67 (59-80) 58 (51-90) 66 (58-80) 65 (58-83) 
Sodium (mmol/L) 136 ± 3 135 ± 4 136 ± 3 136 ± 3 
MELD score 14 ± 5 16 ± 5 14 ± 5 15 ± 5 
Child-Pugh class [n (%)]     
A 20 (36%) 2 (17%) 22 (32%) 13 (30%) 
B 20 (36%) 6 (50%) 26 (38%) 15 (34%) 
C 16 (28%) 4 (33%) 20 (29%) 16 (36%) 
Ascites [n (%)]     
None 28 (50%) 5 (42%) 33 (49%) 19 (43%) 
Mild/diuretic controlled 22 (39%) 4 (33%) 26 (38%) 16 (36%) 
Moderate/severe 6 (11%) 3 (25%) 9 (13%) 9 (21%) 
Anthropometrics     
Height (m) 1.77 ± 0.07 1.64 ± 0.05 1.75 ± 0.08 1.75 ± 0.09 
Dry weight (kg) 82.3 (74.3-91.8) 68.8 (59.6-73.0) 79.9 (69.9-91.6) 78.8 (69.0-87.9) 
BMI (mg/kg2) 26.4 (23.8-29.6) 24.8 (23.3-27.2) 26.2 (23.6-29.3) 26.1 (23.8-27.4) 
Body composition      
DXA fat mass (kg) 21.0 (15.5-27.4) 21.8 (17.6-27.5) 21.3 (15.7-27.4) 20.4 (16.0-25.7) 
DXA fat-free mass (kg) 62.8 ± 8.7 46.7 ± 8.0 59.9 ± 10.5 60.5 ± 10.1 
DXA bone mass (kg) 3.06 ± 0.49 2.31 ± 0.40 2.9 ± 0.6 2.9 ± 0.6 
DXA ALM (kg) 25.3 ± 4.1 17.9 ± 3.6 24.0 ± 4.9 23.9 ± 4.4 
Low DXA SMI [n (%)] 13 (23%) 2 (17%) 15 (22%) 11 (25%) 
CT SMI (cm2/m2) 52.3 (48.3-57.2) 42.2 (41.0-45.5) 51.1 (45.7-56.2) 50.4 (45.5-55.9) 
CT VAT (cm2) 115.8 (75.9-167.9) 79.5 (51.5-106.5) 111.5 (73.2-158.0) 105.4 (65.8-154.6) 
CT SAT (cm2) 152.2 (99.7-217.7) 185.1 (121.9-215.3) 158.7 (103.7-215.3) 155.8 (105.4-214.3) 
Low CT SMI [n (%)] 15 (27%) 0 (0%) 15 (22%) 12 (27%) 
Muscle strength     
HGS [Non-dominant](kg) 38.4 ± 8.2 23.5 ± 4.3 35.8 ± 9.5 35.2 ± 9.4 
Low HGS [n (%)] 8 (14%) 3 (25%) 11 (16%) 7 (16%) 
Mid-thigh pull force (N) 1315 ± 302 734 ± 286 1205 ± 375 1177 ± 344 
Physical performance     
Sit-to-stand test (n) 13 (11-15) 12 (10-16) 13 (11-15) 13 (11-14) 
Impaired STS test [n (%)] 31 (55%) 6 (50%) 37 (54%) 25 (57%) 
SPPB score  11 (10-12) 12 (10-12) 11 (10-12) 11 (10-12) 
Impaired SPPB [n (%)] 9 (16%) 0 (0%) 9 (13%) 8 (18%) 
6MWD (m) 516 ± 91 451 ± 84 504 ± 92 494 ± 92 
Impaired 6MWD [n (%)] 13 (24%) 4 (33%) 17 (25%) 11 (25%) 
Stair climb test (sec) 4.02 (3.40-5.01) 4.75 (4.21-5.32) 4.1 (3.5-5.0) 4.3 (3.5-5.1) 
VT (mL/kg/min) 13.1 (10.9-16.1) 11.7 (10.9-12.5) 12.5 (10.9-15.6) 12.5 (10.1-15.1) 
Impaired VT [n (%)] 10 (18%) 2 (17%) 12 (18%) 10 (23%) 
Values presented as mean (± SD), or median (interquartile range) where data were not normally distributed, and number and 
percentage. HCC – Hepatocellular carcinoma; INR – International normalised ratio; MELD - Model for end-stage liver disease; BMI - 
Body mass index; DXA – Dual energy X-ray absorptiometry; ALM – Appendicular lean mass; PSC – Primary sclerosing cholangitis; SMI 
– Skeletal muscle index; HGS – Handgrip strength; STS – Sit-to-stand test; SPPB – Short Physical Performance Battery; 6MWD – Six-
minute walk distance; VT – Ventilatory threshold; EWGSOP – European Working Group on Sarcopenia in Older Persons 




Table 5-3. Prevalence of pre-sarcopenia and sarcopenia according to the European Working Group 
on Sarcopenia in Older Persons classification system 
EWGSOP Class Men Women All patients Liver transplant recipients 
Normal 43 (77%) 10 (83%) 53 (78%) 33 (75%) 
Pre-sarcopenia 7 (13%) 1 (8%) 8 (12%) 6 (14%) 
Sarcopenia 6 (10%) 1 (8%) 7 (10%) 5 (11%) 
EWGSOP – European Working Group on Sarcopenia in Older Persons 
The relationships between skeletal muscle mass, muscle strength and physical 
performance measurements are presented in Table 5-4. Skeletal muscle mass 
assessment by CT and DXA were strongly correlated. Both measures of skeletal muscle 
mass were moderately correlated with handgrip strength. CT SMI had a weak inverse 
correlation with the stair climb test but otherwise there was no significant relationship with 
measures of physical performance or cardiorespiratory fitness. 
Handgrip strength was moderately correlated with the six-minute walk distance and the 
stair climb test, while no association was found with the sit-to-stand test, Short Physical 
Performance Battery or ventilatory threshold. In a subgroup of 37 patients that underwent 
mid-thigh pull testing, the handgrip strength strongly correlated with the mid-thigh pull peak 
force. 
Physical performance measures were either moderately correlated (sit-to-stand test, Short 
Physical Performance Battery) or strongly correlated (six-minute walk distance, stair climb 
test) with cardiorespiratory fitness (ventilatory threshold). The sit-to-stand test, six-minute 
walk distance and the stair climb test were strongly correlated. 
The impact of cirrhosis severity was strongest on measures of physical performance and 
cardiorespiratory fitness, with several tests (Short Physical Performance Battery, six-
minute walk distance, stair climb test and ventilatory threshold) demonstrating moderate 
correlation with the MELD score. This relationship was further explored by comparing 
sarcopenia measures across Child-Pugh classes [Table 5-5].  
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Table 5-4. Relationships between body composition and physical performance measures 
 MELD 
score DXA SMI CT SMI HGS STS Test SPPB
‡ 6MWD SCT MTP# VT 
MELD score - 0.105 0.042 -0.272* -0.292* -0.317** -0.396** 0.492** -0.441** -0.473** 
DXA SMI (kg/m2) 0.105 - 0.712** 0.492** 0.025 0.061 0.123 -0.123 0.271 0.001 
CT SMI (cm2/m2) 0.042 0.712** - 0.404** 0.096 -0.038 0.180 -0.278* 0.409* -0.072 
HGS (kg) -0.272* 0.492** 0.404** - 0.092 0.050 0.393** -0.374** 0.770** 0.221 
STS Test (n) -0.292* 0.025 0.096 0.092 - 0.819** 0.629** -0.642** 0.317 0.374** 
SPPB score‡ -0.317** -0.061 -0.038 0.050 0.819** - 0.477** -0.539** 0.248 0.435** 
6MWD (m) -0.396** 0.123 0.180 0.393** 0.629** 0.477** - -0.776** 0.674** 0.518** 
SCT (sec) 0.492** -0.123 -0.278* -0.374** -0.642** -0.539** -0.776** - -0.578** -0.500** 
MTP (N)# -0.441** 0.271 0.409* 0.770** 0.317 0.248 0.674** -0.578** - 0.347* 
VT (mL/kg/min) -0.473** 0.001 -0.072 0.221 0.374** 0.435** 0.518** -0.500** 0.347* - 
‡ Spearman (rho) correlation coefficients displayed. # n = 37 
**. Correlation is significant at the 0.01 level (2-tailed). *. Correlation is significant at the 0.05 level (2-tailed) 
MELD - Model for end-stage liver disease; DXA – Dual energy X-ray absorptiometry; CT – Computed tomography; SMI – Skeletal muscle index; HGS – Handgrip strength;  




Table 5-5. Comparison of sarcopenia measures according to sex and Child-Pugh class 
 Sex Child-Pugh A Child-Pugh B Child-Pugh C P Value 
DXA SMI (kg) Men (56) 7.95 ± 0.95 7.94 ± 1.20 8.43 ± 1.12 0.333 
 Overall (68) 7.79 ± 1.0 7.63 ± 1.4 8.11 ± 1.3 0.424 
CT SMI (cm2/m2) Men (56) 51.1 (47.0-55.3) 54.8 (47.1-59.8) 52.2 (50.3-56.9) 0.422‡ 
 Overall (68) 50.62 ± 7.3 52.56 ± 8.8 51.85 ± 8.4 0.718 
Handgrip strength (kg) Men (56) 41.1 ± 8.0 37.3 ± 9.3 36.5 ± 6.4 0.185 
 Overall (68) 39.8 ± 8.6 34.0 ± 10.5 33.7 ± 8.0 0.052 
STS test (n) Men (56) 15 (13-16) 12 (11-14) 11 (8-12) 0.001‡ 
 Overall (68) 15 (14-16) 12 (11-14) 11 (9-13) <0.001‡ 
SPPB score  Men (56) 12 (12-12) 11 (10-12) 10 (9-11) 0.001# 
 Overall (68) 12 (12-12)  11 (10-12) 10.5 (9-12) 0.001# 
6MWD (m) Men (56) 560 ± 82 530 ± 79 443 ± 74 <0.001 
 Overall (68) 560 ± 79 510 ± 85 435 ± 71 <0.001 
SCT (sec) Men (56) 3.67 ± 0.63 4.05 ± 1.06 5.28 ± 1.28 <0.001 
 Overall (68) 3.69 ± 0.6 4.17 ± 1.0 5.32 ± 1.2 <0.001 
VT (mL/kg/min) Men (56) 16.1 (13.2-21.3) 13.4 (12.5-15.1) 10.5 (9.0-12.1) <0.001‡ 
 Overall (68) 16.1 (13.0-20.6) 12.8 (11.6-14.2) 10.5 (9.1-12.1) <0.001‡ 
Values presented as mean (± SD), or median (interquartile range) where data were not normally distributed. 
‡ ANOVA analysis performed on transformed data # Kruskal Wallis analysis 
DXA – Dual energy X-ray absorptiometry; CT – Computed tomography; SMI – Skeletal muscle index; HGS – Handgrip strength; STS – Sit-to-stand;  
SPPB – Short Physical Performance Battery; 6MWD – Six-minute walk distance; SCT – Stair climb test; VT – Ventilatory threshold 
Note:  Insufficient number of female subjects to perform between group analysis
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No significant difference in skeletal muscle mass was noted between the Child-Pugh 
classes. There was a trend for higher handgrip strength in patients with Child-Pugh A 
cirrhosis. Post hoc analysis showed that physical performance was more impaired in those 
with Child-Pugh C cirrhosis compared to those with Child-Pugh A disease [Figure 5-1]. 
Sex-specific differences in physical performance are shown in Supplementary Figure 5-2. 
  
  
Figure 5-1. Comparison of physical performance variables according to Child-Pugh class. (a) Short 
Physical Performance Battery [SPPB]; (b) Six-minute walk distance [6MWD]; (c) Sit-to-stand [STS] 
test; (d) Stair climb test. **** Significant at 0.0001 level *** Significant at 0.001 level ** Significant at 
0.01 level * Significant at 0.05 level 
Analysis of male patients alone yielded similar results to the overall cohort, while analysis 
of female patients was not feasible due to the small numbers.  
Similarly, cardiorespiratory fitness was significantly lower in patients with Child-Pugh C 





Of the 48 patients listed for liver transplant, six (13%) experienced an episode of ‘non-
cholestatic sepsis’. The aetiology of sepsis included SBP (n = 3) and pneumonia (n = 2) 
while in one case no aetiology was established. Five patients (10%) experienced overt HE 
that required hospital admission, four patients (8%) had a variceal haemorrhage and three 
patients (6%) had hepatorenal syndrome. Overall 12 patients (25%) experienced at least 
one waiting list complication of cirrhosis. 
An analysis of male patients who had waiting list complications was performed and is 
shown in Table 5-6. Patients who experienced ‘non-cholestatic sepsis’ and ‘any cirrhosis 
complication’ on the waiting list had a significantly lower sit-to-stand test result and lower 
Short Physical Performance Battery score. The sit-to-stand test result was also 
significantly lower in patients who had HE related admissions. 
A univariate analysis of all variables was performed for waiting list complications [Table 
5-7]. After performing stepwise multiple logistic regression, the optimal model included the 
sit-to-stand test for sepsis and encephalopathy related admission and the Short Physical 
Performance Battery score for ‘any cirrhosis complication’. 
One of the most important aspects of assessing sarcopenia is identifying patients who 
could be targeted for intervention. Therefore, patients were also analysed according to 
whether they met criteria for deficiency in each of the individual sarcopenia measures 
[Table 5-8]. 
Impairment in the sit-to-stand test was more frequent in patients with both non-cholestatic 
sepsis and ‘any cirrhosis complication’. Impairment in six-minute walk distance was 
associated with encephalopathy related admissions, while impaired Short Physical 
Performance Battery was more frequent in those with ‘any cirrhosis complication’. After 
stepwise multiple logistic regression, impaired Short Physical Performance Battery (OR 
11.0, 95%CI 2.14-56.50; P = 0.04) remained significantly associated with ‘any cirrhosis 
complication’. 
Patients classified as having EWGSOP Sarcopenia had a higher rate of ‘any cirrhosis 
complication’ (OR 8.12, 95%CI 1.14-57.90; P = 0.037) in the multivariate model. No other 




Table 5-6. Comparison of male patients (n=41) with cirrhosis related waiting list complications 
 Sepsis  
(n=6) 
No Sepsis 
(n=35) P Value 
HE Admission  
(n=5) 
No HE Admission 





(n = 29) P Value 
DXA SMI (kg/m2) 8.13 ± 1.30 8.00 ± 0.95 0.775 8.42 ± 1.3 7.97 ± 0.95 0.340 7.93 ± 1.38 8.05 ± 0.81 0.770 
CT SMI (cm2/m2) 50.5 ± 5.7 53.5 ± 7.3 0.346 56.7 ± 11.4 52.5 ± 6.4 0.227 51.8 ± 8.3 53.6 ± 6.8 0.479 
HGS (kg) 37.4 ± 9.4 37.3 ± 7.5 0.985 41.7 ± 8.9 36.7 ± 7.4 0.174 36.6 ± 9.9 37.6 ± 6.7 0.701 
STS test (n) # 9 (6-11) 13 (11-15) <0.001 11 (7-12) 13 (11-15) 0.022 11 (8-12) 13 (12-15) <0.01 
SPPB score 10 (9-10) 11 (10-12) 0.013 11 (8-11) 11 (10-12) 0.128 10 (8-12) 12 (11-12) <0.01 
6MWD (m) 453 ± 61 505 ± 92 0.238 447 ± 95 505 ± 87 0.174 480 ± 87 506 ± 92 0.425 
SCT (sec) # 5.03 (4.30-5.49) 4.04 (3.24-5.01) 0.182 5.03 (3.56-6.81) 4.12 (3.39-5.01) 0.200 5.02 (3.84-5.80) 4.04 (3.10-4.83) 0.074 
VT (mL/kg/min) # 10.2 (9.6-11.3) 13.4 (12.0-16.7) 0.041 10.5 (8.9-14.7) 13.3 (10.9-15.9) 0.174 10.4 (9.5-13.9) 13.4 (12.3-18.0) 0.014 
Values presented as mean (± SD), or median (interquartile range) where data were not normally distributed. 
# Analysis performed on transformed data. 
HE – Hepatic encephalopathy; DXA – Dual energy X-ray absorptiometry; CT – Computed tomography; SMI – Skeletal muscle index; HGS – Handgrip strength; STS – Sit-to-stand; SPPB – Short Physical 
Performance Battery; 6MWD – Six-minute walk distance; SCT – Stair climb test; VT – Ventilatory threshold 
Table 5-7. Multiple logistic regression analysis of sarcopenia and waiting list complications in male patients 
 Sepsis HE Admission Any cirrhosis Complication 




















(95% CI) § 
P 
Value 
Age (years) 0.98 (0.91-1.07) 0.694   0.99 (0.90-1.09) 0.875   0.99 (0.93-1.06) 0.824   
MELD score 1.28 (0.99-1.64) 0.051   1.15 (0.92-1.44) 0.208   1.28 (1.06-1.54) 0.012 1.25 (0.95-1.64) 0.107 
HCC  0.13 (0.14-1.26) 0.079   0.18 (0.02-1.76) 0.140   0.31 (0.07-1.26) 0.101   
HCV CLD 2.61 (0.27-24.9) 0.405       7.77 (0.88-68.44) 0.065 10.9 (0.8-146.8) 0.072 
DXA SMI (kg/m2) 1.14 (0.48-2.71) 0.769   1.56 (0.63-3.86) 0.335   0.87 (0.43-1.77) 0.707   
CT SMI (cm2/m2) 1.08 (0.95-1.22) 0.230   1.10 (0.98-1.23) 0.119   0.96 (0.87-1.07) 0.469   
HGS (kg) 1.00 (0.89-1.12) 0.984   1.09 (0.96-1.23) 0.179   0.98 (0.90-1.08) 0.693   
STS test (n) 0.58 (0.38-0.87) 0.008 0.58 (0.38-0.87) 0.008 0.69 (0.48-0.98) 0.041 0.70 (0.49-0.99) 0.045 0.77 (0.60-0.98) 0.031   
SPPB score 0.55 (0.29-1.03) 0.061   0.55 (0.29-1.06) 0.073   0.33 (0.16-0.68) 0.003 0.45 (0.20-1.03) 0.059 
6MWD (m) 0.99 (0.98-1.00) 0.239   0.99 (0.98-1.00) 0.183   1.00 (0.99-1.01) 0.415   
SCT (sec) 1.41 (0.75-2.64) 0.288   1.58 (0.81-3.08) 0.184   1.55 (0.89-2.71) 0.120   
VT (mL/kg/min) 0.68 (0.46-1.02) 0.062   0.81 (0.59-1.12) 0.211   0.76 (0.59-0.98) 0.034   
‡ Cox & Snell R2 = 0.239   Cox & Snell R2 = 0.128 § Cox & Snell R2 = 0.374  Logistic regression not performed as n= 0 in the ‘non-HCV’ group  
OR – Odds ratio; CI – Confidence interval; HE – Hepatic encephalopathy; DXA – Dual energy X-ray absorptiometry; CT – Computed tomography; SMI – Skeletal muscle index; HGS – Handgrip strength; 




Table 5-8. Frequency of pre-transplant outcomes according to impairment in sarcopenia tests 























Low DXA SMI 2 (33%) 9 (21%) 0.609 1 (20%) 10 (23%) 1.000 4 (33%) 7 (19%) 0.430 
Low CT SMI‡ 2 (33%) 10 (24%) 0.637 1 (20%) 11 (26%) 1.000 4 (36%) 8 (22%) 0.435 
Impaired HGS 3 (50%) 6 (14%) 0.071 1 (20%) 8 (19%) 1.000 3 (25%) 6 (17%) 0.671 
Impaired STS  6 (100%) 22 (52%) 0.034 5 (100%) 23 (54%) 0.066 10 (83%) 18 (50%) 0.043 
Impaired SPPB 3 (50%) 6 (14%) 0.071 2 (40%) 7 (16%) 0.231 6 (50%) 3 (8%) 0.004 
Impaired 6MWD§ 3 (60%) 9 (22%) 0.103 3 (75%) 9 (21%) 0.049 4 (36%) 8 (23%) 0.441 
Impaired VT 2 (33%) 8 (19%) 0.591 2 (40%) 8 (19%) 0.276 4 (33%) 6 (17%) 0.241 
‡ n = 47; § n = 46 
HE – Hepatic encephalopathy; DXA – Dual energy X-ray absorptiometry; CT – Computed tomography; SMI – Skeletal muscle index; HGS – Handgrip strength; STS – Sit-to-stand test;  




Forty-four patients with baseline testing received a liver transplant [Table 5-2]. Four 
patients (9%) received a Donation after Circulatory Death (DCD) organ, while eight (18%) 
received a split graft. The median cold ischaemic time was 284 minutes (IQR 225-331).  
The impact of sarcopenia measures on peri-operative outcomes was assessed [Table 
5-9]. Twelve patients met criteria for massive transfusion, three patients required peri-
operative dialysis, and 22 patients had delayed extubation. No variable was found to be a 
predictor of massive transfusion or peri-operative dialysis. There was a trend towards an 
association between delayed extubation and lower DXA SMI as well as lower six-minute 
walk distance. After stepwise multiple logistic regression, DXA SMI (OR 0.36, 95%CI 0.13-
1.01; P = 0.051) was included in the final model, but the association did not reach 
statistical significance. 
Table 5-9. Univariate analysis of sarcopenia and peri-operative outcomes in male patients (n=37) 
 Massive transfusion 
(n = 12) 
Peri-operative dialysis 
(n = 3) 
Delayed extubation 
(n = 22) 
 OR (95% CI) P Value OR (95% CI) 
P 
Value OR (95% CI) 
P 
Value 
DXA SMI (kg/m2) 0.85 (0.40-1.82) 0.678 0.21 (0.04-1.29) 0.093 0.48 (0.21-1.08) 0.077 
CT SMI (cm2/m2) 0.97 (0.88-1.08) 0.611 0.95 (0.75-1.19) 0.641 0.92 (0.82-1.02) 0.111 
HGS (kg) 0.93 (0.84-1.03) 0.173 0.91 (0.77-1.08) 0.287 0.97 (0.89-1.06) 0.464 
STS test (n) 1.01 (0.86-1.19) 0.886 1.03 (0.79-1.35) 0.838 0.90 (0.77-1.06) 0.213 
SPPB score 0.69 (0.34-1.41) 0.308 0.94 (0.48-1.83) 0.846 0.61 (0.33-1.12) 0.111 
6MWD (m) 1.00 (0.99-1.02) 0.631 1.00 (0.99-1.01) 0.465 0.99 (0.98-1.00) 0.087 
SCT (sec) 1.86 (0.95-3.63) 0.069 1.31 (0.49-3.50) 0.591 1.73 (0.88-3.39) 0.112 
VT (mL/kg/min) 0.89 (0.75-1.07) 0.225 0.88 (0.62-1.24) 0.458 0.92 (0.79-1.08) 0.297 
OR – Odds ratio; CI – Confidence interval; DXA – Dual energy X-ray absorptiometry; CT – Computed tomography; SMI – Skeletal 
muscle index; HGS – Handgrip strength; STS – Sit-to-stand; SPPB – Short Physical Performance Battery; 6MWD – Six-minute walk 
distance; SCT – Stair climb test; VT – Ventilatory threshold 
The risk of post-transplant complications within the first 90 days associated with 
sarcopenia measures was assessed [Table 5-10 and No significant relationship was 
identified with acute rejection, need for re-operation or ‘any major complication’ [Table 
5-11]. 
Table 5-11]. Sixteen patients experienced an episode of post-transplant sepsis. The 
aetiologies of sepsis were biliary related sepsis (n = 5); respiratory tract infections (n = 4); 
intra-abdominal collections (n = 3); urinary tract infection (n = 1); toxoplasmosis (n = 1) and 
two cases where no aetiology was determined. Acute rejection was diagnosed in 11 
patients, re-operation was required in eight patients, and ‘any major complication’ occurred 
in 27 patients. 
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Patients who experienced sepsis had lower sit-to-stand test, Short Physical Performance 
Battery score and ventilatory threshold. Univariate analysis revealed that the MELD score 
and a pre-transplant diagnosis of HCC were also associated with sepsis. After multiple 
logistic regression, the optimal model included both Short Physical Performance Battery 
score and DXA SMI [Table 5-10]. 
Table 5-10. Stepwise multiple logistic regression of between sarcopenia and post-transplant sepsis 
in male patients (n = 12) 
 Univariate analysis Multivariate analysis 
 Odds ratio (95% CI) P Value Odds ratio (95% CI)§ P Value 
Age 1.00 (0.93-1.07) 0.907   
MELD score 1.19 (1.01-1.40) 0.042   
HCC  0.15 (0.03-0.70) 0.016 0.11 (0.01-0.94) 0.043 
Cold ischaemic time (min) 1.00 (0.99-1.01) 0.275   
DCD 4.18 (0.34-51.24) 0.263   
DXA SMI (kg/m2) 0.49 (0.20-1.16) 0.105 0.27 (0.07-1.10) 0.068 
CT SMI (cm2/m2) 0.93 (0.83-1.04) 0.228   
Handgrip strength (kg) 0.94 (0.85-1.04) 0.220   
Sit-to-stand test (n) 0.79 (0.63-0.99) 0.047   
SPPB score 0.37 (0.18-0.75) 0.006 0.42 (0.18-0.99) 0.049 
6MWD (m) 0.99 (0.98-1.00) 0.087   
Stair climb test (sec) 1.69 (0.89-3.24) 0.111   
VT (mL/kg/min) 0.79 (0.63-0.99) 0.046   
§ Cox & Snell R2 = 0.393 
MELD - Model for end-stage liver disease; HCC – Hepatocellular carcinoma; DCD – donation after circulatory death; 
DXA – Dual energy X-ray absorptiometry; CT – Computed tomography; SMI – Skeletal muscle index; SPPB – Short 
Physical Performance Battery; 6MWD – Six-minute walk distance; VT – Ventilatory threshold. 
No significant relationship was identified with acute rejection, need for re-operation or ‘any 
major complication’ [Table 5-11]. 
Table 5-11. Univariate analysis of association between sarcopenia and post-liver transplant 
complications within 90 days in male patients 
 Acute rejection 
(n = 11) 
Need for re-operation 
(n = 8) 
Any major complication 
(n = 24) 
 OR (95% CI) P Value OR (95% CI) 
P 
Value OR (95% CI) 
P 
Value 
DXA SMI (kg/m2) 0.64 (0.28-1.47) 0.293 0.84 (0.35-2.00) 0.689 0.46 (0.20-1.07) 0.071 
CT SMI (cm2/m2) 0.97 (0.88-1.08) 0.608 1.05 (0.94-1.17) 0.406 1.00 (0.91-1.10) 0.963 
HGS (kg) 0.94 (0.85-1.04) 0.245 1.00 (0.91-1.11) 0.951 0.92 (0.83-1.01) 0.086 
STS test (n) 1.04 (0.89-1.23) 0.616 1.12 (0.94-1.34) 0.216 0.97 (0.83-1.14) 0.712 
SPPB score 1.39 (0.75-2.60) 0.295 1.05 (0.58-1.88) 0.881 0.72 (0.41-1.29) 0.274 
6MWD (m) 1.00 (0.99-1.01) 0.977 1.00 (0.99-1.01) 0.521 1.00 (0.99-1.01) 0.440 
SCT (sec) 0.62 (0.29-1.32) 0.218 1.13 (0.57-2.21) 0.731 1.39 (0.73-2.61) 0.314 
VT (mL/kg/min) 1.05 (0.89-1.23) 0.581 0.87 (0.69-1.09) 0.210 0.88 (0.75-1.04) 0.128 
OR – Odds ratio; CI – Confidence interval; DXA – Dual energy X-ray absorptiometry; CT – Computed tomography; SMI – Skeletal 
muscle index; HGS – Handgrip strength; STS – Sit-to-stand; SPPB – Short Physical Performance Battery; 6MWD – Six-minute walk 
distance; SCT – Stair climb test; VT – Ventilatory threshold 
The predictive utility of sarcopenia measures after classification, using previously 
published cut-offs, was also explored [Table 5-12]. 
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Table 5-12. Frequency of post-transplant outcomes according to impairment in sarcopenia tests (n = 43) 
 Sepsis  
(n=16) 
No sepsis 





(n = 11) 
No rejection 
(n = 32) 
P 
Value 
Need for  
re-operation 
(n = 8) 
No  
re-operation 





(n = 27) 
No 
complications 
(n = 16) 
P 
Value 
Low DXA SMI 6 (38%) 5 (19%) 0.278 4 (36%) 7 (22%) 0.430 2 (25%) 9 (21%) 1.000 9 (33%) 2 (13%) 0.166 
Low CT SMI 6 (40%) 6 (22%) 0.292 4 (36%) 8 (26%) 0.699 1 (14%) 11 (31%) 0.651 8 (31%) 4 (25%) 0.740 
Impaired HGS 4 (25%) 3 (11%) 0.394 0 (0%) 7 (22%) 0.163 1 (13%) 6 (17%) 1.000 5 (19%) 2 (13%) 0.695 
Impaired STS 11 (69%) 13 (48%) 0.189 5 (46%) 19 (59%) 0.495 4 (50%) 20 (57%) 1.000 16 (59%) 8 (50%) 0.555 
Impaired SPPB 7 (44%) 1 (4%) 0.002 2 (18%) 6 (18%) 1.000 2 (25%) 6 (17%) 0.629 7 (26%) 1 (6%) 0.223 
Impaired 6MWD‡ 6 (40%) 4 (15%) 0.130 7 (54%) 5 (13%) 0.045 2 (29%) 8 (24%) 1.000 9 (36%) 1 (6%) 0.059 
Impaired VT 6 (35%) 3 (9%) 0.049 2 (20%) 7 (22%) 1.000 1 (11%) 9 (21%) 0.667 7 (27%) 2 (13%) 0.442 
# n = 42; ‡ n = 41 
DXA – Dual energy X-ray absorptiometry; CT – Computed tomography; SMI – Skeletal muscle index; HGS – Handgrip strength; STS – Sit-to-stand test; SPPB – Short Physical Performance Battery; 6MWD 
– Six-minute walk distance; VT – Ventilatory threshold 
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Patients with impaired Short Physical Performance Battery and ventilatory threshold were 
more likely to have post-transplant sepsis. Impaired six-minute walk distance was the only 
variable associated with acute rejection and had trend towards association with ‘any major 
complication’. No variables had an association with the need for re-operation. 
After multiple logistic regression, including MELD score and HCC status, impaired Short 
Physical Performance Battery (OR 18.80 95%CI 1.54-229.38; P = 0.022) remained a 
significant predictor of sepsis. 
Higher MELD score (P = 0.100) and longer cold ischaemic time (P = 0.025) were also 
associated (P < 0.2) with acute rejection on univariate analysis. There was a trend towards 
an association with impaired six-minute walk distance in the multivariate model (OR 7.98, 
CI 0.99-63.76; P = 0.050). 
The impact of sarcopenia variables on ICU and hospital length of stay (LOS) is shown in 
Table 5-13. Patients with lower six-minute walk distance had prolonged ICU stay. 
Univariate analysis of risk factors for prolonged ICU stay was performed. On multivariate 
analysis, no variable remained a significant predictor of prolonged ICU stay. 
Table 5-13. Univariate analysis of the impact of sarcopenia on hospital admission 
 Prolonged ICU LOS 
(n = 6) P Value 
Prolonged hospital LOS 
(n = 7) P Value 
DXA SMI (kg/m2) 0.77 (0.29-2.07) 0.602 1.28 (0.43-3.81) 0.655 
CT SMI (cm2/m2) 1.05 (0.93-1.18) 0.417 1.05 (0.92-1.21) 0.451 
Handgrip strength (kg) 1.03 (0.92-1.15) 0.669 1.11 (0.96-1.28) 0.146 
STS test (n) 0.89 (0.70-1.13) 0.342 0.77 (0.55-1.09) 0.144 
SPPB score 0.70 (0.40-1.25) 0.231 0.76 (0.39-1.45) 0.399 
6MWD (m) 0.98 (0.97-0.99) 0.035 0.99 (0.98-1.01) 0.200 
SCT (sec) 1.85 (0.81-4.26) 0.146 0.64 (0.19-2.12) 0.466 
VT (mL/kg/min) 0.70 (0.46-1.07) 0.100 0.85 (0.59-1.23) 0.386 
ICU – Intensive care unit; LOS – Length of stay; DXA – Dual energy X-ray absorptiometry; CT – Computed tomography; SMI – Skeletal 
muscle index; STS – Sit-to-stand; SPPB – Short Physical Performance Battery; 6MWD – Six-minute walk distance; SCT – Stair climb 
test; VT – Ventilatory threshold 
After re-classification of sarcopenia variables based on cut-offs, there was a trend towards 
association of impaired Short Physical Performance Battery and six-minute walk distance 




Table 5-14. Stepwise multiple logistic regression of variables associated with prolonged intensive 
care unit length of stay 
 Univariate analysis Multivariate analysis 
 OR (95% CI) P Value OR (95% CI) 
P 
Value 
Age 1.01 (0.92-1.11) 0.847   
MELD score 1.11 (0.91-1.35) 0.299   
HCC status 2.43 (0.39-15.27) 0.344   
Platelet count  0.97 (0.93-1.01) 0.086 0.97 (0.92-1.01) 0.161 
Aetiology     
Alcoholic liver disease 0.74 (0.07-8.09) 0.806   
Chronic HCV 0.32 (0.03-3.05) 0.320   
Donor Variables#     
Cold ischaemic time (min) 1.00 (0.99-1.01) 0.908   
6MWD (m) 0.98 (0.97-0.99) 0.035 0.98 (0.97-1.00) 0.062 
MELD - Model for end-stage liver disease; HCC – Hepatocellular carcinoma; HCV – Chronic hepatitis C; DCD – donation after 
circulatory death; SPPB – Short Physical Performance Battery # Insufficient numbers to perform binary logistic regression on DCD 
status and graft size. Fisher’s Exact Test P-values were 1.00 and 0.575 respectively. 
Table 5-15. Frequency of hospital admission outcomes according to impairment in sarcopenia tests 
 
Prolonged 












(n = 38) 
P 
Value 
Low DXA SMI 2 (33%) 9 (24%) 0.637 1 (20%) 10 (26%) 1.000 
Low CT SMI# 1 (17%) 11 (31%) 0.655 0 (0%) 12 (32%) 0.298 
Impaired HGS 1 (16%) 6 (17%) 1.000 1 (20%) 6 (16%) 1.000 
Impaired STS Test 5 (83%) 19 (51%) 0.205 3 (60%) 21 (55%) 1.000 
Impaired SPPB 3 (50%) 5 (14%) 0.067 2 (40%) 6 (16%) 0.228 
Impaired 6MWD‡ 3 (60%) 7 (19%) 0.083 3 (75%) 7 (19%) 0.039 
Impaired VT# 1 (20%) 8 (21%) 1.000 0 (0%) 9 (24%) 0.561 
# n = 42 ‡ n = 41 
DXA – Dual energy X-ray absorptiometry; CT – Computed tomography; SMI – Skeletal muscle index; HGS – Handgrip strength; STS – 
Sit-to-stand; SPPB – Short Physical Performance Battery; 6MWD – Six-minute walk distance; SCT – Stair climb test; VT – Ventilatory 
threshold 
Impaired six-minute walk distance was more frequent in those patients with prolonged 
hospital LOS. Univariate analysis also found that pre-transplant MELD score had a weak 
association (OR 1.14, CI 0.94-1.38; P = 0.173) with prolonged hospital LOS. Impaired six-
minute walk distance retained a significant association with prolonged hospital LOS after 
multiple logistic regression (OR 12.86; 95%CI 1.16-142.9; P = 0.038). 
Patients with EWGSOP sarcopenia had a trend towards higher risk of sepsis (OR 8.67, CI 
0.87-86.06; P = 0.065) on univariate analysis. No association was found between 
EWGSOP classification and risk of other adverse outcomes. 
5.7 DISCUSSION 
The assessment of sarcopenia in patients with cirrhosis has frequently focused on the 
measurement of skeletal muscle mass. However, expert working groups, such as the 
EWGSOP, recommend that sarcopenia assessment incorporate measures of skeletal 
muscle mass, muscle strength and physical performance. Prior to this study, limited 
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information was available on the inter-relationship of these sarcopenia measures in 
patients with cirrhosis. Additionally, we provided a comprehensive evaluation of the 
prognostic utility of measures in each of these domains. 
In our cohort, the DXA and CT estimates of skeletal muscle mass were strongly correlated 
consistent with our results in Chapter 3. Neither modality differed amongst Child-Pugh 
classes. With regard to outcomes, there was a trend towards an association between 
lower DXA SMI and delayed extubation (>8 hours). This trend remained after stepwise 
multiple logistic regression, but the association did not reach statistical significance (P = 
0.051). This relationship in part could be explained by co-existent depletion of respiratory 
muscles, which we did not assess. Additionally, there was a trend towards an association 
between lower DXA SMI and post-transplant sepsis after multivariate analysis (P = 0.068). 
Handgrip strength is the recommended modality to assess muscle strength by the 
EWGSOP.27 Data from healthy adults has demonstrated that handgrip strength provides a 
close approximation of overall muscle strength, however there are limited data in patients 
with cirrhosis.47 In a subgroup of 37 patients, handgrip strength strongly correlated with the 
mid-thigh pull, a validated objective measurement of whole-body strength. Severity of liver 
disease appeared to influence handgrip strength, with a trend to lower strength in patients 
with decompensated cirrhosis. When handgrip strength was assessed with regard to 
outcomes, no significant relationships were found. Prior studies have detected a 
prognostic utility of the handgrip strength and the difference may relate to the sample size 
of our cohort, as well as variations in measurement technique.100 
All physical performance measures used in our study demonstrated a strong inter-
relationship, and were moderately correlated to cardiorespiratory fitness (cardiopulmonary 
exercise test derived ventilatory threshold). Decompensated cirrhosis patients (Child-Pugh 
C) had significantly inferior physical performance results than patients with compensated 
cirrhosis (Child-Pugh A). Despite this, physical performance tests were consistently 
associated with pre- and post-transplant adverse events, even after accounting for 
cirrhosis severity using the MELD score. Analysis of the physical performance results as 
continuous variables revealed several relationships. Lower sit-to-stand test result was 
independently associated with pre-transplant non-cholestatic sepsis and encephalopathy 




Identification of patients for intervention clinically requires the use of ‘cut-offs’. Therefore, 
the significance of patients classified as having impairment in each of the measured 
variables was also analysed. We found that ‘any cirrhosis complication’ was independently 
associated with impaired Short Physical Performance Battery. Additionally, we found that 
impaired Short Physical Performance Battery was an independent predictor of post-
transplant sepsis, while impaired six-minute walk distance was associated with prolonged 
hospital stay after multiple logistic regression. 
Our results highlight the importance of using a comprehensive assessment of sarcopenia, 
with each individual component providing different prognostic information. DXA is our 
recommended method for assessment of skeletal muscle mass. Bedside measures may 
also be used, however at the expense of accuracy and reproducibility. Muscle strength 
using handgrip strength is a reproducible and a rapid bedside measure which should be 
used in the clinical setting. Despite some concern with intra-observer variability, we would 
suggest assessment of physical performance with either the Short Physical Performance 
Battery or the sit-to-stand test. These tests can be performed quickly and at the bedside. 
The six-minute walk distance is a reasonable alternative, although is more time consuming 
and requires a suitable area for assessment. 
There are several limitations to our study. Firstly, the patients are non-consecutive, and 
the sample size is relatively small. However, the comprehensive nature of the study 
provides important insight into the relationship of sarcopenia measures and their clinical 
significance. 
Finally, our study numbers precluded an evaluation of sarcopenia measures on mortality, 
and further large prospective studies incorporating all components of the EWGSOP 
classification should be undertaken. 
To conclude, measures of skeletal muscle mass and physical performance demonstrated 
independent associations with pre- and post-transplant outcomes including sepsis, 
delayed extubation and prolonged hospital stay. The multi-component assessment of 
sarcopenia provides different prognostic information in patients with cirrhosis undergoing 
liver transplantation, and comprehensive assessment of sarcopenia as recommended by 





Figure 5-2. Comparison of physical performance variables according to Child-Pugh class and sex. (a) 
Short Physical Performance Battery [SPPB]; (b) Six-minute walk distance; (c) Sit-to-stand test; (d) 
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One of the most significant issues in the long-term management of organ transplant 
recipients is metabolic syndrome and cardiovascular disease (CVD). Early diagnosis and 
management of cardio-metabolic risk factors has been advocated to reduce the risk of 
CVD. However, early identification of high-risk patients with implementation of preventative 
strategies is likely to offer an even greater benefit. We therefore performed a retrospective 






Introduction: Post-liver transplantation metabolic syndrome (PTMS) is a significant 
independent risk factor for the development of cardiovascular disease. Low muscle mass, 
excess visceral adipose tissue, and poor cardiorespiratory fitness are risk factors for 
developing metabolic syndrome in the general population and have not been evaluated in 
the liver transplant setting. The aim of our study was to assess the impact of body 
composition and cardiorespiratory fitness on the risk of PTMS. 
Patients and methods: Seventy-five consecutive adult patients listed for liver transplant 
between August 2012 and August 2015 were included in the analysis. Demographic, 
anthropometric and metabolic data were collected pre-transplant and at three months 
post-transplant. Metabolic Syndrome was defined in accordance with international 
guidelines. Skeletal muscle area, visceral adipose tissue (VAT) area and subcutaneous 
adipose tissue (SAT) area were derived from an abdominal cross-sectional computed 
tomography (CT) slice. Skeletal muscle index (SMI) was calculated by correcting the 
skeletal muscle area for height, squared. Cardiorespiratory fitness [using the ventilatory 
threshold] was determined from a cardiopulmonary exercise test. 
Results: The median age was 56.0 years [interquartile range (IQR) 51.0–59.0] with 58 
(77%) men and 17 (33%) women.  
Ten patients (13%) developed early onset PTMS by 3 months post-transplant. Patients 
who developed PTMS had higher pre-transplant body mass index (P=0.012), VAT 
(P=0.001) and SAT (P=0.008). There was no difference in ventilatory threshold (P=0.772) 
or SMI (P=0.313) between those who did or did not develop PTMS. Univariate logistic 
regression found that body mass index (P=0.019), VAT (P=0.004) and SAT (P=0.01) were 
significant predictors for the development of PTMS. After stepwise multivariate analysis, 
only VAT remained a significant predictor (OR 1.02; 95%CI 1.01-1.04); P=0.004). A 
sensitivity and specificity analysis determined that the optimal cut-off value for VAT 
predicting PTMS was >153.4cm2. 
Conclusion: Pre-transplant VAT is independently associated with the early development of 
PTMS. Body composition analysis, using cross-sectional imaging prior to liver transplant, 
can assist with risk stratification for PTMS. These patients could be targeted for 





Cardiovascular disease (CVD) after liver transplantation is associated with increased 
morbidity and mortality.205, 206 In a large cohort of Spanish transplant recipients, CVD was 
the fourth highest cause of 5 year mortality, accounting for 12% of deaths.206 Previous 
studies have identified several risk factors for the development of CVD. Pre-transplant risk 
factors include older age at time of transplantation, higher body mass index, metabolic 
syndrome and hyperuricaemia, while post-transplant risk factors include mycophenolate-
free immunosuppression, diabetes, obesity and dyslipidaemia.206, 253 Several publications 
have demonstrated that one of the most powerful risk factors for CVD is post-transplant 
metabolic syndrome (PTMS).205 
Pre-transplant variables associated with the development of PTMS include older age, 
diabetes mellitus, dyslipidaemia and obesity.208, 209, 254, 255 In addition, patients with 
alcoholic liver disease appear to be more likely to develop post-transplant diabetes and 
dyslipidaemia at 1 year.208, 256 
Pre-transplant adipose tissue has not been evaluated as a predictor of PTMS. Excess 
visceral adipose tissue (VAT) has been linked with disturbances in metabolic risk factors in 
population studies.67, 68 Furthermore, Vaughn et al. demonstrated that higher VAT was 
associated with late onset diabetes mellitus post-transplant.257 It has also been proposed 
that high levels of VAT relative to subcutaneous adipose tissue (SAT) [VAT:SAT Ratio] 
carry an even greater metabolic risk.210 
Previous population studies have identified other independent predictors of metabolic 
complications including low skeletal muscle mass, reduced strength and poor 
cardiorespiratory fitness.258-261 The risk that these factors carry with regards to PTMS has 
not been previously assessed. The aim of our study was to assess the impact of body 
composition and cardiorespiratory fitness on the risk of PTMS. 
6.4 PATIENTS AND METHODS 
A retrospective cohort study was performed by assessing consecutive patients for 
inclusion who were listed and underwent liver transplant by the Queensland Liver 
Transplant Service between August 2012 and August 2015. Ethical approval was granted 
from the Metro South Hospital and Health Services District and The University of 
Queensland’s Human Research Ethics Committees (Approval numbers: 
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HREC/14/QPAH/714; HMS13/1210). A waiver of consent was obtained under the 
Queensland Government Public Health Act. Patients were excluded if they were less than 
18 years of age; had previously received a liver transplant (n=4); had a multi-organ 
transplant (n=7); had a transplant for fulminant liver failure (n=7); had a pre-transplant CT 
greater than 12 months prior to transplant (n=8); had a pre-transplant diagnosis of 
metabolic syndrome (n=5) or had incomplete data post-transplant (n=9). 
Demographic, clinical, laboratory and anthropometric data including height and weight 
were collected at the closest time point to the CT scan and at three months post-
transplant. Dry body weight was estimated by subtracting the volume of ascites removed 
at transplant or therapeutic paracentesis. Body mass index was calculated using the dry 
body weight. Metabolic syndrome was diagnosed according to World Health Organisation 
(WHO) criteria, which requires dysglycaemia along with any two of obesity, hypertension 
or dyslpidaemia.262 
CT abdomen images were analysed as described in Section 2.2.4. Cross-sectional area of 
subcutaneous adipose tissue (SAT), VAT and skeletal muscle was measured. Skeletal 
muscle area was normalized for stature (cm2/m2), and described as the skeletal muscle 
index (SMI) as previously reported.58 Five patients had a CT with only partial 
subcutaneous adipose tissue area on their imaging and were classified as missing data. 
All images were analysed by a single trained observer (AW). Intra-observer and inter-
observer variability using this technique was assessed and described in Chapter 4.  
Cardiopulmonary exercise testing was performed as described in Section 2.5. Nine 
patients did not have a cardiopulmonary exercise test prior to transplant and were 
classified as missing data. 
6.5 STATISTICAL ANALYSIS 
Statistical analyses were performed using SPSS (Version 24; IBM, New York, USA). 
Continuous data were assessed for normality using a Shapiro-Wilk test and are presented 
as means ± SD, or medians and IQR, depending on distribution of the data. 
Independent t-tests (normal distribution) or Mann-Whitney U tests (non-normal distribution) 
were used to compare continuous variables between two groups. Categorical variables 




Univariate binary logistic regression was performed for all binary outcomes to test the 
relationship with potential predictors. To identify independent pre-transplant predictors of 
PTMS, multiple logistic regression was performed. Variables with a P value <0.2 were 
considered for inclusion in the multivariate analysis. Odd ratios and 95% confidence 
intervals are reported. 
A receiver-operator characteristic (ROC) curve was used to estimate the accuracy of VAT 
in predicting PTMS. The value with the highest sensitivity and specificity for predicting 
PTMS was used to determine the optimal cut-off value. 
6.6 RESULTS 
Seventy-five patients with a median age of 56.0 years (IQR 51.0 – 59.0) were included in 
the analysis. The majority of the study cohort were male (n = 58; 77%) and Caucasian (n = 
68; 91%). The most common cause of liver disease was hepatitis C (58%), primary 
sclerosing cholangitis (13%) and alcohol (12%). Thirty patients (40%) had a diagnosis of 
hepatocellular carcinoma (HCC). Baseline patient characteristics are shown in Table 6-1. 
Standard immunosuppression at our institution is Tacrolimus, Prednisolone and 
Azathioprine. Two patients were changed from Tacrolimus to Cyclosporin within four 
weeks. One patient had early weaning of Prednisolone after four weeks due to fulminant 
cholestatic hepatitis. Eight patients received Mycophenolate instead of Azathioprine.  
Ten patients (13%) developed de novo PTMS at three months post-transplant [Table 6-1]. 




Table 6-1 Baseline characteristics of the study population 
Characteristic Men Women Overall P Value 
Number of patients 58 (77%) 17 (33%) 75  
Age (years) 56 (52-59) 53 (38-60) 55 (51–59) 0.276 
Ethnicity [n (%)]     
Caucasian 52 (90%) 16 (94%) 68 (91%) 0.649‡^ 
Indigenous 2 (3%) - 2 (2.6%)  
Asian 1 (2%) 1 (6%) 2 (2.6%)  
Other  3 (5%) - 3 (4%)  
Aetiology of liver disease [n (%)]     
Hepatitis C 41 (71%) 3 (18%) 44 (58%) <0.001^ 
Primary sclerosing cholangitis 4 (7%) 7 (41%) 10 (13%)  
Alcohol 8 (14%) 1 (6%) 9 (12%)  
Other   12 (16%)  
Hepatocellular carcinoma [n (%)] 25 (43%) 5 (29%) 30 (40%) 0.403 
MELD score  14 (12-19) 15 (11-18) 15 (12-19) 0.689 
Child-Pugh class [n (%)]    0.653‡ 
A 14 (24%) 6 (35%) 20 (27%)  
B 22 (38%) 6 (35%) 28 (37%)  
C 22 (38%) 5 (30%) 27 (36%)  
Ascites [n (%)]    0.459‡ 
None 21 (36%) 9 (53%) 30 (40%)  
Mild/diuretic controlled 24 (41%) 6 (35%) 30 (40%)  
Moderate/severe 13 (22%) 2 (12%) 15 (20%)  
Body composition data     
Height (m) 1.76 ± 0.06 1.65 ± 0.09 1.74 ± 0.08  <0.001 
Dry weight (kg) 81.6 ± 13.9 65.8 ± 11.1 78.0 ± 14.8 <0.001 
Dry BMI (mg/kg2) 26.3 ± 4.0 24.2 ± 3.8 25.8 ± 4.0 0.056 
SMI (cm2/m2) 51.5 ± 9.1 43.2 ± 7.1 49.6 ± 9.3 0.001 
VAT (cm2) 133.0 ± 64.3 69.4 ± 37.8 118.6 ± 64.9 <0.001 
SAT (cm2)§ 142.6 (111.6-205.9) 161.0 (125.0-204.9) 155.6 (115-204) 0.538 
VAT:SAT Ratio 0.74 (0.60-0.99) 0.31 (0.25-0.58) 0.67 (0.48-0.95) <0.001 
BMI category#     0.093‡ 
Normal 20 (35%) 11 (65%) 31 (41%)  
Overweight 27 (47%) 5 (30%) 32 (43%)  
Obese 11 (18%) 1 (5%) 12 (16%)  
Ventilatory threshold (mL.kg-1.min-1)Δ 11.5 (10.0-12.9) 12.3 (11.4-13.0) 11.8 (10.5-12.9) 0.262 
Pre-transplant metabolic risk factors#      
Dysglycaemia 12 (21%) 2 (12%) 14 (19%) 0.502‡ 
Hypertension 11 (19%) 2 (12%) 13 (17%) 0.720‡ 
Dyslipidaemia 17 (29%) 4 (24%) 21 (28%) 0.765‡ 
Values presented as mean (± SD), or median (interquartile range) where data were not normally distributed, and number and 
percentage.  
‡ Fisher’s Exact Test; § n=70; Δ n=66; ^ Reference Level = ‘Other’ ethnicities/aetiologies combined 
# Diagnosed according to World Health Organisation (WHO) criteria40, 262, 263.  
MELD = Model for end-stage liver disease; BMI = Body mass index; VAT = Visceral adipose tissue area; SAT = Subcutaneous adipose 




Table 6-2 Pre-transplant patient characteristics of patients with or without post-transplant metabolic 
syndrome 




Number of patients 10 (13%) 65 (87%)  
Age (years) 59.0 (53-62) 55.0 (51-61) 0.094 
Sex: Male [n (%)] 9 (90%) 49 (75%) 0.439 
Ethnicity [n (%)]   0.649 ‡ 
Caucasian 9 (90%) 59 (91%)  
Indigenous 0 (0%) 2 (3%)  
Asian 0 (0%) 2 (3%)  
Other  1 (10%) 2 (3%)  
Aetiology of liver disease [n (%)]   0.200 ‡ 
Hepatitis C 6 (60%) 38 (58%)  
Primary sclerosing cholangitis 0 (0%) 11 (17%)  
Alcohol 3 (30%) 6 (9%)  
Other 1 (10%) 10 (15%)  
Hepatocellular carcinoma [n (%)] 5 (50%) 25 (38%) 0.508 
MELD score  16.0 (13.8-20.3) 15.0 (11.5-19.0) 0.650 
Child-Pugh class [n (%)]   0.442 ‡ 
A 1 (10%) 19 (29%)  
B 5 (50%) 23 (35%)  
C 4 (40%) 23 (35%)  
Ascites [n (%)]   0.222 ‡ 
None 4 (40%) 26 (40%)  
Mild/diuretic controlled 6 (60%) 24 (37%)  
Moderate/severe 0 (0%) 15 (23%)  
Body composition data    
Height (m) 1.73 ± 0.1 1.74 ± 0.1 0.916 
Dry weight (kg) 86.4 ± 15.0 76.7 ± 14.5 0.055 
Dry BMI (mg/kg2) 28.7 ± 4.5 25.4 ± 3.7 0.012 
SMI (cm2/m2) 52.4 ± 9.2 49.2 ± 9.3 0.313 
VAT (cm2) 182.9 (148-230) 105.6 (55-148) 0.001 
SAT (cm2)§ 217.9 (152-343) 141.6 (107-195) 0.008 
VAT:SAT Ratio 0.70 (0.64-0.96) 0.67 (0.43-0.95) 0.283 
BMI category#    0.088 ‡ 
Normal 2 (20%) 29 (45%)  
Overweight 4 (40%) 28 (43%)  
Obese 4 (40%) 8 (12%)  
Ventilatory threshold (mL.kg-1.min-1)Δ 11.4 (10.1-16.0) 11.8 (10.6-12.9) 0.772 
Pre-transplant metabolic risk factors#     
Dysglycaemia 2 (30%) 12 (18%) 1.000 
Hypertension 1 (10%) 12 (18%) 1.000 
Dyslipidaemia 0 (0%) 21 (32%) 0.053 
Values presented as mean (± SD), or median (interquartile range) where data were not normally distributed, and number and 
percentage.  
‡ Fisher’s Exact Test; § n=70; Δ n=66  
# Diagnosed according to World Health Organisation (WHO) criteria40, 262, 263.  
MELD = Model for end-stage liver disease; BMI = Body mass index; VAT = Visceral adipose tissue area; SAT = Subcutaneous adipose 
tissue area; SMI = Skeletal muscle index 
Evaluation of patients with de novo metabolic complications three months post-transplant 
is presented in Table 6-3. Pre-transplant VAT was significantly elevated in patients who 
had de novo hypertension and dyslipidaemia but not dysglycaemia. Patients with de novo 
dyslipidaemia had a greater severity of cirrhosis pre-transplant reflected in a higher MELD 
score, and lower prevalence of HCC.  There was also a higher proportion of alcoholic liver 
disease patients developing dyslipidaemia. The only de novo metabolic complication 




Table 6-3 Pre-transplant characteristics of patients with de novo cardiometabolic complications# three-months post-liver transplantation 











Number§ 20 (33%) 41 (67%)  25 (40%) 37 (60%)  17 (32%) 37 (68%)  
Age (years) 56.0 (54-59) 55.0 (48-60) 0.569 56 (50-61) 55 (46-59) 0.294 56.0 (48-61) 56.0 (52-59) 0.641 
Sex: male [n (%)] 18 (90%) 28 (68%) 0.111 20 (80%) 27 (73%) 0.564 15 (88%) 26 (70%) 0.189 
MELD score 16.0 (12-18) 16.0 (10-20) 0.776 16 (11-21) 16 (12-19) 0.719 16.0 (13-21) 14.0 (10-16) 0.021 
Aetiology of liver disease^ [n (%)]          
Hepatitis C 12 (60%) 21 (51%) 0.518 14 (56%) 21 (57%) 0.953 10 (59%) 22 (60%) 0.965 
Alcohol 3 (15%) 5 (12%) 1.000 5 (20%) 2 (5%) 0.107 4 (24%) 1 (3%) 0.030 
Hepatocellular carcinoma [n (%)] 10 (50%) 13 (32%) 0.166 10 (40%) 12 (32%) 0.541 4 (24%) 22 (60%) 0.014 
Moderate-severe ascites [n (%)] 3 (15%) 9 (22%) 0.734 5 (20%) 9 (24%) 0.690 4 (24%) 2 (5%) 0.071 
Pre-transplant body composition          
Dry weight (kg) 80.5 ± 16.4 77.8 ± 14.4 0.519 78.7 ± 15 75.2 ± 14 0.350  82.0 ± 14 77.7 ± 16 0.357 
BMI (kg/m2) 26.9 ± 4.4 25.6 ± 3.9 0.221 26.2 ± 4 24.8 ± 3 0.157 26.5 ± 4 26.0 ± 4 0.670 
SMI (cm2/m2) 53.2 ± 7.3 48.2 ± 9.7 0.047 50.3 ± 8 47.0 ± 9 0.144 48.9 ± 8 49.9 ± 10 0.727 
VAT (cm2) 131.2 ± 67 114.2 ± 70 0.369 131.8 ± 67 97.0 ± 49 0.022 173.2 (100-205) 93.5 (48-151) 0.009 
SAT (cm2) 130.8 (114-237) 158.7 (122-194) 0.854 190.4 ± 110  153.8 ± 75 0.126 172.8 (134-225) 153.3 (111-210) 0.263 
VAT:SAT Ratio  0.78 (0.63-0.88) 0.66 (0.34-1.03) 0.198 0.72 (0.59-0.99) 0.65 (0.35-0.84) 0.174 0.72 (0.61-0.98) 0.60 (0.38-0.84) 0.042 
VT (mL.kg-1.min-1) 11.3 (9.8-12.3) 11.9 (11.1-12.9) 0.219 10.9 (9.6-12.3) 11.8 (10.8-12.8) 0.365 11.0 (9.8-12.9) 12.2 (11.4-13.6) 0.076 
§ each analysis excludes patients with pre-existing disease. Therefore, n=61 in dysglycaemia analysis; n=62 in hypertension analysis, and n=54 in dyslipidaemia analysis  
^ Reference level = ‘Other’ aetiologies combined 
# Diagnosed according to WHO criteria. Values presented as mean ± SD, or median (interquartile range) where data were not normally distributed, unless otherwise stated. MELD = 




A univariate and multivariate analysis of factors associated with PTMS was performed 
[Table 6-4]. Univariate analysis found that body mass index, VAT and SAT were all 
significant predictors for the development of PTMS. Age and alcoholic liver disease also 
had P values <0.2 and were included in the backward stepwise multivariate analysis. Only 
VAT remained independently associated with the diagnosis of PTMS in the multivariate 
model. 
Table 6-4 Univariate and multivariate analysis of factors associated with the development of 
metabolic syndrome three-months post-liver transplantation 
 Univariate analysis Multivariate analysis 
 OR 95% CI P Value OR 95% CI P Value 
Age 1.08 0.97 - 1.21 0.152 1.08 0.94 - 1.24 0.280 
Male sex 2.94 0.35 – 25.0 0.324    
MELD score 1.00 0.89 - 1.12 0.975    
Aetiology of liver disease§       
Hepatitis C 1.07 0.27 - 4.14 0.927    
Alcohol 4.21 0.86 – 20.71 0.077 4.64 0.67 – 32.13 0.120 
Hepatocellular carcinoma 1.60 0.42 - 6.09 0.491    
Pre-transplant diabetes 1.10 0.21 – 5.87 0.907    
Pre-transplant hypertension 0.49 0.06 – 4.25 0.518    
Pre-transplant dyslipidaemia #      
Pre-transplant body composition       
BMI (kg/m2) 1.24 1.04 - 1.49 0.019    
SMI (cm2/m2) 1.04 0.97 - 1.12 0.309    
VAT (cm2) 1.02 1.01 - 1.03 0.004 1.02 1.01 - 1.04 0.004 
SAT (cm2) 1.01 1.00 - 1.02 0.010    
VAT:SAT Ratio 0.98 0.32 - 3.04 0.976    
VT (mL.kg-1.min-1) 1.09 0.90 - 1.33 0.374    
Prednisolone dose 1.12 0.54 – 1.21 0.803    
MELD = Model for end-stage liver disease; BMI = Body mass index; VAT = Visceral adipose tissue area; SAT = Subcutaneous adipose 
tissue area; SMI = Skeletal muscle index; VT = Ventilatory threshold; OR – Odds ratio 
§ Reference level = ‘Other’ aetiologies combined # Pre-transplant dyslipidaemia not included in the analysis since n = 0 in ‘Metabolic 
Syndrome’ group 
 
A ROC curve analysis was performed for body mass index and VAT predicting the 
development of PTMS [Figure 6-1]. VAT had a significant area under the curve of 0.84 (CI 
0.73–0.95; P = 0.001) while body mass index did not (P = 0.066). The optimal cut-off value 
of VAT to identify patients that developed PTMS was >153.4cm2 which had a sensitivity 




Figure 6-1 Sensitivity and specificity analysis of body mass index and visceral adipose tissue for 
predicting post-transplant metabolic syndrome 
6.7 DISCUSSION 
The aim of our study was to examine the impact of pre-transplant adipose tissue, muscle 
mass and cardiorespiratory fitness on the development of early post-liver transplant 
metabolic disease. We found that elevated levels of visceral adipose tissue, but not fitness 
or muscle mass, was associated with de novo post-transplant metabolic syndrome, 
hypertension and dyslipidaemia. On multivariate analysis, visceral adipose tissue was a 
significant predictor of de novo PTMS, independent of body mass index or any other 
variables that were assessed. The risk of PTMS was highest with a visceral adipose tissue 
area above 153.4cm2. 
On initial review, an odds ratio of 1.02 for developing PTMS does not appear to be a 
clinically significant relationship. However, it is important to consider that the unit used for 
CT visceral adipose tissue area in the analysis was centimetres squared. Thus, for each 1 
cm2 increase in CT visceral adipose tissue area, there was a 2% increase in risk of PTMS. 
Given the mean CT visceral adipose tissue area in our cohort was 118.6 cm2, we believe 




highest visceral adipose tissue area of 317 cm2 would have a four times higher risk of 
PTMS than someone with the mean value. 
This is the first study to the author’s knowledge to evaluate the impact of visceral adipose 
tissue on the risk of PTMS. A previous study by Vaughn et al. demonstrated that both 
subcutaneous adipose tissue thickness and visceral adipose tissue area were associated 
with de novo diabetes mellitus post-transplant.257 In our cohort, we found no relationship 
with subcutaneous adipose tissue, visceral adipose tissue and dysglycaemia at three 
months post-transplant.  
Early detection and treatment of metabolic risk factors is an important strategy to reduce 
the risk of post-transplant cardiovascular disease. By identifying the highest risk patients, 
interventions could be targeted either pre- or early post-transplantation. Nutritional 
intervention to reduce visceral adipose tissue pre-transplant is difficult to implement due to 
the complex dietary requirements of cirrhotic patients, which typically focuses on 
minimising muscle loss.264 Guidelines have been developed to assist practitioners in the 
management of obese cirrhotic patients.264 The European Association for the Study of the 
Liver (EASL) suggests a moderately hypocaloric (-500–800 kcal/day) diet, including 
adequate protein intake (>1.5 g protein/kg ideal body weight/day), to achieve weight loss 
without compromising protein stores.264 However, in practice, these recommendations are 
difficult to implement as these patients are highly susceptible to muscle loss and require 
close monitoring for this consequence.   
An alternative strategy is early post-liver transplant dietary intervention to improve visceral 
adipose tissue and metabolic profiles. One particular option would be to employ dietary 
interventions which reduce cardiovascular risk, such as the Mediterranean diet.265 Further 
studies are required to evaluate the impact of such diets on the cardiovascular risk profile 
of liver transplant recipients. 
Another potential intervention, either pre- or post-transplantation, is exercise therapy. 
Exercise training appears to reduce visceral adipose tissue independent of a hypocaloric 
diet, as well as improve metabolic risk factors.266-268 In the past there has been a hesitation 
to engage in exercise training of cirrhotic patients with portal hypertension. This is largely 
related to concerns regarding an increase in portal pressure associated with exercise.183 
However, there is no evidence to suggest that this is associated with an increased risk of 
gastrointestinal bleeding. Further studies are required to evaluate the safety and efficacy 
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of exercise training in patients with decompensated liver disease, in particular those listed 
for liver transplant. 
Our investigation had a number of limitations. Firstly, it was a cross-sectional design with a 
relatively small sample size, which precluded sex-specific analysis. However, a strength 
was the inclusion of consecutive patients who met the enrolment criteria. Another limitation 
was use of the WHO criteria for defining the metabolic syndrome. We were restricted to 
this definition since this was a retrospective investigation, and we had insufficient waist 
circumference data to utilise the harmonised definition. 
Despite the limitations, our investigation provides evidence that pre-transplant excess 
visceral adipose tissue is an independent risk factor for developing early PTMS. Further 
studies are required in larger cohorts to confirm these findings, and to assess the impact of 
excess visceral adipose tissue on harder end points, such as cardiovascular morbidity and 
mortality. 
At our institution, and in many other liver transplant centres, cross-sectional imaging is part 
of the routine assessment of patients prior to liver transplant. This study shows that 
analysis of the pre-transplant CT can identify patients at risk of PTMS and therefore, over 
the longer term, cardiovascular disease. The patients at the highest risk for cardiovascular 
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Body composition changes associated with liver transplantation have been described in 
several prior studies. Typically, there is loss of skeletal muscle mass and gain of fat mass 
in the first six months following transplantation. These changes are likely to contribute to 
an increased prevalence of ‘sarcopenic obesity’. Few studies have evaluated this condition 
and its significance post-transplantation. We therefore performed a prospective trial 
looking at the prevalence of sarcopenic obesity post-transplant and its relationship with 





Introduction: Sarcopenic obesity is associated with an increased prevalence of 
cardiometabolic risk factors in the general population. Sarcopenic obesity is also 
associated with increased risk of physical performance impairment, as is the metabolic 
syndrome. The aims of this study were: (a) to describe the change in body composition, 
muscle strength and physical performance from pre-transplant to six months post-
transplant; (b) to examine the prevalence of sarcopenic obesity at six months post-liver 
transplant, and evaluate its association with functional impairments and the risk of 
cardiometabolic complications; and (c) to define the association of body composition and 
physical performance with post-transplant metabolic syndrome (PTMS). 
Patients and methods: We conducted a single centre prospective longitudinal study by 
recruiting patients from the Queensland Liver Transplant Service. Patients were assessed 
pre-transplant and six months post-transplant. Body composition analysis was performed 
using a whole body dual energy X-ray absorptiometry (DXA) scan. DXA measurements 
were used to diagnose low DXA skeletal muscle index (SMI), obesity and sarcopenic 
obesity. Handgrip strength was measured in the non-dominant hand with a hand 
dynamometer. Physical performance was assessed with the Short Physical Performance 
Battery, sit-to-stand test, six-minute walk distance and the stair climb test. Pre-transplant 
computed tomography (CT) analysis was performed to measure visceral adipose (VAT) 
and subcutaneous adipose tissue (SAT) surface area. Metabolic syndrome and its 
cardiometabolic criteria were diagnosed according to international guidelines. 
Results: Thirty-four patients (29 men; 5 women) were included in the analysis, with a 
median age of 55.5 years (interquartile range [IQR] 46.0-59.3). At baseline pre-transplant 
assessment, the median dry weight and body mass index were 79.7 kg (IQR 69.4-88.0) 
and 26.2 kg/m2 (IQR 23.7-27.6) respectively. Comparing DXA measurements in male 
patients from pre-transplant and 6 months post-transplant revealed there was a significant 
increase in DXA fat mass (P=0.021), along with a decline in DXA bone mass (P=0.037) 
and DXA appendicular lean mass (P=0.004). Similar trends were seen in female patients 
which did not reach statistical significance. 
In male patients, there was a trend towards improvement in handgrip strength (P=0.085) 
from pre- to post-transplantation while all physical performance measures significantly 
improved. Female patients demonstrated a significant improvement in sit-to-stand test 
(P=0.041) and stair climb test (P=0.002) results.  
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The prevalence of sarcopenic obesity six months post-liver transplant was 24%. In male 
patients, post-transplant sarcopenic obesity was associated with a lower handgrip strength 
(P=0.022), and Short Physical Performance Battery score (P=0.029) compared to the 
‘non-sarcopenic’ patients. Sarcopenic obesity patients had a lower sit-to-stand test result 
(P=0.012) compared to the ‘sarcopenic non-obese’ patients. Sarcopenic obesity was 
associated with a longer post-operative ventilation time (P=0.036) and ICU length of stay 
(P=0.003). No association was found between sarcopenic obesity and post-transplant 
cardiometabolic risk factors. PTMS was associated with inferior physical performance 
assessed at baseline and post-transplant. Multiple logistic regression of pre-transplant risk 
factors for PTMS identified that CT VAT (P=0.033) and Short Physical Performance 
Battery score (P=0.025) were significant independent predictors. 
Conclusion: There was a high prevalence of sarcopenic obesity at 6 months post-liver 
transplant, which was associated with inferior muscle strength and physical performance. 
No significant relationship between sarcopenic obesity and cardiometabolic risk was 
identified. The strongest independent predictors of PTMS were pre-transplant CT visceral 
adipose tissue and Short Physical Performance Battery score, which could be utilised to 





Liver transplantation alters body composition, with most studies describing an increase in 
fat mass and decline in lean body mass in the first 12 months after transplantation.59, 211, 
212 Longitudinal studies have shown that there is an initial dramatic decline in both fat 
mass and lean body mass in the first 30 days after liver transplantation. Subsequently 
there is typically an increase in both compartments although this is more pronounced for 
fat mass.213, 214 This discordant change in fat mass and lean body mass is likely to 
increase the risk of developing ‘Sarcopenic obesity’. 
Sarcopenic obesity is defined as the co-presence of both low skeletal muscle mass and 
excess fat mass, and has been linked with a higher risk of cardiometabolic complications 
than obesity alone.215-218 It is hypothesised that the loss of skeletal muscle mass 
accentuates the insulin resistance associated with excess adipose tissue.219 
An investigation by Choudhary et al., using bioelectrical impedance analysis (BIA) to 
diagnose sarcopenic obesity in a cohort of Indian liver transplant recipients, found a 
prevalence of 88%.211 Patients with sarcopenic obesity had a significantly higher 
prevalence of post-transplant metabolic syndrome (PTMS) compared to those without 
sarcopenic obesity. However, no significant differences were found for the individual 
cardiometabolic variables that comprise the metabolic syndrome. 
Another consequence of sarcopenic obesity in the elderly is the association with physical 
performance impairment.220, 221 Baumgartner and colleagues demonstrated that patients 
with sarcopenic obesity had a higher prevalence of disturbances in physical 
performance.221 Subsequently, it was shown that the presence of sarcopenic obesity was 
a risk factor for the development of de novo physical performance impairment.220 Given 
that the presence of the metabolic syndrome has been associated with poor physical 
performance, further studies are necessary to examine the relationship of these variables, 
both at the population level and in the post-liver transplant setting. 
The aims of this study were: (a) to describe the change in body composition, muscle 
strength and physical performance from pre-transplant to six months post-transplant; (b) to 
examine the prevalence of sarcopenic obesity at six months post-liver transplant, and 
evaluate its association with functional impairments and the risk of cardiometabolic 
complications; (c) to define the association of body composition and physical performance 
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with PTMS; and (d) to evaluate the pre-transplant predictors of PTMS, including physical 
performance. 
7.4 PATIENTS AND METHODS 
A prospective longitudinal cohort study was performed by recruiting patients with cirrhosis 
who were referred to the Queensland Liver Transplant Service between May 2014 and 
January 2017. Ethical approval was granted from the Metro South Hospital and Health 
Services District and The University of Queensland’s Human Research Ethics Committees 
(Approval numbers: HREC/14/QPAH/23; 2014000254). Written informed consent was 
obtained prior to participation. Patients were excluded if they were less than 18 years of 
age, received a multi-organ transplant and/or had previously received a liver transplant. 
Eight patients who participated in a pre-transplant exercise training programme as part of 
a clinical study were excluded. Thirty-four patients consented to participation.  
Patients were assessed in the outpatient department pre-transplant (median time pre-
transplant = 118 days [interquartile range (IQR) 44-194]) and six months post-transplant 
(median time post-transplant = 202 days [IQR 190-208]). Baseline clinical data was 
collected pre-transplant, including patient demographics, medical history and prescribed 
medications. Biochemical results were recorded including bilirubin, albumin, international 
normalised ratio (INR), creatinine and vitamin D. During the pre-transplant visit, 
assessment for hepatic encephalopathy (HE) was performed by a single experienced 
observer (AW) according to the West Haven criteria. Patients were not assessed if they 
had evidence of overt HE (greater than or equal to West Haven Grade 2 HE).12 
Body composition assessment 
Anthropometric data, including height and weight, were collected by a single observer 
(AW) using standard procedures. Dry body weight was estimated by subtracting the 
volume of ascites removed at transplant, or by therapeutic paracentesis at the closest time 
point to the pre-transplant assessment. Body mass index was calculated using the dry 
body weight. 
Body composition analysis was performed using a whole body DXA scan (GE Prodigy 
Scanner; GE Healthcare Lunar, Madison, WI, USA) as described in Section 2.2.5. DXA 
appendicular lean mass (ALM) was used to calculate the DXA skeletal muscle index (SMI) 
according to the following equation: DXA SMI (kg/m2) = DXA ALM/Height2.27  
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Low DXA SMI was defined as <7.26kg/m2 for males and <5.45kg/m2 for females.53 DXA 
Obesity was defined as a %Body Fat >27% for males and >38% for females.221 
‘Sarcopenic obesity’ was defined as the presence of both low DXA SMI and DXA 
Obesity.221 
Pre-transplant CT abdomen images were analysed as described in Section 2.2.4. Pre-
transplant Computed Tomography (CT) of the abdomen images were analysed as 
described in Section 2.2.4. Cross-sectional area of subcutaneous adipose tissue (SAT), 
visceral adipose tissue (VAT) and skeletal muscle was measured. Intra- and Inter-observer 
variability using this technique was assessed and reported in Chapter 3.  
Muscle strength assessment 
Upper limb muscle strength was assessed by measuring isometric handgrip strength on 
the non-dominant side as described in Section 2.3.1. Impairment in muscle strength was 
defined as a handgrip strength less than the EWGSOP recommended sex and body mass 
index specific cut-offs.27 
Physical performance assessment 
Physical performance was examined with the sit-to-stand test, Short Physical Performance 
Battery, six-minute walk distance, and the stair climb test as described in Section 2.4.21, 90, 
93, 96, 247  
Impairment of physical performance was classified as a Short Physical Performance 
Battery less than 10 points.89, 93 Cut-off for low six-minute walk distance was calculated 
using the equation by Enright et al.248 Impairment in sit-to-stand test was defined as less 
than 14 chair rises for men and less than 12 for women.96 
All bedside measures of muscle strength and physical performance were assessed for 
reproducibility and reported in Chapter 5 [Table 5-1 above on page 103]. 
Metabolic syndrome 
Metabolic syndrome was defined according to the ‘Harmonised Metabolic Syndrome’ 
criteria, which requires the presence of ≥3 of the following 5 cardiometabolic criteria:  
1. Ethnic specific elevated waist circumference (Caucasian males >102cm or >92cm 
females); 2. Elevated fasting triglycerides (≥ 1.7mmol/L); 3. Reduced fasting high density 
lipoprotein (<1.0mmol/L males or <1.3mmol/L females); 4. Elevated blood pressure [BP] 
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(Systolic BP ≥130mmHg and/or Diastolic BP ≥90); 5. Elevated Fasting Blood Glucose 
(≥5.6mmol/L).269 Drug treatment is considered an alternate indicator for dyslipidaemia, 
hypertension and/or diabetes mellitus. 
7.5 STATISTICAL ANALYSIS 
Statistical analyses were performed using SPSS (Version 24; IBM, New York, USA). 
Continuous data were assessed for normality using a Shapiro-Wilk test and are presented 
as means ± SD, or medians and IQR, depending on distribution of the data. Non-normally 
distributed data were transformed (logarithmic or square root) where possible to reduce 
skewness for statistical analysis. 
Independent t-tests (normal distribution) or Mann-Whitney U tests (non-normal distribution) 
were used to compare continuous variables between 2 groups. Categorical variables were 
compared using the Pearson Chi Square test or the Fisher Exact test when appropriate. 
Comparison of paired continuous variables was examined using paired t-tests (normal 
distribution) or the Wilcoxon Signed Rank Test (non-normal distribution). Categorical 
variables were compared using the Related Samples McNemar Test. 
To assess the relationship of sarcopenic obesity with physical performance and 
cardiometabolic disease, patients were divided into three groups (SO; ‘sarcopenic non-
obese’; and ‘non-sarcopenic’). Comparison between groups was conducted using one-way 
ANOVA analysis and Tukey’s post hoc test (normal distribution), or Kruskal Wallis analysis 
and Dunn’s post hoc test (non-normal distribution). 
Univariate binary logistic regression was performed to test the relationship of PTMS with 
potential predictors. Odd ratios and 95% confidence intervals are reported. To identify 
independent pre-transplant predictors of PTMS, stepwise multiple logistic regression was 
performed. Variables with a P value <0.2 were considered for inclusion in the multivariate 
analysis. Only the final model selected is presented. 
A receiver-operator characteristic (ROC) curve was used to evaluate the accuracy of 
variables in predicting PTMS. The value with the highest sensitivity (Sn) and specificity 




Thirty-four patients with a median age of 55.5 years (IQR 46.0–59.3) were included in the 
analysis. The study cohort was predominately male (85%), and 85% were Caucasian. 
Baseline patient characteristics are shown in Table 7-1. 
Table 7-1. Baseline clinical characteristics 
Characteristic Men Women Overall 
Number of patients [n; (%)] 29 (85%) 5 (15%) 34 
Age 55 (46-59) 58 (47-65) 56 (46-59) 
Ethnicity [n; (%)]    
Caucasian 24 (83%) 5 (100%) 29 (85%) 
Asian 3 (10%) - 3 (9%) 
Indigenous 2 (7%) - 2 (6%) 
Aetiology of liver disease [n; (%)]    
Chronic hepatitis C 17 (59%) 1 (20%) 18 (53%) 
Alcohol 3 (10%) 1 (20%) 4 (12%) 
Primary sclerosing cholangitis 1 (3%) 2 (40%) 3 (9%) 
Other 8 (28%) 1 (20%) 9 (26%) 
Hepatocellular carcinoma [n; (%)]   15 (44%) 
Laboratory values    
Bilirubin (µmol/L) 39 (24-59) 139 (48-285) 44 (25-72) 
Albumin (g/L) 31 ± 6 30 ± 7 31 ± 6 
INR 1.5 ± 0.3 1.7 ± 0.4 1.5 ± 0.3 
MELD score 14 ± 5 19 ± 7 15 ± 5 
Child-Pugh class [n; (%)]    
A 9 (30%) 1 (20) 10 (29%) 
B 10 (35%) 1 (20%) 11 (32%) 
C 10 (35%) 3 (60%) 13 (38%) 
Ascites [n; (%)]    
None 12 (41%) 2 (40%) 14(41%) 
Mild/diuretic controlled 11 (38%) 1 (20%) 12(35%) 
Moderate/severe 6 (21%) 2 (40%) 8 (24%) 
Continuous variables presented as mean (± SD), or median (interquartile range) where data was not normally distributed, and number 
and percentage for categorical variables. INR – International normalised ratio; MELD - Model for end-stage liver disease 
Change in body composition and physical performance 
Body composition, muscle strength and physical performance at the pre-transplant 
assessment and six months post-transplant are shown in Table 7-2. There was no 
significant difference in dry weight and body mass index in both men and women. In men 
there were significant increases in DXA fat mass and percentage body fat post-
transplantation, along with a decline in DXA fat-free mass, bone mass, appendicular lean 





Table 7-2. Pre- and post-liver transplantation difference in body composition, muscle strength and 
physical performance (n = 34) 
Characteristic Sex Pre-transplant Post-transplant P Value 
Anthropometrics       
Height (m) M 1.77 ± 0.07 -  
 F 1.65 ± 0.04 -  
Dry weight (kg) M 79.7 (69.4-88.0) 80.2 (69.9-88.6) 0.658 
 F 70.0 (64.9-72.8) 67.6 (62.4-73.9) 0.686 
BMI (kg/m2) M 26.2 (23.9-28.1) 26.1 (24.5-27.9) 0.787 
 F 26.0 (23.4-26.9) 25.9 (22.1-27.8) 0.686 
Body composition     
DXA fat mass (kg)Δ M 20.4 (15.3-25.6) 23.8 (18.0-30.1) 0.021 
 F 22.0 (18.7-25.3) 26.7 (14.8-30.0) 0.500 
DXA % body fat  M 23.3 (19.9-28.7) 29.6 (23.4-34.7) <0.001 
 F 29.7 (27.0-38.1) 40.2 (22.9-41.3) 0.500 
DXA fat-free mass (kg) M 64.0 ± 8.7 57.5 ± 6.7 <0.001 
 F 47.3 ± 6.9 44.0 ± 5.2 0.238 
DXA bone mass (kg) M 3.05 ± 0.53 2.98 ± 0.49  0.037 
 F 2.17 ± 0.44 2.06 ± 0.36  0.217 
DXA ALM (kg) M 25.3 ± 3.9 23.6 ± 3.7 0.004 
 F 18.7 ± 3.1 17.6 ± 1.7 0.384 
DXA SMI (kg/m2) M 8.04 ± 0.97 7.50 ± 0.87 0.005 
 F 6.85 ± 1.18  6.49 ± 0.49 0.456 
Low DXA SMI‡ [n (%)] M 7 (24%) 12 (41%) 0.344* 
 F 1 (20%) 0 (0%)  
Obesity (DXA)‡ [n (%)] M 8 (28%) 16 (55%) 0.013* 
 F 1 (20%) 3 (60%)  
Sarcopenic obesity [n (%)] M 0 (3%) 7 (24%) 0.070* 
 F 1 (20%) 0 (0%)  
Muscle strength     
Non-dominant HGS (kg) M 37.4 ± 6.9 39.6 ± 7.5 0.085 
 F 21.8 ± 3.5 23.5 ± 2.1 0.355 
Low HGS [n (%)] M 5 (17%) 2 (7%) 0.125* 
 F 2 (40%) 0 (0%)  
Physical performance     
Sit-to-stand test (n) M 12 (11-15) 15 (13-19) 0.002 
 F 13 (10-14) 14 (12-17) 0.041 
Low STS test [n (%)] M 18 (62%) 9 (31%) 0.006* 
 F 2 (40%) 1 (20%)  
SPPB score  M 11 (10-12) 12 (11-12) 0.009 
 F 12 (10-12) 11 (11-12) 0.564 
Impaired SPPB [n (%)] M 7 (24%) 2 (7%) 0.063* 
 F 0 (0%) 0 (0%)  
Six-minute walk distance (m)§ M 496 ± 92 535 ± 107 0.002 
 F 458 ± 96 485 ± 75 0.153 
Low 6MWD [n (%)]§ M 8 (29%) 6 (21%) 0.375* 
 F 1 (20%) 0 (0%)  
Stair climb test (sec) M 4.40 ± 1.10 3.64 ± 0.78 <0.001 
 F 5.29 ± 0.76 4.23 ± 0.68 0.002 
Values presented as mean (± SD), or median (interquartile range) where data were not normally distributed, and number and 
percentage. ‡ Defined according to sex-specific DXA cut-offs § n = 33  n = 32 
Δ Analysis performed on transformed data; * Combined McNemar test result (sex-specific cut-offs used) 
M – Male; F - Female; ALM – Appendicular lean mass; BMI - Body mass index; DXA – Dual energy X-ray absorptiometry; SMI - Skeletal 
muscle index; HGS – Handgrip strength; STS – Sit-to-stand; SPPB – Short Physical Performance Battery; 6MWD – Six-minute walk 
distance  
Using standard DXA thresholds, there was a significant increase in the prevalence of 
obesity, while there was no significant change in diagnosis of low DXA skeletal muscle 
index. This corresponded to a trend towards increase in the prevalence of sarcopenic 
obesity [Table 7-2]. 
In male patients at six months post-liver transplant, there was a significant improvement in 
physical performance measures including the sit-to-stand test, Short Physical Performance 
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Battery, six-minute walk distance and the stair climb test. A trend towards improvement in 
handgrip strength was also observed. In female patients, a significant improvement was 
seen in sit-to-stand test and stair climb test at six months post-transplantation. 
Individual changes in body composition and measures of physical performance are shown 
in Figure 7-1 and Figure 7-2, respectively. In Figure 7-1, patients were divided into the 
presence or absence of ascites, which is a potential confounder for change in fat-free 
mass and appendicular lean mass. In Figure 7-2, patients were divided according to the 
presence or absence of hepatic encephalopathy, another confounder in physical 
performance assessment. Consistent with the overall analysis, the majority of patients 
demonstrated increases in fat mass, declines in appendicular lean mass, along with 
concomitant improvements in physical performance. 
 
 
Figure 7-1. Change in body composition variables from baseline to six months post-liver transplant 
according to the presence of ascites pre-transplant (a) Dual energy X-ray absorptiometry [DXA] fat 
















































































Figure 7-2. Change in physical performance measures from baseline to six-months post-liver 
transplant according to the presence of hepatic encephalopathy pre-transplant (a) Sit-to-stand test 
(b) Short Physical Performance Battery [SPPB] score (c) Six-minute walk distance [6MWD] (d) Stair 
climb test. HE – hepatic encephalopathy; Tx – transplant. 
Risk factors for decline in physical performance were examined using logistic regression. 
Decline in physical performance was seen in eight patients for sit-to-stand test, three 
patients for the Short Physical Performance Battery, four patients for the six-minute walk 
distance and four patients for the stair climb test. Patients with a decline in sit-to-stand test 
had a significantly lower pre-transplant MELD score, while patients with a decline in stair 
climb test had a trend towards younger age. Otherwise, no significant association was 
found [Table 7-3]. 
A comprehensive assessment of sarcopenia was performed according to the European 
Working Group on Sarcopenia in Older People (EWGSOP) criteria [Table 7-4]. Of the four 
patients that met criteria for pre-transplant sarcopenia, only one remained sarcopenic, with 
the remaining three patients being re-classified due to improvement in physical 
performance. In contrast, there were two new cases of sarcopenia post-transplant which 
were in the ‘normal’ category pre-transplant. Due to the small numbers, further statistical 




















































































Table 7-3. Pre- and post-transplant risk factors for decline in physical performance 
 Decline STS (n = 8) 
Decline SPPB 
(n = 3) 
Decline 6MWD 
(n = 4) 
Decline SCT 
(n = 4) 
Characteristic Odds ratio  (95% CI) P Value 
Odds ratio  
(95% CI) 








Pre-transplant variables         
Age (years) 0.98 (0.91-1.05) 0.531 0.99 (0.89-1.11) 0.889 1.14 (0.93-1.40) 0.203 0.91 (0.83-1.00) 0.055 
MELD score 0.82 (0.67-0.99) 0.044 1.06 (0.85-1.33) 0.593 0.88 (0.71-1.11) 0.279 0.97 (0.80-1.19) 0.782 
HCC  5.67 (0.94-34.03) 0.058 0.61 (0.05-7.42) 0.696 4.25 (0.39-45.96) 0.234 1.15 (0.14-9.39) 0.894 
BMI (kg/m2) 1.11 (0.95-1.28) 0.186 1.14 (0.95-1.36) 0.152 1.09 (0.92-1.29) 0.305 0.66 (0.41-1.07) 0.093 
DXA FM (kg) 1.06 (0.99-1.13) 0.104 1.04 (0.97-1.12) 0.229 1.04 (0.97-1.11) 0.297 0.86 (0.70-1.05) 0.142 
DXA SMI (kg/m2) 1.27 (0.59-2.73) 0.541 1.28 (0.41-3.96) 0.674 1.22 (0.46-3.26) 0.692 0.87 (0.33-2.30) 0.773 
Donor variables#         
Cold ischaemic time (min) 1.00 (0.99-1.01) 0.421 1.01 (0.99-1.02) 0.231 1.00 (0.99-1.01) 0.758 1.00 (0.99-1.01) 0.942 
Split graft (n) 2.56 (0.35-18.92) 0.358 3.38 (0.25-46.36) 0.363 2.89 (0.22-37.35) 0.417 2.78 (0.22-35.95) 0.434 
Post-transplant variables         
Operation time (hours) 1.01 (0.99-1.02) 0.372 1.01 (1.00-1.03) 0.094 1.01 (0.99-1.02) 0.300 1.00 (0.98-1.02) 0.800 
ICU LOS (hours) 1.00 (0.98-1.03) 0.979 1.0 (0.97-1.04) 0.909 1.00 (0.97-1.03) 0.952 1.00 (0.97-1.03) 0.922 
Hospital LOS (days) 1.02 (0.99-1.06) 0.261 1.11 (0.96-1.28) 0.151 1.03 (0.99-1.08) 0.184 1.05 (0.93-1.19) 0.404 
MELD – Model for end-stage liver disease; HCC – Hepatocellular carcinoma; BMI - Body mass index; DXA – Dual energy X-ray absorptiometry; FM – Fat mass; SMI - Skeletal muscle index; STS – Sit-to-
stand; SPPB – Short Physical Performance Battery; 6MWD – Six-minute walk distance; SCT – Stair climb test; ICU – Intensive care unit; LOS – Length of stay  
# DCD not included in the analysis due to insufficient numbers 




Normal Pre-sarcopenia Sarcopenia 
Pre- transplant 
Normal 19 5 2 26 
Pre-sarcopenia 3 1 0 4 
Sarcopenia 0 3 1 4 
Total 22 9 3 34 




At six months post-transplant, seven patients (21%) met criteria for sarcopenic obesity, 
while five (15%) were classified as ‘sarcopenic non-obese’, and 22 (65%) were ‘non-
sarcopenic’. 
Given sex-specific differences in body composition and physical performance, female 
patients (n=5; 15%) were excluded from the subsequent sarcopenic obesity analysis. 
Between group differences were explored [Table 7-5]. There was no significant difference 
in age, however, patients with sarcopenic obesity had a higher pre-transplant MELD score 
compared to both the ‘sarcopenic non-obese’ (P = 0.047) and ‘non-sarcopenic’ (P = 0.023) 
cohorts. There were no significant differences in pre-transplant vitamin D, CT visceral 
adipose tissue or CT subcutaneous adipose tissue. 
Assessment of peri-transplant variables demonstrated a significant difference in ventilation 
time and intensive care unit length of stay. Post hoc analysis showed that patients with 
sarcopenic obesity had longer ventilation time (P = 0.036) and longer intensive care unit 
stay (P = 0.003) compared to the ‘non-sarcopenic’ group. No significant difference was 
found between the ‘sarcopenic non-obese’ and sarcopenic obesity groups for these 
variables. 
At six months post-transplant, patients with sarcopenic obesity had lower handgrip 
strength (P = 0.022) and Short Physical Performance Battery score (P = 0.029) compared 
to the ‘non-sarcopenic’ group after post hoc analysis. Sarcopenic obesity patients also had 
lower sit-to-stand test result (P = 0.012) compared to the ‘sarcopenic non-obese’ group, 
and a trend toward lower results compared to the ‘non-sarcopenic’ group (P = 0.066). 
There was no significant difference between groups in systolic BP, fasting blood glucose 
or high-density lipoprotein. There was a trend towards higher triglyceride levels (P = 0.072) 





Table 7-5. Characteristics of men (n = 29) with sarcopenic obesity, sarcopenia and without 
sarcopenia at 6-months post-transplantation 





Number of patients 17 (59%) 5 (17%) 7 (24%)  
Age 56 (42-60) 58 (51-61) 54 (46-56) 0.700 
Pre-transplant variables     
MELD score 13 ± 5 12 ± 3 18 ± 3 0.018 
25-OH vitamin D (nmol/L) 53 (37-76) 44 (41-79) 56 (41-57) 0.888 
CT VAT (cm2) 96.8 (53.2-173.7) 74.0 (56.3-106.8) 170.8 (112.6-237.4) 0.061§ 
CT SAT (cm2) 149.5 (92.4-204.8) 79.9 (55.8-195.0) 215.3 (141.3-437.5) 0.107§ 
Non-dominant HGS (kg) 39.1 ± 7.4 34.4 ± 5.3 35.7 ± 6.2 0.320 
Sit-to-stand test (n) 13 (12-15) 14 (11-23) 9 ± 3 0.003 
SPPB score 11 (11-12) 12 (10-12) 9 (9-11) 0.024§ 
Six-minute walk distance (m) 516 ± 79 530 ± 115 425 ± 79 0.056 
Stair climb test (sec) 4.07 (3.09-4.83) 3.81 (3.29-5.74) 5.07 (5.02-6.04) 0.024§ 
Donor variables     
Cold ischaemic time (min) 304 ± 88 257 ± 45 329 ± 118 0.406 
Whole graft [n; (%)] 15 (88%) 4 (80%) 7 (100%) 0.740 
Peri-transplant variables     
Ventilation time (hours) 7 (4-13) 15 (7-31) 16 (10-27) 0.028§ 
ICU LOS (hours) 23 (22-26) 37 (23-135) 71 (43-87) 0.002 
Hospital LOS (days) 10 (8-14) 12 (10-18) 16 (11-34) 0.092 
Post-transplant variables     
Non-dominant HGS (kg) 42.8 ± 7.3 35.7 ± 4.5 34.4 ± 5.9 0.014 
Sit-to-stand test (n) 17 (14-18) 23 (15-27) 13 (9-15) 0.011 
SPPB score 12 (12-12) 12 (12-12) 11 (9-12) 0.034 
Six-minute walk distance (m) 538 (523-574) 573 (469-655) 492 (487-529) 0.159 
Stair climb test (sec) 3.53 (3.01-4.05) 3.25 (3.18-4.27) 3.58 (3.38-4.67) 0.519 
Cardiometabolic variables     
Systolic blood pressure (mmHg) 144 ± 12 150 ± 17 144 ± 19 0.715 
Fasting blood glucose (mmol/L) 6.3 (5.1-7.3) 5.3 (5.3-11.8) 6.1 (5.2-7.8) 0.669 
HDL (mmol/L) 1.3 (0.9-1.5) 0.9 (0.8-1.2) 0.9 (0.8-1.7) 0.385§ 
Triglycerides (mmol/L) 1.0 ± 0.5 1.4 ± 0.8 1.6 ± 0.6 0.062 
Values presented as mean (± SD), or median (interquartile range) where data were not normally distributed, and number and 
percentage. § Analysis performed on transformed data.  Fisher’s Exact Test 
MELD - Model for end-stage liver disease; BMI - Body mass index; DXA – Dual energy X-ray absorptiometry; SMI - Skeletal muscle 
index; CT – Computed tomography; VAT – Visceral adipose tissue; SAT – Subcutaneous adipose tissue; HGS – Handgrip strength; 
SPPB – Short Physical Performance Battery; ICU – Intensive care unit; LOS – Length of stay; HDL – high density lipoprotein 
Post-transplant metabolic syndrome  
The prevalence of PTMS after six months was 38% (n = 13) in this cohort. Hypertension, 
dyslipidaemia and dysglycaemia was found in 88%, 38% and 47% of patients respectively. 
Analysis of sarcopenic obesity as a categorical variable found no association with PTMS 
(P = 0.387). Similarly, no association was found between sarcopenic obesity and 
hypertension (P = 0.559), dysglycaemia (P = 0.681), or dyslipidaemia (P = 0.387). 
The risk factors for PTMS were further examined [Table 7-6]. Patients with PTMS had 
significantly higher pre-transplant MELD score, waist circumference, DXA fat mass, CT 
visceral adipose tissue and CT subcutaneous adipose tissue. Pre-transplant dyslipidaemia 
was also associated with PTMS. Whilst there was no difference in pre-transplant handgrip 
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strength, all pre-transplant physical performance measures were inferior in those who had 
PTMS. The physical performance measures in patients with PTMS remained significantly 
inferior when measured post-transplant than those without PTMS. 
To identify independent pre-transplant predictors of PTMS, stepwise backward multiple 
logistic regression was performed [Table 7-7]. The optimal model (Cox & Snell R2 = 0.570) 
included pre-transplant MELD score, CT visceral adipose tissue area and Short Physical 
Performance Battery score. 
A sensitivity and specificity analysis showed that CT visceral adipose tissue area had the 
highest area under the ROC (0.881, CI 0.768-0.993); P < 0.001) compared to the Short 
Physical Performance Battery score (0.863, CI 0.730-0.997; P < 0.001) and MELD score 
(0.779, CI 0.602-0.956; P = 0.008). The optimal cut-off values for CT visceral adipose 
tissue area, Short Physical Performance Battery score and MELD score predicting PTMS 





Table 7-6. Comparison of patients with and without post-transplant metabolic syndrome 
Characteristic Metabolic syndrome No metabolic syndrome P Value 
Number of patients 13 (38%) 21 (62%)  
Pre-transplant variables    
Age§ 56 (46-59) 54 (46-60) 0.561 
Male sex 11 (85%) 18 (86%) 1.000 
MELD score 17.2 ± 5.0 13.2 ± 5.1 0.032 
25-OH vitamin D (nmol/L) § 55 (44-64) 58 (40-79) 0.868 
Weight (kg) § 87.4 (76.3-96.8) 78.2 (67.2-87.8) 0.086 
BMI (kg/m2) § 26.8 (25.7-33.6) 25.8 (23.6-27.3) 0.062 
DXA fat mass (kg) § 24.7 (18.9-29.7) 19.6 (13.5-21.7) 0.008 
DXA % body fat 30.6 ± 8.7 23.1 ± 5.9 0.005 
DXA bone mass (kg) 2.89 ± 0.66 2.94 ± 0.58 0.798 
DXA appendicular SMI (kg/m2) 7.72 ± 1.32 7.96 ± 0.92 0.533 
CT SMI (cm2/m2) 48.8 ± 9.2 52.7 ± 7.6 0.198 
CT VAT (cm2) § 191.7 (101.7-225.0) 69.0 (51.9-110.4) <0.001 
CT SAT (cm2) § 186.6 (152.7-332.3) 124.9 (83.0-188.7) 0.025 
Non-dominant HGS (kg) 36.0 ± 9.6 34.6 ± 8.1 0.667 
Sit-to-stand test (n) § 10 (8-12) 14 (13-16) <0.001 
SPPB score  10 (9-11) 12 (11-12) 0.001 
Six-minute walk distance (m) 426 ± 51 532 ± 90 <0.001 
Stair climb test (sec) 5.32 ± 0.53 4.07 ± 1.08 <0.001 
Metabolic syndrome [n (%)] 5 (38%) 3 (14%) 0.211 
Dysglycaemia [n (%)] 5 (38%) 8 (38%) 1.000 
Hypertension [n (%)] 3 (23%) 6 (29%) 1.000 
Dyslipidaemia [n (%)] 9 (69%) 5 (24%) 0.009 
Donor Variables    
Cold ischaemic time (min) 321 ± 103 286 ± 86 0.296 
DCD [n (%)] 0 (0%) 3 (14%) 0.270 
Whole graft [n (%)] 12 (92%) 17 (81%) 0.627 
Post-transplant variables    
Weight (kg) § 87.1 (68.9-99.2) 77.2 (69.1-83.9) 0.233 
BMI (kg/m2) 28.0 ± 4.9 25.6 ± 3.2 0.097 
DXA fat mass (kg) 30.2 ± 15.2 22.4 ± 8.3 0.061 
DXA % body fat 33.8 ± 11.4 28.1 ± 7.9 0.095 
DXA SMI (kg/m2) 7.13 ± 0.85 7.50 ± 0.91 0.253 
DXA FMI:SMI ratio 1.37 ± 0.68 0.98 ± 0.38 0.038 
Non-dominant HGS (kg) 36.8 ± 9.9 37.5 ± 8.7 0.844 
Sit-to-stand test (n) 13 (10-18) 16 (14-19) 0.046 
SPPB score 11 (11-12) 12 (12-12) 0.039 
6MWD (m) 488 (458-525) 568 (506-643) 0.001 
Stair climb time (sec) 4.32 ± 0.74 3.39 ± 0.59 <0.001 
Prednisolone dose (mg) 5 (3.5-5.0) 5 (4.5-5.0) 0.576 
Standard dose CnI inhibitor [n (%)] 12 (92%) 18 (86%) 1.000 
Values presented as mean (± SD), or median (interquartile range) where data were not normally distributed, and number and 
percentage. § Analysis performed with transformed data 
MELD - Model for end-stage liver disease; BMI - Body mass index; DXA – Dual energy X-ray absorptiometry; SMI - Skeletal muscle 
index; FMI – Fat mass index; CT – Computed tomography; VAT – Visceral adipose tissue; SAT – Subcutaneous adipose tissue; HGS – 





Table 7-7. Univariate and multivariate analysis of pre-transplant measures with post-transplant 
metabolic syndrome 
Characteristic Univariate analysis P Value Multivariate analysis 
P 
Value 
Age 1.03 (0.96-1.11) 0.462   
Male sex 1.09 (0.16-7.59) 0.930   
MELD score 1.17 (1.00-1.37) 0.044 1.36 (0.98-1.88) 0.068 
Weight (kg) 1.04 (0.99-1.08) 0.102   
BMI (kg/m2) 1.20 (0.99-1.45) 0.063   
DXA fat mass (kg) 1.14 (0.99-1.30) 0.055   
DXA appendicular SMI (kg/m2) 0.81 (0.41-1.57) 0.522   
CT SMI (cm2/m2) 0.94 (0.85-1.03) 0.199   
CT VAT (cm2)  1.03 (1.01-1.05) 0.005 1.02 (1.00-1.04) 0.033 
CT SAT (cm2) 1.01 (1.00-1.02) 0.047   
Dyslipidaemia 7.20 (1.53-33.85) 0.012   
Non-dominant HGS (kg) 1.02 (0.94-1.11) 0.656   
Sit-to-stand test (n) 0.42 (0.22-0.79) 0.007   
SPPB score  0.30 (0.14-0.67) 0.003 0.20 (0.05-0.82) 0.025 
Six-minute walk distance (m) 0.98 (0.97-0.99) 0.006   
Stair climb test (sec) 4.69 (1.50-14.61) 0.008   
MELD - Model for end-stage liver disease; BMI - Body mass index; DXA – Dual energy X-ray absorptiometry; SMI - Skeletal muscle 
index; CT – Computed tomography; VAT – Visceral adipose tissue; SAT – Subcutaneous adipose tissue; HGS – Handgrip strength; 
SPPB – Short Physical Performance Battery 
7.7 DISCUSSION 
The aim of this study was to explore the relationship of body composition, physical 
performance and post-transplant cardiometabolic disease. We found that post-transplant 
sarcopenic obesity was associated with inferior muscle strength and physical performance 
(Short Physical Performance Battery score) compared to the ‘non-sarcopenic’ cohort. The 
sit-to-stand test result was also lower in sarcopenic obesity patients compared to the 
‘sarcopenic non-obese’ group. No relationship was found between sarcopenic obesity and 
cardiometabolic disease, including PTMS. However, our results did find a significant 
independent association of PTMS with pre-transplant visceral adipose tissue excess and 
inferior physical performance. 
These results build on previous published data demonstrating the changes in body 
composition, muscle strength and physical performance associated with liver 
transplantation. Body composition changes were similar to those previously described with 
a significant increase in DXA fat mass, as well as declines in both DXA lean mass and 
bone mass after six months. This corresponded to a sarcopenic obesity prevalence of 21% 
at six months post-transplant. 
Our comprehensive evaluation highlighted that although muscle mass declined, there were 
significant overall improvements in measures of physical performance. It has previously 
been described that age-related decline in muscle strength and physical performance 
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occur at a faster rate than loss of skeletal muscle mass.79, 270, 271 Conversely, since liver 
transplantation provides a cure for a disease with a chronic catabolic state, it could be 
expected that recovery of muscle strength and physical performance would precede that of 
skeletal muscle mass. Another possibility is the impact of pre-transplant hepatic 
encephalopathy on assessment of muscle strength and physical performance. The neural 
control of muscles and movement is a critical component of physical function which is 
altered by hepatic encephalopathy.272, 273 Our pre-transplant assessment of hepatic 
encephalopathy involved a clinical assessment to exclude patients with overt hepatic 
encephalopathy. It has been established that clinical assessment lacks sensitivity in 
detecting minimal encephalopathy, and this is a limitation of our study.13 Further studies 
using more sensitive and specific objective testing of hepatic encephalopathy could further 
evaluate the impact of this potential confounding factor. 
Despite these limitations, the magnitude of change shown here suggests that liver 
transplant corrects a large proportion of physical performance deficits by six months. 
Mizuno et al. noted no significant change in six-minute walk distance even with a formal 
rehabilitation program at one-month post-transplant.147 VanWagner and colleagues also 
noted an improvement in six-minute walk distance for female patients but not male 
patients after one year.151 
Sarcopenic obesity is becoming increasingly recognised as a risk for cardiometabolic 
disease and impairment in physical performance.216-218, 220, 221 Despite the overall 
improvements in muscle strength and physical performance, patients with sarcopenic 
obesity had inferior handgrip strength and Short Physical Performance Battery results than 
‘non-sarcopenic’ patients. Sarcopenic obesity patients also had lower sit-to-stand test 
results compared to the ‘sarcopenic non-obese’ group. 
Exploration of pre- and peri-transplant variables associated with post-transplant 
sarcopenic obesity found that higher MELD score, and inferior pre-transplant sit-to-stand 
test, Short Physical Performance Battery test and stair climb test results were risk factors. 
We also observed that patients with sarcopenic obesity had a history of longer ventilation 
time and ICU length of stay compared to the ‘non-sarcopenic’ group, which would 
accelerate skeletal muscle mass loss. One variable, that in part explains this relationship, 
is the higher MELD score of patients with sarcopenic obesity. In Chapter 3, MELD score 
was significantly associated with delayed extubation post-transplant. Prolonged recovery 
after liver transplantation is likely to be associated with an increase in sedentary time, and 
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therefore contribute to gain of fat mass, loss of skeletal muscle mass and ultimately 
development of sarcopenic obesity. 
This is the first study to the author’s knowledge to describe the relationship of post-
transplant sarcopenic obesity, metabolic syndrome and physical performance. Comparison 
of categorical and continuous cardiometabolic variables related to sarcopenic obesity did 
not establish any significant relationships. We suspect this is most likely related to a lack of 
power due to the cohort size rather than a lack of effect. In addition, we used an overall 
measure of adiposity (DXA percentage body fat), which has a weaker association with the 
metabolic syndrome than visceral adiposity.274 
Exploration of pre-transplant risk factors for PTMS revealed that CT visceral adipose 
tissue and Short Physical Performance Battery score were independent predictors on 
multiple regression analysis. The association of PTMS with CT visceral adipose tissue was 
also found in Chapter 6, although a different optimal cut-off was found. This difference is 
not unexpected given the two cohorts were assessed at different time points post-
transplant. Other factors include the small sample size studied for both analyses, and 
different criteria for defining metabolic syndrome. Both thresholds, however, fall within the 
range of visceral adipose tissue levels associated with the development of metabolic 
complications in the general population.67, 68 Further larger scale studies are required to 
confirm our findings and establish the optimal threshold of visceral adipose tissue which is 
associated with the development of metabolic complications. 
Most measures of physical performance, both pre- and post-transplant, had a significant 
association with PTMS on univariate analysis. Previous investigations have shown that 
individuals with poor physical performance also have a more sedentary lifestyle, which is a 
risk factor for the metabolic syndrome.275 Moreover, it has been hypothesised that insulin 
resistance and increased inflammation, characteristics of the metabolic syndrome, may 
lead to impairment in physical performance.219, 276 The combination of pre-transplant CT 
visceral adipose tissue and Short Physical Performance Battery score could be used to 
target high risk patients for intervention. 
The main limitation to this study was the relatively small sample size which limited the 
comparison of some variables. However, we performed a high quality, three-compartment 
body composition assessment using DXA, which has been previously shown to have 
superior accuracy in patients with cirrhosis than more accessible methods such as 
bioelectrical impedance analysis or anthropometrics.42 Similar to other two- and three-
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compartment models, DXA does still carry some error due to overhydration of the fat-free 
mass, which is well documented pre-transplant and can persist at 12 months post-
transplant.213 Use of appendicular lean mass measurements limits the impact of ascites on 
skeletal muscle mass estimation.  
Another strength of this study was the comprehensive nature of our physical performance 
assessment. Many physical performance tests have been evaluated in the elderly 
population, however few have been studied in the pre- and post-liver transplant setting. 
VanWagner et al. previously highlighted the difficulty in applying the six-minute walk 
distance in the liver transplant setting as a general screening tool due to exclusion of many 
patients.151 Our results support the predictive utility of the Short Physical Performance 
Battery and/or the sit-to-stand test in providing a valuable assessment of physical 
performance which could be applied to most cirrhotic patients, with the exception of those 
with overt hepatic encephalopathy. 
In conclusion, this study provides important insight into body composition and physical 
performance changes associated with liver transplantation. Sarcopenic obesity was found 
to be prevalent at six months post-liver transplantation and was associated with inferior 
physical performance. Sarcopenic obesity was not identified as a risk factor for PTMS in 
our cohort. The strongest independent pre-transplant predictors for PTMS were CT 
visceral adipose tissue and Short Physical Performance Battery score. These variables 
could be used to target high risk patients for pre- or early post-transplant intervention. 
Future studies of PTMS should include measurement of visceral adipose tissue and 
physical performance to facilitate risk evaluation. 
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The introduction of liver transplantation in the 1960s by Thomas Starzl represented a 
pivotal event in the management of decompensated cirrhosis. It offered the potential for 
cure of a condition which in most cases was considered irreversible and terminal. Over the 
last 20 years, it has also been established as an effective therapy for hepatocellular 
carcinoma, in particular patients not suitable for surgical resection or radio-frequency 
ablation. 
Refinements in liver transplant organ allocation, such as the introduction of the MELD 
score in 2002, have resulted in a reduction of the waiting list mortality.190, 191 Despite the 
clear utility of the MELD score in organ allocation, there is evidence that its predictive 
accuracy can be improved, in particular for those patients with lower MELD scores 
(≤14).192 Since 2016, serum sodium has been combined with the MELD score in the USA 
for organ allocation after several studies demonstrated that is was an independent 
predictor of waiting list mortality.195 However, the identification of further predictors of 
waiting list complications has the potential to improve patient outcomes and is the subject 
of ongoing research, including this thesis. Prior research has identified that several 
predictors may be of potential use, including sarcopenia, frailty, sarcopenic obesity and 
excess adipose tissue. Further research is required to confirm such variables are 
predictors of post-transplant adverse events as this has the potential to improve survival 
rates through risk stratification, as well as providing a target for therapeutic interventions.  
Several publications have identified that pre-transplant low skeletal muscle mass is an 
independent predictor of post-transplant morbidity and mortality.25, 133-135 Likewise, lower 
handgrip strength has been associated with prolonged intensive care unit length of stay.24 
To date there is a paucity of data on the impact of impaired physical performance on post-
transplant outcomes. 
One of the most significant issues affecting transplant recipients is cardio-metabolic 
disease. Elevated body mass index has been strongly linked to these complications. In the 
general population, a visceral distribution of adipose tissue, and the presence of 
sarcopenic obesity carry the highest risk for cardio-metabolic disease. These risk factors 
remain relatively unexplored with regard to liver transplant recipients. 





Sarcopenia and frailty 
As described earlier [Section 1.4 above on page 35], sarcopenia and frailty are two 
conditions that are closely inter-related. Traditional tools for assessing frailty are largely 
subjective, and those with objective measurements often include weight. Use of weight in 
patients with decompensated cirrhosis carries significant error due to accumulation of 
extracellular fluid. For this reason, assessment of physical performance has been 
proposed as a suitable alternative for measuring frailty.103 
Assessment of physical performance is also a key component of sarcopenia evaluation 
according to the EWGSOP guidelines.27 It has been suggested that assessment for 
sarcopenia should encompass measurement of skeletal muscle mass, muscle strength 
and physical performance. Unfortunately, assessment of skeletal muscle mass in patients 
with cirrhosis, like weight, is confounded by extracellular fluid retention. This creates a 
disturbance in the hydration fraction of fat-free mass which contributes to significant error 
at the individual level when using two-compartment models. 
Direct measurement of skeletal muscle mass at the tissue level is one technique that has 
been proposed to avoid such issues. Body composition analysis using MRI, CT and 
ultrasound offer this advantage. The retrospective use of CT imaging for body composition 
analysis has received considerable attention in recent years. CT scans are routinely 
performed as part of pre-liver transplant work-up in many centres. Re-analysis of this 
existing imaging has provided many insights into the predictive utility of low skeletal 
muscle mass. 
However, a major limitation with the use of CT for skeletal muscle mass evaluation is the 
lack of normative reference data to provide information on extremes of body composition. 
Many retrospective studies have used CT skeletal muscle index cut-offs that were derived 
from patients with malignancy. Expert groups, including the EWGSOP, recommend that 
low skeletal muscle mass be defined as two standard deviations below sex-specific young 
healthy population values. The data in Chapter 2 provides such information in a cohort of 
healthy Caucasian people. Our proposed cut-offs of 43.5cm2/m2 for males and 30.0cm2/m2 
for females are much lower than prior suggested thresholds. However, loss of skeletal 
muscle mass is progressive, and the cut-offs representing one standard deviation below 
the reference value (48.9cm2/m2 for males and 36.3cm2/m2 for females) approximate the 
cut-offs of Prado et al. and Carey et al., which have been shown to be predictive of 
mortality in patients with cirrhosis.56, 141 We would suggest that future studies using CT 
skeletal muscle index should consider the use of a tier classification of skeletal muscle 
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mass depletion, for example Class I and Class II skeletal muscle mass depletion using the 
thresholds described above. 
Another limitation with using CT for skeletal muscle mass evaluation in patients with 
cirrhosis is that this technique has not been validated in patients with cirrhosis, in particular 
those with ascites. In Chapter 3, our results demonstrated that CT skeletal muscle index 
had a weaker relationship to the body cell mass reference in patients with ascites. One 
possible explanation for the weaker relationship is that ascites and oedema can have a 
similar radiodensity to muscle and thus cause interference with the image analysis 
software. However, it is important to note that this comparison had limitations due to the 
small sample size (n = 21), sub-optimal “gold standard” reference model and the inability 
to use Bland and Altman analysis for statistical analysis. 
DXA appendicular lean mass had a stronger relationship to our body cell mass reference 
models than CT skeletal muscle index, however the relationship to the reference was also 
considerably weaker in patients with ascites. Bioelectrical impedance spectroscopy (BIS) 
and mid-arm muscle circumference (MAMC) estimates provided the best correlation 
coefficients of the bedside techniques. Consistent with prior publications, the BIS 
techniques had weaker correlation coefficients in patients with ascites.41, 42 The MAMC 
was the only skeletal muscle mass estimate which had better correlation coefficients in 
patients with ascites. This was an unexpected finding, as skeletal muscle mass estimates 
using this technique have previously had similar issues to other two-compartment models 
in cirrhotic patients.41, 42 Whilst this technique remains an option for the bedside estimation 
of skeletal muscle mass, it has other limitations including the requirement for specialised 
training and equipment, and significant intra- and inter-observer variability [see Section 1.2 
above].  
Evaluation of a novel skeletal muscle mass estimation technique using ultrasound was 
unable to improve accuracy over anthropometrics. US muscle thickness of the thigh, in 
particular, had inferior correlation coefficients compared to the body cell mass reference 
model. Use of US muscle thickness was not supported by our results. 
Multifrequency BIA techniques have been refined in recent years, including the use of BIS 
prediction models. We compared the utility of BIS at estimating fat mass, fat-free mass, 
total body water and extracellular water. When fat mass and fat-free mass BIS estimates 
were compared to DXA measurements, we found a significant mean bias of 2.1 kg and -
2.1 kg respectively, with wide limits of agreement (9.2kg and 9.5kg respectively). 
Regression of the limits of agreement (LOA) analysis values revealed that BIS 
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underestimated fat mass with increasing fat mass values. When BIS estimates of total 
body water and extracellular water were compared to isotope dilution reference values, we 
found the total body water was underestimated (mean bias 2.9L), while extracellular water 
had no significant mean bias (-0.7L). However, the concordance correlation coefficient for 
extracellular was poor (rc = 0.586), suggesting a large deviation from the line of identity. 
The regression line from the LOA analysis revealed that BIS underestimates extracellular 
water with increasing mean extracellular values. Overall these results suggest that BIS still 
has limitations at estimating body water compartments, and subsequent estimates of fat 
mass, fat-free mass and skeletal muscle mass. 
The results from Chapter 3 demonstrate that all techniques used to estimate skeletal 
muscle mass have limitations in patients with cirrhosis. We recommend the use of DXA 
appendicular lean mass for assessment of skeletal muscle mass in patients with cirrhosis 
where feasible. DXA scanning for bone mineral density (BMD) forms part of the standard 
protocol of pre-transplant assessment at our institution. Performing whole body scanning 
at the time of the BMD scan can provide valuable body composition information, including 
appendicular lean mass. This technique also has an advantage over CT skeletal muscle 
index, in that serial measurements can be used to monitor progress.   
There is sparse data on the clinical significance of EWGSOP sarcopenia with regard to 
liver transplant outcomes. As outlined previously, the significance of low skeletal muscle 
mass, low handgrip strength and impaired physical performance have been evaluated as 
individual entities.29, 57, 100 In Chapter 4, we examined the impact of EWGSOP sarcopenia 
and the individual components on clinical outcomes. We found that measures of skeletal 
muscle mass and physical performance demonstrated associations with pre- and post-
transplant outcomes including sepsis, ‘any cirrhosis complication’, delayed extubation and 
prolonged hospital stay. The most striking association was the independent link of poor 
physical performance to pre-transplant (lower sit-to-stand test result) and post-transplant 
(low Short Physical Performance Battery score) sepsis. One hypothesis for this 
association, is the elevated inflammatory activity that has been found in elderly patients 
with sedentary lifestyle and poor physical performance.277 It has been suggested that 
patients with poor physical performance have higher levels of inflammation due to 
increased insulin resistance, as well as increased susceptibility to reactive oxygen species 
produced in normal metabolic processes.277 Intervention with exercise therapy is one 
therapy that has the potential to counteract these abnormalities and improve outcomes. 
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Further randomised controlled trials are required to determine if there is clinical benefit in 
patients awaiting liver transplantation. 
Visceral adipose tissue 
PTMS is a significant clinical issue post organ transplant. In the setting of liver 
transplantation, it has been identified as an independent predictor of cardiovascular 
events.205 Previous studies have identified pre-transplant risk factors for PTMS including 
pre-existing cardiometabolic disease and higher body mass index.208, 209 The risk 
associated with visceral distribution of adipose tissue is relatively unexplored. In Chapter 
6, we conducted a retrospective study of liver transplant recipients, and identified that pre-
transplant CT measured visceral adipose tissue was an independent predictor of early 
PTMS. Other traditional risk factors for metabolic syndrome, such as cardiorespiratory 
fitness and low skeletal muscle mass, were not identified as predictors in this cohort. 
Specific assessment of visceral adipose tissue was superior to body mass index and 
subcutaneous adipose tissue at predicting PTMS.  
In Chapter 7, we re-explored this association prospectively using a different cohort at six-
months post-transplantation. Again, a significant association was identified with pre-
transplant CT visceral adipose tissue and PTMS. A comparison of the two studies is 
shown in Table 8-1. 
Table 8-1. Comparison of post-transplant metabolic syndrome predictors from Chapters 6 and 7 
Variable Chapter 6 Chapter 7 
Study design Retrospective Prospective 
Number of patients 58 (77%) men; 
17 (33%) women 
29 (85%) men; 
5 (15%) women 
Time point for assessment of PTMS 3 months 6 months 
Criteria for PTMS WHO Harmonised criteria 
Prevalence of PTMS 13% 38% 




Threshold level of CT VAT for 
prediction of PTMS >153.4cm
2 >105.2cm2 
PTMS – Post-transplant metabolic syndrome; WHO - World Health Organisation; CT – Computed tomography; VAT – 
Visceral adipose tissue; SPPB – Short Physical Performance Battery 
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Whilst both studies identified a significant association between PTMS and CT visceral 
adipose tissue, different optimal cut-offs were found. There are several factors contributing 
to this difference. Firstly, the cohorts were assessed at different time points post-
transplantation. Secondly, due to limitations in waist circumference data in Chapter 6, 
different criteria were used to define metabolic syndrome. This may have had an impact on 
the difference in PTMS prevalence observed, and thus optimal visceral adipose tissue 
thresholds. Finally, both studies had small sample sizes for inclusion in the respective 
analyses, as well as different co-factors. Despite these differences, both thresholds fall 
within the range of visceral adipose tissue levels associated with the development of 
metabolic complications in the general population.67, 68 Despres et al. found that in both 
men (n = 115) and women (n = 72), CT visceral adipose tissue area >100cm2 was 
associated with moderate disturbances in cardio-metabolic profiles.68 Furthermore, 
thresholds >135cm2 in men and >128cm2 in women demonstrated further deterioration in 
cardio-metabolic profile.68  
Further research using larger sample sizes are required to confirm our findings and 
establish the optimal threshold of visceral adipose tissue which is associated with the 
development of metabolic complications. 
Sarcopenic obesity  
Post-transplant alterations in body composition have been described in several 
publications, with most documenting a disproportionate increase in fat mass relative to 
skeletal muscle mass. This places transplant recipients at risk of sarcopenic obesity, which 
has been described as a condition associated with increased risk of cardio-metabolic 
disease, as well as impairment in physical performance. In Chapter 7, we examined the 
prevalence of sarcopenic obesity at six-months post-transplant and its association with 
cardiometabolic disease and physical performance. Using a comprehensive, high quality 
assessment of body composition, muscle strength and physical performance, we 
demonstrated several important findings. Firstly, the observed change in body composition 
within six months of transplant, reflected that of prior studies. Our cohort had a significant 
reduction in DXA appendicular lean mass and bone mass, along with an increase in fat 
mass. This corresponded to a high prevalence of sarcopenic obesity (21%) post-
transplant. Secondly, we noted a dramatic improvement after transplantation in all physical 
performance measures, as well as muscle strength. 
Despite the overall improvements in physical performance, we found that patients with 
sarcopenic obesity had inferior results than the non-sarcopenic cohort. We did not identify 
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sarcopenic obesity as a significant risk factor for cardiometabolic disease. The most likely 
explanation for this, in our opinion, was a lack of power due to sample size. 
Future directions 
Our data have identified that pre-transplant impairment in skeletal muscle mass, muscle 
strength and most importantly, physical performance impacts on liver transplant outcomes. 
Patients can be effectively assessed using multiple techniques and this information used 
for risk stratification, or to identify patients for intervention. The optimal method of 
intervention is the subject of ongoing research. One obvious option that has the potential 
to improve all aspects of sarcopenia, as well as visceral adipose tissue, is exercise 
therapy. There is moderate quality evidence that exercise interventions improve muscle 
strength and physical performance in the elderly.182 However, the impact on liver 
transplant outcomes is relatively unexplored. This is largely due to concerns regarding the 
safety of exercise therapy in patients with cirrhosis and portal hypertension. A randomised 
controlled trial of aerobic exercise therapy in patients with cirrhosis by Zenith et al. was not 
associated with any adverse events. Additionally, our research group has unpublished 
data showing than an eight-week pre-transplant exercise regime (combined aerobic and 
circuit resistance training performed three times per week) was associated with good 
adherence, no major complications, and a trend towards improvement in cardiorespiratory 
fitness. This study was not powered to detect an impact on outcomes, which should be the 
focus of future, multi-centre prospective research trials. 
Nutrition interventions are also likely to have favourable impact on skeletal muscle mass, 
muscle strength and to a lesser extent, physical performance. Prior trials evaluating the 
impact of nutritional intervention in patients with cirrhosis have demonstrated benefit, 
however concerns have been expressed regarding the quality of these trials.179 
There are also several potential pharmacological interventions for sarcopenia under 
evaluation. One such therapy is testosterone replacement in male patients. Sinclair et al. 
conducted a randomised control trial of intramuscular testosterone replacement in male 
patients and found a significant improvement in appendicular lean mass and bone mineral 
density compared to placebo.184 Larger scale studies are required to evaluate the impact 
of testosterone replacement on transplant-free mortality, as well as liver transplant 
outcomes. 
One final consideration for improving outcomes is the introduction of sarcopenia as a 
variable in organ allocation. Our data supports the prior studies of Lai et al. and Montano-
163 
 
Loza et al., which propose incorporation of these variables into equations for assisting 
organ allocation decisions.26, 278 
Conclusion 
To conclude, this thesis significantly contributes to the literature by providing evidence of 
the clinical utility of a comprehensive body composition assessment in cirrhosis patients 
undergoing liver transplantation. Furthermore, a sarcopenia evaluation incorporating 
assessment of skeletal muscle mass, muscle strength and physical performance provides 
the ultimate risk assessment for pre- and post-transplant adverse events. For optimal 
assessment, we would recommend assessment of skeletal muscle mass with DXA 
appendicular lean mass, muscle strength with handgrip strength, and physical 
performance with the sit-to-stand test or Short Physical Performance Battery. The use of 
CT for body composition assessment offers the additional advantage of providing an 
assessment of visceral adipose tissue, which we identified as an independent risk factor 
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APPENDIX B: Patient information and consent form 
PARTICIPANT INFORMATION AND CONSENT FORM 
Full Project Title: Assessment of muscle mass, hepatic function and outcomes in patients 
awaiting liver transplantation 
Principal Investigator: Assoc Prof Graeme Macdonald 
Part 1 What does my participation involve? 
1. Introduction   
You are invited to take part in this research project. This is because you have been 
diagnosed with significant liver disease and have been referred for consideration of liver 
transplantation. The research project is aiming to study patients with advanced liver disease 
to better understand the factors that contribute to poor outcomes particularly in those 
awaiting liver transplantation. The main focus is assessing muscle mass and the impact of 
low muscle mass on outcomes. 
 
This Participant Information and Consent Form tells you about the research project. It 
explains the procedures involved. Knowing what is involved will help you decide if you want 
to take part in the research. 
 
Please read this information carefully. Ask questions about anything that you don’t 
understand or want to know more about. Before deciding whether or not to take part, you 
might want to talk about it with a relative, friend or healthcare worker. 
 
Participation in this research is voluntary. If you don’t wish to take part, you don’t have to. 
You will receive the best possible care whether you take part or not. 
 
If you decide you want to take part in the research project, you will be asked to sign the 
consent section. By signing it you are telling us that you: 
  
 understand what you have read;  
 consent to take part in the research project; 
 consent to participate in the research processes that are described; 
       consent to the use of your personal and health information as described 
 
You will be given a copy of this Participant Information and Consent Form to keep. 
 
2. What is the purpose of this research project? 
The primary aims of the project are to examine inpatients awaiting liver transplantation: 
a. Non-invasive measures of muscle mass and liver function, and  
b. The relationship between these and outcomes in this population 
 
This study will involve patients with advanced liver disease who are assessed for liver 
transplantation at the Princess Alexandra Hospital. We hope to involve 50 patients in total.  
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3. What does participation in this research project involve? 
Participation in this research project will involve several tests which measure muscle mass 
and function. Many of these are routine assessments already performed in assessing 
patients prior to transplant. A CT of the abdomen will be used to assess muscle mass 
however we will use the CT which is already performed as part of the standard transplant 
assessment.  
 
In addition, there are some tests that are not part of current standard clinical practice. These 
tests are non-invasive and have a very low risk of complications. The additional tests 
include: 
 Total body potassium measurement 
 Total Body Water measurement (Deuterium test & bioelectrical impedance analysis) 
 Extracellular Water measurement (Bromide test) 
 Assessment of muscle function with handgrip strength, sit-to-stand test & Lower Limb 
Power test 
 13C-Methacetin Breath Test 
 Fibroscan 
 Indocyanine green (ICG) Retention Test 
 
Total body potassium assessment will require travel to the Royal Children’s Hospital and will 
take approximately 2 hours including travel time. You will be required to lie flat within the 
potassium counting machine for approximately 40 minutes.  
 
The remaining tests are performed at the PA Hospital Endoscopy unit in a single outpatient 
appointment and will take approximately 6 hours. The ICG test involves intravenous injection 
of 25mg of ICG. Blood samples are taken at baseline & 15 minutes after injection. The 
Methacetin breath test involves drinking ~150mL water containing 75mg of Methacetin. Ten 
breath samples are then collected at regular intervals over 2 hours.  
 
Total body water and extraceullar water tests involve consumption of ~150mL water 
containing Deuterium & Bromide which are non-toxic agents. A blood sample will then be 
taken 4 hours and 6 hours after ingestion. You will be required to remain fasting until all 
blood samples have been collected.  
 
Muscle function and bioelectrical impedance analysis will also be tested during your visit to 
the Endoscopy Unit. Bioelectrical impedance analysis involves placement of small 
electrodes on different parts of the body. It is a painless, risk free test of body water and fat 
which takes less than 15 minutes. The handgrip strength test, sit-to-stand test and Lower 
Limb Power test are not strenuous assessments and will take less than 30 minutes.  
 
With your consent, data will be collected from your medical records including your age, 
ethnicity, past medical history, underlying cause of liver disease, blood and radiology results. 
Information will be de-identified and stored in a database. Any use of information in the 
database for future projects will require a separate Human Research Ethics committee 
approval.  
 
Details of any major illnesses & events which occur before, during and after liver 
transplantation will be collected from your medical records. All information will be collated in 
a way which ensures you will not be able to be directly identified. Follow-up will be at the 




There are no costs associated with participating in this research project, nor will you be paid. 
You will be reimbursed for travel & parking costs associated with the Total body potassium 
measurement which is performed at the Royal Children’s Hospital. 
4 What do I have to do? 
You are not required to make any changes to your usual diet, lifestyle or medications for 
this study. 
5. Do I have to take part in this research project? 
Participation in this study is voluntary. It is completely up to you whether or not you wish to 
participate. Your choice not to participate will not affect the treatment you receive now or in 
the future. Whatever your decision, it will not affect your relationship with the staff caring for 
you.  
 
Before you make your decision, a member of the study team will be available so you can 
ask any questions you have about the study. You can ask for any information you want.  
 
If you decide to take part and later change your mind, you are free to withdraw from the 
project at any stage. 
 
If you do decide to take part, you will be given this Participant Information and Consent Form 
to sign and you will be given a copy to keep. Sign the consent form only after you have had 
a chance to ask your questions and have received satisfactory answers.  
6. What are the alternatives to participation?  
You do not have to take part in this research project to receive treatment at this hospital.  
Other options are available; these include continuing with transplant assessment without 
participating in the study. 
7. What are the possible benefits? 
There will be no clear benefit to you from your participation in this research. Identifying 
patients at higher risk of adverse outcomes whilst awaiting liver transplantation will help 
future patients on the transplant waiting list by improving prioritisation and also assist with 
interventional studies.  
 
8. What are the possible risks and disadvantages of taking part? 
While this research does not involve any interventional treatment, you will be undergoing 
tests that rarely cause side effects (less than 1 in 1,000,000). If you have any side effects, 
or are worried about them, talk with the study doctor. During the study procedures, the study 
doctor will be monitoring you for side effects. 
 
There may be side effects that the researchers do not expect or do not know about and that 
may be serious. Tell your study doctor immediately about any new or unusual symptoms. 
 
The majority of the project’s tests are part of your standard clinical management and have 
minimal risk.  Several non standard of care tests will be performed including measurement 
of Total body potassium, Total Body Water, Extracellular Water, Fibroscan, ICG retention 
test and the Methacetin Breath Test. The Total body water test, Extracellular water test, ICG 
retention test and Methacetin breath tests have the rare risk (less than 1 in 1,000,000) of 
allergic reaction. The reactions vary from: Mild (hives, sweating, nausea); to Moderate (wide 
spread hives, facial swelling, shortness of breath) to Severe (life threatening heart 
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palpitations, very low blood pressure, throat swelling, fits and/or cardiac arrest). The total 
body potassium measurement and the Fibroscan carry no risk. 
9. What will happen to my test samples? 
No additional collection of your blood and/or tissue during the research project will occur 
other than that routinely performed for liver transplant assessment. 
10. Can I have other treatments during this research project? 
It is important to tell your doctor and the research staff about any treatments or medications 
you may be taking, including over-the-counter medications, vitamins or herbal remedies, 
acupuncture or other alternative treatments. You should also tell your doctor about any 
changes to these during your participation in the research. 
11. What if I withdraw from this research project? 
If you wish to withdraw from the study once it has started, you can do so at any time without 
having to give a reason. If you decide to withdraw from this research project, please notify 
a member of the research team before you withdraw. A member of the research team will 
inform you if there are any special requirements linked to withdrawing. 
 
If you decide to leave the project, the researchers would like to keep (the personal and health 
information about you) that has been collected. This is to help them make sure that the 
results of the research can be determined properly.  
 
Your study doctor may withdraw you from this study if he/she does not think it is in your best 
interests to continue or if you are unable to complete the study procedures.  
12. How will I be informed of the results of this research project? 
Your treating doctor will notify you of any test results at your usual follow up outpatient or 
inpatient consultation.   
Part 2 How is the research project being conducted? 
13.  What will happen to information about me? 
All aspects of the project, including results, will be kept strictly confidential and only the 
principal investigators will have access to the information. It will be disclosed only with your 
permission, or as permitted by law. 
 
Medical results will be stored in medical files (paper copy) or computer file (AUSLAB, PACS) 
as is current Queensland Health practice.  Information about you may be obtained from your 
health records held at this and other health services for the purpose of this research. By 
signing the consent form you agree to the research team accessing health records if they 
are relevant to your participation in this research project. 
 
Information will be collected in a way that ensures you will not be able to be directly identified. 
The recorded data is kept in a secure password coded databank file on a computer which 
has password protection. This file will be destroyed after 10 years. The computer is 
accessible only in a locked office in the Department of Gastroenterology.  
 
After completion of the study, data collated will continue to be securely stored and may be 
used for other future research projects, subject to approval from the Princess Alexandra 




Your health records and any information obtained during the study may be examined by 
authorised representatives of the Metro South Hospital and Health Service Human 
Research Ethics Committee (HREC) which reviews the ethical conduct of the study.  
 
It is anticipated that the results of this research project will be published and/or presented in 
a variety of forums. In any publication and/or presentation, information will be provided in 
such a way that you cannot be identified, except with your permission. 
 How can I access my information? 
In accordance with relevant Australian and/or Queensland privacy and other relevant laws, 
you have the right to access the information collected and stored by the researchers about 
you. You also have the right to request that any information, with which you disagree, be 
corrected. Please contact one of the researchers named at the end of this document if you 
would like to access your information. 
 
 
14. Complaints and compensation 
 
If you suffer any injuries or complications as a result of this research project, you should 
contact the study team as soon as possible and you will be assisted with arranging 
appropriate medical treatment. If you are eligible for Medicare, you can receive any medical 
treatment required to treat the injury or complication, free of charge, as a public patient in 
any Australian public hospital. 
 
15. Who is organising and funding the research? 
 
This research project is being conducted by Associate Professor Graeme Macdonald and is 
being funded by a Grant provided by the PA Research Foundation. No member of the 
research team will receive a personal financial benefit from your involvement in this research 
project (other than their ordinary wages). 
 
16. Who has reviewed the research project? 
 
All research in Australia involving humans is reviewed by an independent group of people 
called a Human Research Ethics Committee (HREC).  The ethical aspects of this research 
project have been approved by the HREC of the Metro South Hospital and Health Service.  
 
This project will be carried out according to the National Statement on Ethical Conduct in 
Human Research (2007) produced by the National Health and Medical Research Council of 
Australia. This statement has been developed to protect the interests of people who agree 
to participate in human research studies. 
 
17. Further information and who to contact 
The person you may need to contact will depend on the nature of your query.  
If you want any further information concerning this project or if you have any medical 
problems which may be related to your involvement in the project (for example, any side 





Clinical contact person 
 
 
If you have any complaints about any aspect of the project, the way it is being conducted 
or any questions about being a research participant in general, then you may contact: 
 




Name Dr Aidan Woodward 
Position Gastroenterology Registrar 
Telephone 3176 2111 [Pager 8045] 
Email aidan.woodward@health.qld.gov.au 
Reviewing HREC name Metro South Hospital and Health Service 




Consent Form  
 
Title Assessment of muscle mass, hepatic 
 and outcomes in patients awaiting liver 
 transplantation. 
Principal Investigator Assoc Prof Graeme Macdonald 
Associate Investigator Dr Aidan Woodward 




Declaration by Participant 
 
I have read the Participant Information Sheet or someone has read it to me in a language 
that I understand.  
 
I understand the purposes, procedures and risks of the research described in the project. 
 
I have had an opportunity to ask questions and I am satisfied with the answers I have 
received. 
 
I freely agree to participate in this research project as described and understand that I am 
free to withdraw at any time during the project without affecting my future health care. 
 
I understand that I will be given a signed copy of this document to keep. 
 
 
  Name of Participant (please print)    
 
 Signature   Date   
  
 
Declaration by Study Doctor/Senior Researcher† 
 
I have given a verbal explanation of the research project, its procedures and risks and I 
believe that the participant has understood that explanation. 
  Name of Study Doctor/ 
Senior Researcher† (please print)
  
  
 Signature   Date   
 
† A senior member of the research team must provide the explanation of, and information concerning, the research project.  
 
Note: All parties signing the consent section must date their own signature. 
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APPENDIX C: Child-Pugh score 
The Child-Pugh Score is calculated by assessing five domains with a score of 1 to 3 
[Error! Reference source not found.].1 Scores from each Domain are added to give the 
final score which has a range of 5 to 15. Patients can be further assigned to a Child-Pugh 
Class using the following cut-offs: A (score of 5–6), B (score of 7–9), or C (score of ≥10). 
Table 8-2. Child-Pugh score domains 
 
Points Toward Total Score  
1 2 3 
Serum bilirubin (μmol/L) <34 34–51 >51 
Serum albumin (g/L) >35 30–35 <30 
INR <1.7 1.7–2.3 >2.3 
Ascites None Easily controlled Poorly controlled 
Hepatic encephalopathy None Minimal Advanced 
INR - International Normalised Ratio 
 
APPENDIX D: Model for End-stage Liver Disease (MELD) score 279 
MELD Score = 10 * ((0.957 * loge [Creatinine‡/88.4]) + (0.378 * loge [Bilirubin‡/17.1]) + 
(1.12 * loge [INR])) + 6.43 
‡ Unit = mmol/L 




APPENDIX E: Protocol for measurement of ultrasound muscle thickness [adapted 
from Campbell et al]44  
Ultrasound (US) estimation of skeletal muscle mass was performed using a Phillips EPIQ 
Ultrasound Scanner (Phillips, Andover, MA, USA) with a linear transducer 12-5 MHz.  
Three muscle thickness measurements were taken at each of the following sites on the 
dominant side of the body:  
1. Mid Forearm - With the elbow extended and the forearm supinated, a point was 
marked midway between the antecubital skin crease and the ulnar styloid. The thickness 
of the flexor compartment is measured at this level anteriorly between the superficial fat-
muscle interface and the interosseous membrane. 
2. Mid Upper Arm Anteriorly - With the elbow extended, the mid-acromale-radiale point 
was marked on the skin. Then with the subject supine, the elbow extended and the 
forearm supinated, the thickness of the flexor compartment was measured at this level, 
over the biceps, between the superficial fat-muscle interface and the humerus.  
3. Mid Thigh - With the subject supine and the knee extended, the midway point 
between the ASIS and the upper pole of the patella was identified and the thickness of the 
quadriceps muscle group between the superficial fat-muscle interface and the femur was 
measured anteriorly. 
Observers applied probe pressure as light as possible to minimise compression of the 





APPENDIX F: Protocols for assessment of handgrip strength and physical 
performance 
Handgrip strength [adapted from Roberts et al]228 
Handgrip strength to be measured on the non-dominant and dominant side using a Jamar 
dynamometer as follows: 
1. Position the participant in a comfortable standing position.  
2. Ask them to position their upper arm and forearm at 90 degrees.  
3. Demonstrate how to use the hand dynamometer (Mentone, Melbourne, Australia) to 
show that gripping very tightly registers the best score.  
4. Start with the right hand.  
5. Position the hand inside the instrument. The instrument should feel comfortable in 
the hand. Alter the position of the handle if necessary.  
6. Encourage the participant to squeeze as long and as tightly as possible or until the 
needle stops rising. Once the needle stops rising the participant can be instructed to 
stop squeezing.  
7. Read grip strength in kilograms from the outside dial and record the result to the 
nearest 0.5 kg on the data entry form.  
8. Repeat measurement in the left hand.  
9. Do two further measurements for each hand alternating sides to give three readings 
in total for each side.  
10. The average of the three grip strength measurements on each side is used in 
statistical analyses.  
11. Also record hand dominance, ie right, left or ambidextrous (people who can 
genuinely write with both hands).  
Sit-to-stand test [as per Jones et al]96  
The chair-stand test was administered using a standard chair without arms. The chair, with 
rubber tips on the legs, was placed against a wall to prevent it from moving during the test.  
The test began with the participant seated in the middle of the chair, back straight, feet 
approximately shoulder-width apart and placed on the floor at an angle slightly back from 
the knees, with one foot slightly in front of the other to help maintain balance when 
standing. Arms were crossed at the wrists and held against the chest.  
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At the signal "Go", the participant rose to a full stand (body erect and straight) and then 
returned back to the initial seated position. The participants were encouraged to complete 
as many full stands as possible within a 30 second time limit. The participant was 
instructed to be fully seated between each stand. While monitoring the participant's 
performance to assure proper form, the tester silently counted the completion of each 
correct stand. Following a demonstration by the tester, a practice trial of one repetition was 
given to check proper form, followed by the 30 second test trial. The score was the total 
number of stands executed correctly within 30 seconds (more than halfway up at the end 
of 30 seconds counted as a full stand). Incorrectly executed stands were not counted. 
Short Physical Performance Battery [as per Guralnik et al]93 
Balance 
Tests of standing balance included tandem, semi-tandem, and side-by-side stands. For 
each stand, the interviewer first demonstrated the task, then supported one arm while 
participants positioned their feet, asked if they were ready, then released the support and 
began timing. The timing was stopped when participants moved their feet or grasped the 
interviewer for support, or when 10 seconds had elapsed. Each participant began with the 
semi-tandem stand, in which the heel of one foot was placed to the side of the first toe of 
the other foot, with the participant choosing which foot to place forward. Those unable to 
hold the semi-tandem position for 10 seconds were evaluated with the feet in the side by-
side position. Those able to maintain the semi-tandem position for 10 seconds were further 
evaluated with the feet in full tandem position, with the heel of one foot directly in front of 
the toes of the other foot.  
Gait Speed Test 
To test walking speed, a 4-metre walking course is used with no obstructions for an 
additional 1 metre at either end. Participants were instructed to "walk to the other end of 
the course at your usual speed, just as if you were walking down the street to go to the 
store". Participants could use assistive devices if needed, and each participant was timed 
for two walks. The faster of the two is used for analyses.  
Chair Stand Test 
To test the ability to rise from a chair (termed the chair stand), a straight-backed chair was 
placed next to a wall; participants were asked to fold their arms across their chest and to 
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stand up from the chair one time. If successful, participants were asked to stand up and sit 
down five times as quickly as possible, and were timed from the initial sitting position to the 
final standing position at the end of the fifth stand.  
Overall score 
Categories of performance were created for each set of performance measures to permit 
analyses that included those unable to perform a task. Participants who could not 
complete the 4m walk and repeated chair stands were assigned a score of 0. Those 
completing the task were assigned scores of 1 to 4, corresponding to the quartiles of time 
needed to complete the task, with the fastest times scored as 4. The three tests of 
standing balance were considered as hierarchical in difficulty in assigning a single score of 
0 to 4 for standing balance. A summary performance scale was created by summing the 
category scores for the walking, chair stand, and balance tests. 
Six-minute walk distance [adapted from Coombes et al]91 
Patients to be tested using the Princess Alexandra Hospital Department of Respiratory 
walking course. The walking course is 25m in length so that one lap (out and back) is 
50m.This course has pre-existing markers at 1m intervals. 
The observer should conduct the test as follows: 
6. A script similar to the following text is advised to be used to ensure test accuracy:  
“The objective of this test is to walk as far as possible for 6 minutes. You will walk 
back and forth in this hallway/space. Six minutes is a long time to walk, so you will 
be exerting yourself. You will probably get out of breath or become exhausted. You 
are permitted to slow down, to stop, and to rest as necessary. You may lean against 
the wall/chair while resting, but resume walking as soon as you are able. You will be 
walking back and forth around the furthest cones. You should pivot briskly around 
the cones and continue back the other way without hesitation. Now I'm going to 
show you. Please watch the way I turn without hesitation.” 
7. Demonstrate by walking one lap yourself. Walk and pivot quickly around the turning 
cone.  
8. Ask the participant to stand behind the start marker with a foot close to the start line 
and ask them if they have any questions.  
9. Say “Go” and start the stopwatch when the participant begins walking.  
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10. Keep track of the distance walked on the data recording sheet each time a lap is 
completed.  
11. If the participant stops to rest, the stopwatch keeps running.  
12. The observer should encourage participants by using the following standardised 
statements:  
a. 1st minute: ‘You are doing well. You have 5 minutes to go.’  
b. 2nd minute: ‘Keep up the good work. You have 4 minutes to go.’  
c. 3rd minute: ‘You are doing well. You are halfway done.’  
d. 4th minute: ‘Keep up the good work. You have only 2 minutes left.’  
e. 5th minute: ‘You are doing well. You have only 1 minute to go.’  
13. Do not use other words of encouragement (or body language) during the test.  
14. When the 6 minutes have elapsed note the exact point on the floor where the 
participant finished, inform them that the test is complete and they can now walk 
slowly for 1 minute to cool down.  
15. Record the distance walked.  
Stair climb test [as per Bean et al]229 
7. Stair climb time was measured by the following procedure.  
8. The observer stood with the subject at the base of a well-lighted, 10-stair flight of 
stairs. 
9. Subjects were instructed to safely ascend the stairs as fast as they could.  
10. They were further instructed that they could use the handrail if they thought it was 
necessary for safety purposes 
11. The examiner starts the test by saying: “Ready, set, go.”  
12. Timing began after the examiner said “go” and once each subject began moving.  
13. When both feet of a subject reached the top step, the timing stopped.  
14. Time was recorded to the nearest 0.01 second, and the best of 3 trials was taken.  
